

REFINITIV

DELTA REPORT

10-K

ACCOLADE, INC.
10-K - FEBRUARY 28, 2023 COMPARED TO 10-K - FEBRUARY 28, 2022

The following comparison report has been automatically generated

| | |
|--------------|------|
| TOTAL DELTAS | 2541 |
| CHANGES | 244 |
| DELETIONS | 1198 |
| ADDITIONS | 1099 |

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended February 28, 2022 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number: 001-39348

ACCOLADE, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

01-0969591
(I.R.S. Employer
Identification No.)

1201 Third Avenue, Suite 1700
Seattle, WA 98101
(Address of principal executive offices including
zip code)

Registrant's telephone number, including area code: (206) 926-8100

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading symbol | Name of each exchange on which registered |
|--|----------------|--|
| Common Stock, \$0.0001 par value per share | ACCD | The Nasdaq Stock Market LLC (The Nasdaq Global Select Market) |

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☐

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

| | | | |
|-------------------------|--------------------------|---------------------------|--------------------------|
| Large accelerated filer | <input type="checkbox"/> | Accelerated filer | <input type="checkbox"/> |
| Non-accelerated filer | <input type="checkbox"/> | Smaller reporting company | <input type="checkbox"/> |
| | | Emerging growth company | <input type="checkbox"/> |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☐

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately \$2.8 billion \$658.5 million as of the last business day of the registrant's most recently completed second fiscal quarter, based upon the closing sale price on The Nasdaq Global Select Market reported for such date.

Excludes an aggregate of 6,650,953 6,849,852 shares of the registrant's common stock held as of such date by officers, directors and stockholders that the registrant has concluded are or were affiliates of the registrant. Exclusion of such shares should not be construed to indicate that the holder of any such shares possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.

As of April 26, 2022 April 21, 2023, 67,294,511 73,634,043 shares of the registrant's common stock were outstanding.

Documents Incorporated by Reference

Part III incorporates information by reference from the registrant's definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the registrant's 2022 2023 Annual Meeting of Stockholders.

ACCOLADE, INC. TABLE OF CONTENTS

| | | |
|--|--|-------|
| Part I | | |
| Item 1 | Business | 4 |
| Item 1A | Risk Factors | 16 |
| Item 1B | Unresolved Staff Comments | 54 55 |
| Item 2 | Properties | 55 |
| Item 3 | Legal Proceedings | 55 |
| Item 4 | Mine Safety Disclosures | 55 |
| Part II | | |
| Item 5 | Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 55 56 |
| Item 6 | [Reserved] | 56 57 |
| Item 7 | Management's Discussion and Analysis of Financial Condition and Results of Operations | 56 57 |
| Item 7A | Quantitative and Qualitative Disclosures about Market Risks | 74 |
| Item 8 | Financial Statements and Supplementary Data | 75 74 |
| Item 9 | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 75 74 |
| Item 9A | Controls and Procedures | 75 |
| Item 9B | Other Information | 77 76 |
| Item 9C | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 77 76 |
| Part III | | |
| Item 10 | Directors, Executive Officers and Corporate Governance | 78 77 |
| Item 11 | Executive Compensation | 78 77 |
| Item 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 78 77 |
| Item 13 | Certain Relationships and Related Transactions, and Director Independence | 78 77 |
| Item 14 | Principal Accountant Fees and Services | 78 77 |
| Part IV | | |
| Item 15 | Exhibit and Financial Statement Schedules | 78 77 |
| Item 16 | Form 10-K Summary | 82 81 |
| Signatures | | |
| Index to Consolidated Financial Statements | | |

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY

This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements include information related to our financial performance and possible or assumed future results of operations and expenses, our outlook, business strategies and plans, business environment, market size, product capabilities, timing of new product releases, the impact of our focus areas and key initiatives, and potential future growth. Forward-looking statements include all statements that are not historical facts.

You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Annual Report on Form 10-K primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in this Annual Report on Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form 10-K. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that such information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

The forward-looking statements made in this Annual Report on Form 10-K relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Annual Report on Form 10-K to reflect events or circumstances after the date of this Annual Report on Form 10-K or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

RISK FACTOR SUMMARY

Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading "Item 1A—Risk Factors," below.

- We have a history of net losses, we anticipate increasing expenses in the future, and we may not be able to achieve or maintain profitability.
- We derive a significant portion of our revenue from our largest customers. The loss of any of these customers, or renegotiation of any of our contracts with these customers, could negatively impact our results.

-
- We have a limited operating history with some of our current offerings, in particular those which we have acquired, which makes it difficult to evaluate our current and future business prospects and increases the risk of your investment.

- Our business, results of operations, and financial condition may fluctuate on a quarterly and annual basis, which may result in a decline in our stock price if such fluctuations result in a failure to meet any projections that we may provide or the expectations of securities analysts or investors.
- Our sales cycle can be long and unpredictable and requires considerable time and expense. As a result, our sales, revenue, and cash flows are difficult to predict and may vary substantially from period to period, which may cause our results of operations to fluctuate significantly.
- Certain of our operating results and financial metrics may be difficult to predict as a result of seasonality and due to the fact that a portion of our revenue is subject to the achievement of performance metrics and healthcare cost savings.
- If we fail to effectively manage our growth and organizational change, our mission-driven culture could be impacted, and our business could be harmed.
- If we are unable to attract, integrate, and retain additional qualified personnel, especially for Accolade Health Assistants, clinical, including primary care physicians and medical specialists, and various product and technology roles, our business could be adversely affected.
- We have and may again in the future acquire other companies or technologies, which could divert our management's attention, result in dilution to our stockholders, and otherwise disrupt our operations, and we may have difficulty integrating any such acquisitions successfully or realizing the anticipated benefits therefrom, any of which could have an adverse effect on our business, financial condition, and results of operations. For example, in March 2021 we acquired Innovation Specialists LLC d/b/a 2nd.MD (2nd.MD) and in June 2021 we acquired PlushCare, Inc. (PlushCare).
- We may face intense competition, which could limit our ability to maintain or expand market share within our industry, and if we do not maintain or expand our market share our business and operating results will be harmed.
- The evolving effects of Macroeconomic factors including high inflation, the Coronavirus Disease 2019 (COVID-19) COVID-19 pandemic, and associated global economic instability geopolitical risk may have further adverse effects on result in decreases to the workforces of, or benefits spending by, our operations and negatively customers which would impact our business, operational and financial condition, and results of operations performance.
- If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business could be harmed.
- Unstable market and economic conditions, including adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, may have serious adverse consequences on our business, financial condition, results of operations, and stock price.

Part I

Item 1. Business

Our Mission

At Accolade, we envision a world where every person can live their “healthiest life” — a concept that encompasses physical, emotional, financial, and professional wellness. Our mission is to empower people through expertise, empathy, and technology to make the best decisions for their health and well-being.

Business Overview

Accolade enables our members to receive the right healthcare for their individual needs. We call it Personalized Healthcare. Accolade solutions are personal, data driven, and value based to provide a healthcare experience that helps people better understand, navigate, and

utilize the healthcare system and workplace benefits. We provide personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. Our customers are primarily employers that deploy Accolade solutions in order to provide employees and their families (our "members") a single place to turn for their health, healthcare, and benefits needs. We also offer expert medical opinion services to **employer commercial customers (which includes employers, health plans, and governmental entities)** and virtual primary care and mental health support, both directly to consumers and to **employer commercial customers**. Our innovative platform, which we call our True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. We leverage our integrated capabilities, connectivity with providers and the broader healthcare ecosystem, and longitudinal data to engage across the entire member population, rather than focusing solely on high-cost claimants or those with chronic conditions. Our goal is to build trusted relationships with our members that ultimately position us to deliver personalized recommendations and interventions. We believe that our True Health Engine dramatically improves the member experience, encourages better health outcomes, and lowers costs for both our members and our customers.

The U.S. healthcare system is complex and places significant strain on consumers, who struggle to effectively use their healthcare and benefits, make informed decisions about their health, and navigate the fragmented network of providers and third-party benefit programs. Additionally, access to appropriate care and the quality of available care varies widely based on a number of reasons, including economic, social, and geographic. This is commonly referred to as Health Equity. We designed our solutions to follow a clinical model that emphasizes both contextual and concordant care – healthcare that takes into account a person's lifelong healthcare experience delivered by a team of people who understand their individual need. This approach also takes into account the numerous social determinants of health, such as social, economic, race, and geographic barriers that impact the quality and accessibility of healthcare. The **ongoing COVID-19 global pandemic has only served to further exacerbate exacerbated** the complexity and frustration faced by consumers, as they **seek information about the availability and accuracy of virus and antibody testing, seek information about vaccinations, or face faced** limits on their ability to access traditional care **safely**. **Partly as a result safely or struggled to find current and accurate information about the virus including the availability of these challenges, the testing or vaccinations.** Healthcare payors, **of healthcare**, including managed care companies, the government, employers, and consumers, face significant and rising costs. For large employers in particular, the direct costs are substantial: the total annual employer cost for healthcare is estimated at more than \$10,000 per employee. Employers also bear indirect costs in the form of absenteeism, decreased productivity, and diminished morale, all potentially intensified during times when their employees are forced to work remotely due to threats to public health. Despite the significant and growing spend on care, health outcomes are not improving, and misaligned incentives among key constituents thwart meaningful change. A suboptimal consumer experience persists.

We believe the most effective way to improve health outcomes and control cost is to help consumers make better, data-driven healthcare and benefits-related decisions. Based on this belief, we have developed a differentiated

platform to support and influence consumer decision-making that is built on a foundation of mission-driven people and purpose-built technology:

- **Accolade Health Assistants.** Our Accolade Health Assistants are highly trained professionals who develop trusted relationships with our members and serve as their primary and ongoing point of contact for all issues related to healthcare and benefits.
- **Clinicians.** Our clinicians include registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.
- **Technology.** Our technology platform was designed to deliver highly personalized member experiences at scale, leveraging data and machine learning to derive actionable insights, optimize our care teams' workflows, and accelerate the pace of our innovation. We ingest and link disparate data points to Accolade-generated data to create a 360-degree member view which our Accolade Health Assistants and clinicians access in our purpose-built member CRM tool, InView. Our secure, open technology platform supports our continuous innovation and the development of additional capabilities to benefit our members.

- **Trusted Partner Ecosystem.** In addition to Accolade's owned solutions, we have assembled a roster of high-quality partners whose condition-specific solutions are complementary to our services and capable of delivering additional value to our members and customers or capabilities that meet specific customer needs. The Trusted Partner Ecosystem encompasses a set of partnerships in areas that we believe matter to our customers because medical spend in them is high, such as diabetes or musculoskeletal care, and/or having services related to them is viewed favorably in terms of attracting and retaining talent (e.g., fertility care, LGBTQIA+ affirming care). Accolade vets Trusted Partners along clinical, data security, financial, and operational dimensions. Ultimately, customers can streamline selection, procurement, and implementation when working with our Trusted Partners. We also enable a set of integrated features to support incremental, appropriate utilization of the Trusted Partners' services.

Developing trusted relationships positions us to positively influence members' healthcare and benefits-related decision-making and ultimately deliver on our value proposition.

Through trusted, ongoing engagement, we can meaningfully influence member decisions and help increase valuable healthcare utilization (e.g., primary care visits, prescription refills) and reduce wasteful healthcare utilization (e.g., unnecessary emergency room visits, hospital readmissions, excessive inpatient stays). We further enhance the member experience by educating members on relevant, available benefits, such as wellness programs and telemedicine. In raising awareness of these benefits and seamlessly integrating them into our platform, we can significantly increase their utilization rates.

Our investments in a scalable technology platform have enabled us to acquire complementary services and implement a multi-offering strategy that meets the diverse needs of our existing and prospective customers. Buyers of our offerings have varying priorities and appetites for change to their existing health and benefits packages, and we have therefore developed a solutions portfolio that is designed to support a range of capabilities and services for employers of all sizes. We sell our solutions in four primary offerings that incorporate different aspects of our services:

- Accolade Expert MD – Expert medical consultations that connect patients to highly qualified condition-specific specialists for both adult and pediatric care
- Accolade Care – Integrated primary care and mental health support
- **Core Plus** and **Plus Connect** – A benefits navigation and care solution designed to work with our customers' existing benefits ecosystem, incorporating elements of all Accolade solutions including Advocacy, Accolade Expert MD, Accolade Care, and the Accolade partner ecosystem. Different offering configurations may also

5

include member services, provider services, and an expanded set of clinical programs that address case and disease management to maximize member engagement and return on investment.

- Accolade One – A value-based option that includes all of the Accolade solutions and the Accolade partner ecosystem with a pricing structure that includes a higher portion of revenues associated with outcomes-based measures

Additionally, our modular technology platform has enabled us to quickly offer solutions that meet specific healthcare needs of our population, including solutions such as Accolade Covid Response Care and Mental Health Integrated Care.

5

Recent Acquisitions

In March 2021, we acquired 2nd.MD, a leading expert second opinion consultation and health care decision support company based in Houston, Texas. 2nd.MD provides a service that allows members to access board-certified national experts across the country for high-value consultations in a real-time video call or by phone in order to provide the member with a rapid second opinion on their medical condition enabling the member to make more informed decisions regarding significant and high-cost care decisions, such as whether to have surgery or elect to have a specific treatment.

In June 2021, we acquired PlushCare, a provider of virtual primary care and mental health support. The addition of a primary care team extends our ability to improve clinical health outcomes for members and deliver additional cost savings for employers.

In September 2021, we acquired substantially all the assets of HealthReveal, Inc. (HealthReveal). HealthReveal is a clinical artificial intelligence company focused on ensuring patients receive optimal, personalized chronic care to preempt adverse outcomes.

Competitive Strengths

Our operational and financial success is based on the following key strengths:

Commitment to a differentiated member engagement model. We fundamentally believe in engaging the *entire* member population to have a sustainable impact on health outcomes and cost. This stands in contrast to the historic industry norm of engaging only the highest-cost, sickest patients with the most complex needs. To do this, we have built a platform to engage with each customer's eligible member population, build trusted relationships with members, and leverage those relationships to deliver important healthcare interventions when they matter the most.

Highly qualified and empathetic team with deep clinical experience. Our engagement model integrates "human touch" with a proprietary technology platform to encourage better outcomes for our members. While the right mix of experience and skills is critical, all care team members must demonstrate empathy to be hired, and maintain it to be retained.

Long-term strategic partner to our customers. We are engaged by employers to solve real issues around the design, coordination, and utilization of their employee benefits programs. Because we help their employees live their healthiest lives, our customers view us as a strategic partner that can provide population health insights and help them manage healthcare benefit costs and complexity, including, crucially, how to ensure the safety of employees returning to the workplace during a pandemic.

Significant investment in our purpose-built, scalable technology platform. Our offerings are built on an open, cloud-based intelligent platform designed to deliver a highly personalized member experience. Our platform is built for scale — architected to deliver repeatable results and high service levels at a sustainable cost to serve — and leverages extensive data ingestion capabilities and artificial intelligence to derive predictive analytics, deliver targeted population health insights, and recommend the right care intervention for our members at the right time.

Attractive operating model supported by a PMPM per-member-per-month (PMPM) recurring revenue model, providing a high degree of visibility. As of February 28, 2022 February 28, 2023, we had over 600 employer 800 commercial customers that collectively purchase access to our solutions for more than 10 million 12 million members. We principally generate revenue from our customers on a recurring PMPM fee basis, with contracts generally three years in length, which together provide us with significant revenue visibility. Our ability to deliver significant and measurable return on investment for our customers in the form of improved clinical and financial outcomes has led to a gross dollar retention of 98% 87%, 99% 98%, and 99% for the fiscal years ended February 28(29) February 28, 2023, 2022, and 2021, and 2020, respectively.

Deeply experienced management team dedicated to cultivating a mission-driven culture. Our senior leadership team has extensive healthcare, technology, and business-scaling expertise from decades of leadership

experience at world-class organizations. Our senior management team has a long track record of working together, both at Accolade and at previous firms, with some members of our senior leadership team having worked together for over 20 years. We share our mission with the dedicated and passionate people that we employ, and our culture is a driving factor in our ability to attract and retain top talent.

Our Growth Strategy

Key elements of our growth strategy include:

Grow our customer base. We believe there is a substantial opportunity to further grow our customer base in our large and under-penetrated market that includes thousands of self- and fully-insured employers in the United States. Our sales and marketing team draws on

advanced demand-generation strategies to reach and educate the market about our offerings and increase the opportunities to grow our customer base. We maintain a cohort of highly referenceable customers in support of new customer acquisition.

Retain and expand relationships with our customers. By delivering measurable outcomes to our customers, we can achieve strong customer retention, which enables us to expand and deepen these relationships. The addition of

6

expert medical opinion through the acquisition of 2nd.MD and virtual primary care through the acquisition of PlushCare are examples of new offerings that complement our existing solutions and can be sold as standalone solutions or provide cross-sell opportunities to drive incremental revenue. As we build upon our trusted partner status with these customers, we have the opportunity to cross-sell our additional capabilities, as well as services offered by our ecosystem partners.

Invest in technology. We have made significant investments in our technology platform to expand our capabilities with respect to how we engage with our members and deliver our solutions and care interventions. By leveraging our technology in areas such as machine learning, predictive analytics, and multimodal communication, we believe we can generate more efficiencies in our operating model while simultaneously improving our ability to deliver better health outcomes and lower costs for both our members and our customers.

Continue to develop new offerings. We are constantly innovating to enhance our model and develop new offerings, including our recently introduced Accolade Care and Accolade One. Connect. Our ability to act as a trusted advisor to our members and customers positions us to identify new opportunities for additional offerings that can meet their existing and emerging needs. Our open technology platform also allows us to efficiently add new applications on top of our existing technology stack, such as Accolade COVID Response Care and Mental Health Integrated Care.

Expand into adjacent markets. We see significant additional opportunity in adjacent markets, including expanding with the TRICARE population and working with other government-sponsored health plans, such as Medicare Advantage and Managed Medicaid (as well as traditional Medicare and Medicaid), along with those administered by Veterans Affairs. Our focus and experience in the navigation and coordination of benefits and healthcare, coupled with our technology investments, position us to take advantage of emerging healthcare trends surrounding care coordination and value-based care initiatives. We believe that we can leverage our existing platform and scalable solutions to successfully expand into these markets.

Opportunistically pursue partnerships. We have historically integrated new and complementary capabilities into our offerings by forming strategic partnerships and other relationships with third parties. We believe our partners choose us because of our entrepreneurial and collaborative culture, and dedication to continuous innovation, innovation, and track record of exceptionally high member engagement rates. We develop and maintain partnerships with a number of healthcare companies to offer our customers a broader range of services and our members a more seamless healthcare experience, experience on the back of the core Accolade engagement model. Those partnerships include health plan partners such as Humana United Healthcare, Aetna, Blue Shield of California, and Blue Cross of California, Priority Health, technology partners like Change Healthcare, and chronic and clinical solutions providers such as SWORD, Sword, Virta, RxSavings Solutions, Carrot Fertility, Headspace Health, and Headspace. FOLX.

Our Clinical Philosophy

We believe health outcomes are improved and overall healthcare spend is lowered when personalized care guidance and coordination are effectively delivered. Our clinical philosophy governs the ways we help members as they

7

contemplate and consume care. Increasing healthcare spend is a lagging indicator of the need for support — our engagement model seeks to engage all members, regardless of healthcare spend or the complexity of medical needs, and support them as early as possible in their care journeys.

Our Offerings

We have developed a continuum of offerings to address the market's varied perspectives on how best to improve healthcare and benefits utilization, along with buyers' varying appetites for change. All of our offerings have been built on the same technology stack, meaning each is capable of fully leveraging our integrated platform — combining people and technology to deliver value to our customers. We can unpack and combine our capabilities into differentiated bundles, while maintaining scale and efficiency by operating on a single platform.

7

Overview of Accolade's Multi-offering Strategy

Accolade Total Health and Benefits has historically been our most comprehensive offering from which the majority of our revenues are derived today. Our technology platform enabled us to unbundle aspects of this comprehensive offering to create additional standalone offerings and integrate newly acquired solutions. Following our acquisition of 2nd.MD in March 2021, we began offering customers expert medical consultation (primarily for high-complexity, high-cost conditions) as a standalone service as well as a capability that can be incorporated into other core offerings. Following our acquisition of PlushCare in June 2021, we began offering virtual primary care and mental health services directly to consumers and commercial customers. We have further leveraged our technology platform to develop add-on offerings and to integrate acquired solutions that target specific challenges faced by our customers.

As of September 2021, Today, we began offering offer our solutions as four primary offerings, including two new solutions and new naming for the solutions described above, standalone or bundled offerings. The new solutions – Accolade One and Accolade Care – combine current solution portfolio combines the capabilities of Accolade's historical navigation and advocacy solutions with our acquired primary care, mental health, and expert medical opinion services, augmented by artificial intelligence, machine learning, and data-driven recommendations. The new solutions are in their early stages of implementation, with initial customer implementations started in January 2022. Additionally, we announced new solution bundles incorporating all of our existing solutions to reflect the evolution and maturation of our offering portfolio. With these changes, our Our current offerings include:

- Accolade Expert MD – Expert medical consultations that connect patients to highly qualified condition-specific specialists for both adult and pediatric care
- Accolade Care – Integrated primary care and mental health support
- CorePlus and Plus Connect – A benefits navigation and care solution designed to work with our customers' existing benefits ecosystem, incorporating elements of all Accolade solutions including Advocacy, Accolade Expert MD, Accolade Care, and the Accolade partner ecosystem. Different offering configurations may also include member services, provider services, and an expanded set of clinical programs that address case and disease management to maximize member engagement and return on investment.
- Accolade One – A value-based option that includes all of the Accolade solutions and the Accolade partner ecosystem with a pricing structure that includes a higher portion of revenues associated with outcomes-based measures

Accolade has also developed additional add-on solutions, such as Mental Health Integrated Accolade Covid Response Care and Tricare Select Navigator that directly address the pronounced need specific needs among our employer commercial customers for help with overall benefits management.

Our Technology Platform

With great conviction that technology can help scale and optimize the Accolade engagement model, we began making substantial investments to create an industry-leading, open, cloud-based platform in 2016. This technology

8

platform, built utilizing artificial intelligence, microservices, and data analytics, enables us to deliver personalized experiences to our full member population throughout their healthcare journeys. We have established a highly experienced Product & Technology organization that has extensive experience in machine learning, artificial intelligence, data science, engineering, and product management.

In order to fuel our machine learning processes, we have made a concerted effort to source what we view as a massive, powerful, and differentiated data set. We pair Accolade data (encounter and activation history, conditions/medications/procedures, barriers to care, assessment responses, care plans) with the data we ingest from:

- our employer commercial customers (eligibility and membership data);
- carriers and pharmacy benefits managers (claims data, plus benefit plan and formulary details);
- providers (verification of benefits and eligibility checks, pre-authorizations, and utilization management discharge instructions);

8

-
- the Centers for Medicare & Medicaid Services (CMS) and commercial insurers (billions of claims, comprehensive provider directories, and price data); and
 - ecosystem partners (registrations, interactions, assessments/care plans).

With this combination of data, we are able to apply machine learning tactics to generate predictive insights about our members. For example, we calculate various scores for members that quantify their relationship with us, overall health status, and their propensity to take a desired action. These scoring techniques inform recommended actions for our Accolade Health Assistants and clinicians that are surfaced to InView, as well as recommendations delivered directly to our members as part of our activation capabilities and/or self-service.

Our Go-to-Market Strategy

We employ a multipronged go-to-market strategy to drive adoption of our solutions. We have strategically curated our offerings portfolio to ensure we have a compelling value proposition at an appropriate price point that resonates with each specific customer segment.

Sales Organization. We principally sell our solutions through our direct salesforce and distribution agreements with healthcare industry third parties, such as large and regional health plans and governmental entities. We have invested meaningfully in creating a scaled and focused team to capture the new customer growth opportunities across different customer sizes, verticals, and geographies. Our field sales professionals are organized by account size, region, and existing versus prospective customers. This organizational structure enables us to deliver context-specific, tailored messaging that resonates with each customer segment. Our sales team possesses deep domain expertise in health benefits management and boasts long-term relationships with key decision makers within our prospective customer organizations. We also have a sales team solely focused on our health plan distribution relationships. We believe the effectiveness of our sales organization is evidenced by growing adoption of our platform by large strategic customers, as well as strong more recent traction with enterprise and mid-market customers where we see meaningful additional revenue opportunity.

Customer Success Organization. Our customer success team (formerly known as customer partnerships) provides strategic insights, point solutions recommendations, and day-to-day account support to our customers. The team is focused on deepening existing customer relationships and cross-selling new offerings where appropriate. This organization is comprised of dedicated customer support teams to serve each customer's specific needs and also focuses on deepening existing customer relationships through sales of our new offerings.

Strategic Partnerships. We selectively form partnerships to further drive customer acquisition and adoption of our personalized, technology-enabled solutions platform. For example, in March 2019, 2022, we partnered announced partnerships with Humana Blue Shield of California and formed a joint go-to-market strategy, which we launched in two initial geographic markets. In October 2019, concurrent with a \$20 million preferred stock investment from Humana, we expanded our partnership to add a broader base of solutions targeting self- and fully insured customer prospects and significantly expand our target geographic markets.

9

In addition, in February 2020, we entered into a strategic relationship with Change Priority Health to increase each party's capabilities for serving its customers and members. The arrangement includes the joint development provide our services as part of new and improved capabilities and service agreements their employer-focused virtual first health plan offerings. These relationships allow us to expand datasets available to Accolade for various analytics to better support members, reach a wider customer audience through regionally-focused organizations.

We believe the breadth of our go-to-market and distribution strategy enables us to reach customers of nearly every size across markets.

Marketing

We generate customer leads, accelerate sales opportunities, and drive brand awareness through our marketing programs. Our marketing programs target benefits and finance executives, senior business leaders, health professionals, brokers, consultants, third-party administrators, and suppliers.

In addition to our direct sales organization, we maintain relationships with a range of third parties including brokers, benefits consultants, third-party administrators, and trusted suppliers. Trusted Partner Ecosystem. These partners supplement our direct sales force and help sell our offerings into select end markets by way of warm introductions and advice as we field prospective customers' requests for proposals. We have developed strong relationships with our partners and have a

well-established reputation within our partner community. We proactively educate our partners on our solutions and value proposition to ensure we are appropriately represented to prospective customers.

Competition

We believe no single competitor offers a similarly comprehensive platform combining personalized, technology-enabled solutions with highly trained professionals. However, we have experienced and expect to continue to experience competition from a number of companies, including those who are well-established and may have greater resources, and those who may become meaningful competitors in the future. Our competitors generally fall into three categories: large health plans that provide member and provider services, such as the Blue Cross Blue Shield health plans (e.g., Anthem), Cigna, UnitedHealth Group, and Aetna; services; traditional advocacy and navigation companies, such as Quantum Health and Health Advocate; Included Health; and an emerging cohort of companies that traditionally provided provide varying levels of virtual primary and mental health care, telemedicine, and expert medical opinion services, and/or exclusively digital services and are increasingly adding some version of navigation support to their offering, most notably such as Included Health (Grand Rounds), Amino, Alight (Compass), Teladoc, and Vera Whole Health (Castlight), Advocate. We believe the primary competitive factors for our industry include:

- level of member engagement;
- ability to influence members to improve health and financial outcomes;
- level of customer and member satisfaction;
- ease of integration with employer benefits programs;
- price;
- breadth and depth of platform functionality;
- modern and open technology supporting integration with third-party applications;
- ability to recruit and retain skilled employees and clinicians;
- access to and ability to derive insights from large, disparate data sets;

-
- advanced analytics capabilities to create personalized recommendations;
 - brand awareness and reputation;
 - regulatory compliance; and
 - ability to rapidly innovate and respond to changing customer needs and legislative developments.

While certain of our competitors may have greater resources, recognition, larger customer bases, or longer-standing offerings, we believe that we compete favorably against our competitors based on these criteria. We believe that our platform dramatically improves member experience, encourages better health outcomes, and lower costs for both our members and our customers. As our market grows and continues to evolve through technology or regulatory-driven changes, we expect it will continue to attract interest from existing larger companies who may be able to invest more resources in solutions development and sales and marketing while leveraging their existing relationships, as well as interest from new entrants, who could introduce new solutions.

Intellectual Property

We believe that our intellectual property rights are valuable and important to our business. We rely on trademarks, patents, copyrights, trade secrets, intellectual property assignment agreements, confidentiality procedures,

10

nondisclosure agreements, and employee nondisclosure and invention assignment agreements to establish and protect our proprietary rights.

These intellectual property rights and procedures may not prevent others from creating a competitive technology platform or otherwise competing with us. We may be unable to obtain, maintain, and enforce the intellectual property rights on which our business depends, and assertions by third parties that we violate their intellectual property rights could have a material adverse effect on our business, financial condition, and results of operations.

We continually review our product and technology efforts to assess the existence and patentability of new intellectual property, and have been granted several patents in the United States and **continue to may** prosecute **several pending additional** patent applications in the **United States, future.** We have several registered trademarks in the United States.

Government Regulation

HIPAA and Other Privacy and Security Requirements

Numerous state, federal, local, and foreign laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of personal or sensitive data (including **PHI protected health information (PHI)** and **PII personally identifiable information (PII)**). These laws and regulations include the Health Insurance Portability and Accountability Act (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), the Federal Trade Commission Act, the Telephone Consumer Protection Act of 1991 (**TCPA**), the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (**CAN-SPAM**), and the California Consumer Privacy Act of 2018 (**CCPA**), **as amended by the California Privacy Rights Act (CPRA)**. In addition, several states within the United States have enacted or proposed data privacy **laws. For example, laws, including Virginia, passed the Consumer Data Protection Act, Colorado, passed the Colorado Privacy Act, Utah, and Utah passed the Consumer Privacy Act. Connecticut.** Additionally, we are, or may become, subject to various U.S. federal and state consumer protection laws which require us to publish statements that accurately and fairly describe how we handle personal data and choices individuals may have about the way we handle their personal data.

For example, HIPAA establishes a set of national privacy and security standards for the protection of PHI by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and individuals and entities that perform services for them which involve the use, or disclosure of, individually identifiable health information, known as business associates and their subcontractors. We

are considered a business associate under HIPAA. As such, we could be subject to periodic audits for compliance with the HIPAA Privacy and Security Standards

11

by the U.S. Department of Health and Human Services (HHS) and our customers. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims. HIPAA imposes mandatory penalties for certain violations. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs, and attorneys' fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.

In addition, HHS is required under HIPAA to establish a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator, which is yet to be publicly proposed or implemented. HIPAA further requires that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals. HIPAA specifies that such notifications must be made without unreasonable delay and within a certain time period after discovery of the breach. Depending on the number of patients affected by a breach, it may be required to be reported to HHS without unreasonable delay, and HHS will post the name of the breaching entity on its public web site. Breaches affecting a certain number of patients in the same state or jurisdiction must also be reported to the local media. For breaches affecting smaller numbers of patients, the covered entity must record it in a log and notify HHS at least annually.

11

Likewise, the CCPA creates individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA imposes obligations on covered companies to provide specific disclosures related to a company's collection, use, and disclosure of personal data and to respond to certain requests from California residents, related to their personal data (for example, requests to know of the business's personal data processing activities, to delete the individual's personal data, and to opt out of certain personal data disclosures). In addition, it is anticipated that the California Privacy Rights Act of 2020 (CPRA), data. The CPRA, effective January 1, 2023, will expand expands the CCPA. The CPRA will, among other things, give CCPA by giving California residents the ability to limit use of certain sensitive personal data, establish establishing restrictions on personal data retention, expand expanding the types of data breaches that are subject to the CCPA's private right of action, and establish establishing a new California Privacy Protection Agency to implement and enforce the new law.

There are numerous other federal, state, and foreign laws and regulations that protect the confidentiality, privacy, availability, integrity, and security of PHI and other types of PII. These laws and regulations in many cases are more restrictive than, and may not be preempted by, HIPAA and its implementing rules. These laws and regulations are often uncertain, contradictory, and subject to changed or differing interpretations, and we expect new laws, rules, and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future.

Foreign data privacy and security laws (including but not limited to the EU GDPR General Data Protection Regulation (EU GDPR) and the UK GDPR) impose significant and complex compliance obligations on entities that are subject to those laws. As one example, the EU GDPR applies to any company established in the EEA European Economic Area (EEA) and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. These obligations may include limiting personal data processing to only what is necessary for specified, explicit, and legitimate purposes; requiring a legal basis for personal data processing; requiring the appointment of a data protection officer in certain circumstances; increasing transparency obligations to data subjects; requiring data protection impact assessments in certain circumstances; limiting the collection and retention of personal data; increasing rights for data subjects; formalizing a heightened and codified standard of

data subject consents; requiring the implementation and maintenance of technical and organizational safeguards for personal data; mandating notice of certain personal data breaches to the relevant supervisory authority(ies) and affected individuals; and mandating the appointment of representatives in the UK and/or the EU in certain circumstances.

12

Other Health Care Laws

Our business activities are subject to a complex set of regulations and rigorous enforcement, including by the Food and Drug Administration (FDA), U.S. Department of Justice, HHS, Office of the Inspector General and Office of Civil Rights, and numerous other federal and state governmental authorities. In addition, our employees, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. Federal and state healthcare laws and regulations that may affect our ability to conduct business include:

- HIPAA, as amended by HITECH, and its implementing regulations, which impose certain requirements relating to the privacy, security, and transmission of protected health information on certain healthcare providers, health plans and healthcare clearinghouses, their business associates as well as their covered subcontractors that access or otherwise process individually identifiable health information on their behalf; HIPAA also created criminal liability for knowingly and willfully falsifying or concealing a material fact or making a materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;
- state laws governing professional licensure, the corporate practice of medicine and other healthcare professions and related fee-splitting laws;
- the federal Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the CMS programs, including Medicare and Medicaid;
- the federal civil false claims laws, including the federal False Claims Act, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government;
- federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

12

-
- the federal Physician Payments Sunshine Act, or Open Payments, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, (collectively, the Affordable Care Act), and its implementing regulations, which requires manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;
 - Federal Food, Drug, and Cosmetic Act (FDCA), which requires, among other things, manufacturers of medical devices, including certain software technology companies, to comply with requirements related to pre-market clearances, approved labeling, medical device adverse event reporting, and on-going post-market monitoring and quality assurance;
 - state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; and

13

-
- federal and state laws and regulations regarding: (i) the corporate practice of medicine and other health care professions, the provision of management or administrative services in connection with practice of medicine and other health care professions, employment of professionals by non-professionals, professional fee splitting; (ii) professional licensing and standards of professional conduct; (iii) the provision of telemedicine, telehealth or other health care services, including medical record retention requirements; and (iv) the billing, submission, or collection of claims or payments for healthcare services.

The Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. Further, our operations may subject us to various laws relating to the licensure and corporate practice of a health care profession. These laws, in particular, vary greatly by state and are subject to broad interpretations by regulators.

Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our activities could be subject to challenge under one or more of such laws. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. We may be subject to private "qui tam" actions brought by individual whistleblowers on behalf of the federal or state governments, with potential liability under the federal False Claims Act including mandatory treble damages and significant per-claim penalties.

If our operations are found to be in violation of any of the federal or state laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant criminal, civil, and administrative penalties, damages and fines, disgorgement, additional reporting requirements, and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, imprisonment and exclusion from participation in government programs, such as Medicare and Medicaid, as well as contractual damages, curtailment of our business activities, and reputational harm.

Additionally, in the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care, including the proposed modification to some of the aforementioned laws. We expect there to continue to be a number of healthcare-related legislative initiatives that may significantly affect the healthcare industry, particularly in light of the new presidential administration. industry. These reform initiatives may, among other things, result in modifications to the aforementioned laws and/or the implementation of new laws affecting the healthcare industry.

13

Employees and Human Capital Resources

Our employees are critical to our success. We share our mission with the dedicated and passionate people that we employ, and our culture is a driving factor in our ability to attract and retain top talent. We foster a culture of transparency and alignment whereby we educate our employees on how their contributions each day drive us toward the achievement of our mission. We work together to solve complex problems, and we strive to "do well and do good."

Oversight and Management

Our Board of Directors and Board committees provide oversight on certain human capital matters, including our Inclusion and Diversity programs and initiatives, and are updated periodically by our executive management and our People and Culture team. Our People and Culture team is principally tasked with identifying and recruiting a highly skilled, empathetic and diverse workforce aligned with our mission of changing healthcare and supporting our members and customers. Diversity and inclusion, inclusive of pay equity, is a focus of our human capital management programs, as is enabling high levels of employee engagement and professional development and advancement.

14

We regularly conduct anonymous surveys to seek feedback from our employees on a variety of topics, including but not limited to, their engagement with and joy in their roles, whether they intend to remain at the company, confidence in company leadership, career growth opportunities and improvements on how we can make the company a more desirable place to work and grow. The results are shared with our employees and reviewed by senior leadership, who analyze areas of progress or deterioration and prioritize actions and activities in response to such survey results.

Overview of our Team

As of February 28, 2022 February 28, 2023, we had approximately 2,350 2,370 employees. Our largest group of employees are in our front line care teams comprised of our Accolade Health Assistants, Clinicians (including nurses, pharmacists, and medical directors), and other service and operations team members. Other groups are comprised as follows: Product and Technology, Field Operations, including sales and marketing, Solutions and Growth, and General and Administration roles. We also supplement our workforce with contractors and consultants depending on business need.

Our two largest offices and co-headquarters locations are located in Seattle, Washington and Plymouth Meeting, Pennsylvania. We also have concentrations of employees in various cities throughout the United States and Prague, Czech Republic, as well as a number of employees who work from home in various States, states. None of our employees is represented by a labor union. We have not experienced any work stoppages, and we consider our relations with our employees to be good.

Our largest group of employees is our front line care team, including our Accolade Health Assistants and clinicians who serve our members and customers, who are highly trained professionals who develop trusted relationships with our members and serve as their primary and ongoing point of contact for myriad issues related to healthcare and benefits as part of our services. We employ individuals who demonstrate empathy and problem solving skills, and we hire from diverse professional backgrounds, including social work, teaching, customer care, and benefits. Our Accolade Health Assistants are trained in our proprietary engagement approach and leverage our integrated technology platform to provide data informed, personalized health and benefits support to members in friendly, straightforward terms. Our clinicians include registered nurses, physician medical directors, pharmacists, behavioral health specialists, and women's health specialists, and have deep expertise across a wide variety of specializations. Our nurses work with our other clinicians to help members demystify their care needs through personalized, evidence based, and data driven protocols.

Total Rewards

We seek to retain our employees through appropriate incentives. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. Our Board of Directors, and particularly,

14

our Compensation Committee, in consultation with executive management and our People and Culture team, are responsible for reviewing our total rewards packages, including compensation and health and welfare benefits.

As part of our total rewards programs, our employees are eligible to receive benefits including:

- Comprehensive health benefits for all full-time employees working an average of who regularly works 30 hours or more per week, including medical, dental and vision plans with employer contributions.
- Various employee assistance and health-related programs to provide our employees access to important health resources, including telehealth, mental health programs, expert medical opinion, family planning, and the Accolade for Accolade program that enables our employees to receive the Accolade service.
- Comprehensive parental leave with up to 9 weeks of maternity leave, 9 weeks of bonding leave, and 4 weeks of phase-back time for all employee parents for new births, adoptions and foster placements.
- Paid time off program, including an employee and family sick time program.

- A COVID-19 program, including waived copays for telehealth visits related to COVID-19 and a Caregiver program to provide adapted schedules and leave to support working caregivers.

15

- A 401(k) plan with pre- and post-tax contributions and an employer match, pre-tax commuter benefit, and access to a financial support navigation service.

We continually evaluate our total rewards programs to provide our employees a compelling suite of benefits aligned with their needs.

Corporate Information

We were formed under the laws of the state of Delaware in January 2007 under the name Accretive Care LLC, and we converted to a Delaware corporation under the name Accolade, Inc. in June 2010. Our principal executive offices are located at 1201 Third Avenue, Suite 1700, Seattle, WA 98101, and we have co-headquarters at 660 West Germantown Pike, Suite 500, Plymouth Meeting, PA 19462. Our telephone number is (206) 926-8100. Our website address is www.accolade.com.

Available Information

We are required to file reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports.

Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and amendments to those reports, are available free of charge on our website at <http://www.accolade.com>. Information found on, or accessible through, our website is not part of, and is not incorporated into, this Annual Report on Form 10-K. These reports are posted as soon as reasonably practicable after we file them electronically with the SEC at <http://www.sec.gov>.

15

Item 1A. Risk Factors

You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes. Our business, results of operations, financial condition, and prospects could also be harmed by risks and uncertainties that are not presently known to us or that we currently believe are not material. If any of the risks actually occur, our business, results of operations, financial condition, and prospects could be materially and adversely affected. Unless otherwise indicated, references in these risk factors to our business being harmed will include harm to our business, reputation, brand, financial condition, results of operations, and prospects. In such event, the market price of our common stock could decline.

Risks Related to Our Business and Industry

We have a history of net losses, we anticipate increasing expenses in the future, and we may not be able to achieve or maintain profitability.

We have incurred net losses in most periods since our inception and continue to have an accumulated deficit. We expect our costs will increase substantially in the foreseeable future and our losses will continue as we expect to invest significant additional funds towards growing our business and as we continue to invest in increasing our customer base, expanding our operations, hiring additional employees, and developing future offerings. These efforts may prove more expensive than we currently anticipate, and we may not succeed in increasing our revenue sufficiently to offset these higher expenses. We are unable to accurately predict when, or if, we will be able to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. To date, we have financed our operations principally from the sale of our equity, revenue from sales of our offerings, and the incurrence of indebtedness. Our cash flow from operations was negative for each of the last three fiscal years, and we may not generate positive cash flow from operations in any given

period. If we are not able to achieve or maintain positive cash flow in the long term, we may require additional financing, which may not be available on favorable terms or at all and/or which may be dilutive to our stockholders. If we are unable to successfully address these risks and challenges as

16

we encounter them, our business may be harmed. Our failure to achieve or maintain profitability or positive cash flow could negatively impact the value of our common stock.

We derive a significant portion of our revenue from our largest customers. The loss of any of these customers, or renegotiation of any of our contracts with these customers, could negatively impact our results.

Historically we have relied on a limited number of customers for a significant portion of our revenue. The loss of any of our largest customers or the renegotiation of any of our largest customer contracts has in the past, and could in the future, adversely affect our results of operations. For example, in April 2022, Comcast Cable notified us that it would be exercising exercised its right to terminate our its contract with us "for convenience" effective at the end as of the current calendar year ending December 31, 2022, subject to a right to elect to receive transition services for a period post-termination. Comcast accounted for less than 10%, 16%, and 24% of our revenue for the fiscal years ended February 28(29), February 28, 2023 and 2022, 2021, and 2020, respectively. 16% of our revenue for the fiscal year ended February 28, 2021. The loss of another significant customer, if we are not able to replace such revenue from other existing or new customers, could harm our business and our financial results. Although we We typically enter into three-year contracts with our customers and certain of these contracts, including existing contracts with some of our largest customers, are terminable for convenience by our customers after an initial period and a notice period has passed. In the ordinary course of business, including in connection with renewals or extensions of these agreements, we engage in active discussions and renegotiations with our customers in respect of the solutions we provide and the terms of our customer agreements, including our fees. In addition, as our customers' businesses respond to market dynamics and financial pressures, and as our customers make decisions with respect to the health and other benefits they provide to their employees, our customers may seek to renegotiate or terminate their agreements with us, or may stage competitive request for proposal processes, any of which could result in the loss or reduced profitability of such customers' agreements with us. Macroeconomic factors including the COVID-19 pandemic, rising heightened inflation, recent and potential future bank failures, and geopolitical risk tension may affect our customers' desire to renew their contracts, or if they contracts. If customers undergo layoffs or reductions in force then our membership numbers would decrease, which would result in a reduction in our base and variable fee per-member-per-month (PMPM) and reduce our revenues. For example, during the initial year of the

16

COVID-19 pandemic, customers in the airline industry have had significant headcount reductions, which have resulted in, and are likely to continue to result in a reduction of revenues associated with these customers. We Additionally, we may not experience the impact of changes to our customers' headcount immediately because employees that are on furlough or are receiving continuing health coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act (COBRA) may still have access to our services during such period and be included in our member count, although our member counts will be reduced upon completion of these members' COBRA access, and there can be no guarantee that all such members will elect COBRA in lieu of alternative healthcare options. In addition, there is substantial uncertainty about further economic disruption as initial fiscal stimulus programs end and due to macroeconomic factors, including the COVID-19 pandemic, continues to disrupt the economy, heightened inflation, recent and potential future bank failures, and geopolitical tension. Any of these factors could result in reductions to the fees and changes to the scope of offerings contemplated by our original customer contracts and consequently could negatively impact our business. Because we rely on a limited number of customers for a significant portion of our revenue, delayed payments by a few of our largest customers could result in a reduction in, and greater volatility of, our free cash flow and available cash. We also depend on the creditworthiness of these customers. If the financial condition of one or more of our largest customers declines, our credit risk could increase. In one case, a smaller customer filed for Chapter 11 bankruptcy and terminated its health plan and associated Accolade services as of October 31, 2020. Should one or more of our largest customers declare

bankruptcy, it could adversely affect the collectability of our accounts receivable and affect our bad debt reserves, net income, free cash flow, and available cash.

We have a limited operating history with our current offerings, which makes it difficult to evaluate our current and future business prospects and increases the risk of your investment.

While we served our first customer in 2009, we have significantly altered our offerings and executive management team since 2015. Our limited operating history with respect to our current offerings and current executive management team makes it difficult to effectively assess or forecast our future prospects. For example, with the acquisitions of 2nd.MD and PlushCare, and any new integrated offerings Accolade we may offer in connection therewith, our sales efforts with respect to these offerings may not be as successful as our sales of Accolade Total Health and Benefits – our historical primary offering. You should consider our business and prospects in light of the risks and difficulties we encounter or may encounter. These risks and difficulties include our ability to cost-effectively acquire new customers, retain existing customers and expand the scope of solutions we sell to new and existing customers.

17

Furthermore, in pursuit of our growth strategy, we have and may continue to enter into new partnerships to further penetrate our targeted markets and adoption of our solutions, but it is uncertain whether these efforts will be successful. If we fail to address the risks and difficulties that we face, including those associated with the challenges listed above, our business may be harmed.

Our business, results of operations, and financial condition may fluctuate on a quarterly and annual basis, which may result in a decline in our stock price if such fluctuations result in a failure to meet any projections that we may provide or the expectations of securities analysts or investors.

Our operating results have in the past and could in the future vary significantly from quarter-to-quarter and year-to-year and may fail to match our past performance, our projections or the expectations of securities analysts because of a variety of factors, many of which are outside of our control and, as a result, should not be relied upon as an indicator of future performance. As a result, we may not be able to accurately forecast our operating results and growth rate. Any of these events could cause the market price of our common stock to fluctuate. Factors that may contribute to the variability of our operating results include:

- our ability to attract new customers and engage new members, and retain and engage with existing customers and members;
- achievement of performance metrics and the realization of savings in healthcare spend by our customers resulting from the utilization of our solutions;
- the upfront costs in our customer, member and trusted supplier Trusted Partner Ecosystem relationships;
- the enrollment cycles and employee benefit practices of our customers;

17

- the financial condition of our current and potential customers;
- changes in our sales and implementation cycles;
- introductions and expansions of our offerings, or challenges with their introduction;
- changes in our pricing or fee structures or those of our competitors;
- the timing and success of new offering introductions by us or our competitors or any other change in the competitive landscape of our industry, including consolidation among our competitors;

- increases in operating expenses that we may incur to grow and expand our operations and to remain competitive;
- our ability to successfully expand our business;
- breaches of information security or privacy;
- changes in stock-based compensation expenses;
- the amount and timing of operating costs and capital expenditures related to the expansion of our business;
- adverse litigation judgments, settlements, or other litigation-related costs;
- changes in the structure of healthcare provider and payment systems;

18

-
- changes in the legislative or regulatory environment, including with respect to healthcare, privacy, or data protection, or enforcement by government regulators, including fines, orders, or consent decrees;
 - the cost and potential outcomes of ongoing or future regulatory investigations or examinations, or of future litigation;
 - changes in our effective tax rate;
 - our ability to make accurate accounting estimates and appropriately recognize revenue for our existing and future offerings;
 - changes in accounting standards, policies, guidance, interpretations, or principles;
 - instability in the financial markets;
 - general economic conditions, both domestic and international;
 - volatility in the uncertain credit and global financial markets;
 - political, economic, and social instability, including terrorist activities, the ongoing conflict between Ukraine and Russia, and outbreaks of public health threats, such as coronavirus, influenza, or other highly communicable diseases or viruses, and any disruption these events may cause to the global economy; and
 - changes in business or macroeconomic conditions.

18

The impact of one or more of the foregoing and other factors may cause our operating results to vary significantly. As such, we believe that quarter-to-quarter and year-to-year comparisons of our operating results may not be meaningful and should not be relied upon as an indication of future performance.

Our sales cycle can be long and unpredictable and requires considerable time and expense. As a result, our sales, revenue, and cash flows are difficult to predict and may vary substantially from period to period, which may cause our results of operations to fluctuate significantly.

The timing of our sales, revenue, and cash flows is difficult to predict because of the length and unpredictability of our sales cycle. The sales cycle for our solutions from initial contact to launch varies widely by potential customer. Some of our potential customers, especially in the case of our prospective strategic and enterprise customers, undertake a significant and prolonged evaluation process, including to determine whether our solutions meet the specific needs of their group health plan, employee benefits programs, corporate budgets, and

other goals, which frequently involves evaluation of not only our solutions but also an evaluation of other available solutions. Such evaluations have in the past resulted in extended sales cycles that, due to changes in corporate objectives, leadership involved in the selection process, and other factors, may result in delayed or suspended decision-making in awarding the sale. In addition, our sales cycle may become more lengthy and difficult as a result of macroeconomic factors, including the travel restrictions and business interruptions caused by the ongoing COVID-19 pandemic, or if prospective customers slow down their decision-making about purchases due to the economic effects of COVID-19, heightened inflation, recent and potential future bank failures, and geopolitical tension. During the sales cycle, we expend significant time and money on sales and marketing activities, which lowers our operating margins, particularly if no sale occurs. For example, there may be unexpected delays in a potential customer's internal procurement processes, which involve intensive financial, operational, and security reviews, and for which our solutions represent a significant purchase. In addition, the significance and timing of our offering enhancements, and the introduction of new products by our competitors, may also affect our potential customers' purchases. For all of these reasons, it is difficult to predict whether a sale will be completed, the particular period in which a sale will be completed, or the period in which revenue from a sale will be recognized.

19

Certain of our operating results and financial metrics may be difficult to predict as a result of seasonality.

We believe there are significant seasonal factors that may cause us to record higher revenue in some quarters compared with others. We believe this variability is largely due to our focus on the healthcare industry. For example, with respect to our customers, in particular our Accolade Total Health and Benefits customers with contract years commencing at the beginning of a calendar year, we record a disproportionate amount of revenue from such customers during the fourth quarter of our fiscal year relative to the first three quarters of our fiscal year. This timing is caused, in part, by the measurement, achievement, and associated revenue recognition of performance metrics and healthcare costs savings components of certain of our customer contracts during the fourth quarter of each fiscal year. While we believe we have visibility into our growth rate and the seasonality impact of our business, our rapid growth rate acquisitions over the last several years may have made seasonal fluctuations more difficult to detect. If our rate of growth slows over time, seasonal or cyclical variations in our operations may become more pronounced, and our business may be harmed.

The recognition of a portion of our revenue is subject to the achievement of performance metrics and healthcare cost savings and may not be representative of revenue for future periods.

We price the majority of our services based upon a per-member-per-month (PMPM) PMPM fee times the number of eligible members, typically with a portion of the PMPM fee fixed (base PMPM fee) and the remainder of the fee variable (variable PMPM fee). Revenue from variable PMPM fees can be earned through either, or a combination of, the achievement of certain performance metrics or the realization of healthcare savings resulting from the utilization of our services. Although we have typically achieved these performance metrics and realization in savings of healthcare spend, resulting in our earning over 90% of the aggregate maximum potential revenue under our customer contracts (measured on the corresponding calendar year basis in fiscal years 2023, 2022, 2021, and 2020 2021), our revenue and financial results in the future may be variable based on whether we earn this performance-based revenue. For example, lower healthcare utilization could result in lower engagement with Accolade services than expected and put our ability to meet certain performance metrics at risk. In addition, since our customers typically pay the full PMPM fee in advance on a periodic basis, any required refund as a result of our failure to earn the performance-based revenue could have a negative impact on cash flows. Under U.S. generally accepted accounting principles (GAAP), we recognize revenue when control of the promised services is transferred to our customers in an amount that reflects the consideration to which we expect to be

19

entitled in exchange for those services. The majority of the fees we earn are considered to be variable consideration under GAAP. We typically invoice our customers on a periodic basis for the base PMPM fees and variable PMPM fees in advance of performing the services, and these advances are classified as deferred revenue on our consolidated balance sheet until such time that the associated revenue can be recognized.

Due to the need for us to satisfy performance metrics and healthcare savings requirements, deferred revenue at any particular date may not be representative of actual revenue for any current or future period.

If we fail to effectively manage our growth and organizational change, our mission-driven culture could be impacted, and our business could be harmed.

We have experienced, and may continue to experience, growth and organizational change, which has placed, and may continue to place, significant demands on our management, operational, and financial resources. For example, resources, including the need to hire new employees to support our headcount has grown to approximately 2,350 as of February 28, 2022. Most of our employees have been with us for fewer than three years as a result of our rapid growth. We believe that our mission-driven culture has been an important contributor to our success, which we believe fosters empathy, innovation, teamwork, and passion for providing high levels of customer satisfaction and member engagement. If we fail to successfully integrate, develop, and motivate new employees, it could harm our mission-driven culture. In addition, as we grow and develop the infrastructure of a public company, we may find it difficult to maintain the important aspects of our mission-driven culture, which could limit our ability to innovate and operate effectively. Any failure to preserve our culture could also negatively affect our ability to retain and recruit personnel, maintain our performance, or execute on our business strategy.

In addition, from time to time, we implement organizational changes to pursue greater efficiency and realign our business and strategic priorities. For example, during the year ended February 28, 2023, we initiated several measures to accelerate the integration of recent acquisitions through strategic reductions in our workforce, including increasing hiring in lower cost regions to support our growth, scale, and profitability objectives. Additional risks associated with the continuing impact of the organizational changes include employee attrition beyond our intended reduction and adverse effects on employee morale, diversion of management attention, adverse effects to our reputation as an employer (which could make it more difficult for us to hire new employees in the future), and potential failure or delays to meet operational and growth targets due to the loss of qualified employees. If we do not realize the expected benefits of our organizational changes on a timely basis or at all, our business, results of operations, and financial condition could be adversely affected.

To manage our current and anticipated future growth and organizational change effectively, we must also continue to maintain, and may need to enhance, our information technology infrastructure and financial and accounting systems and controls, as well as manage expanded operations in geographically distributed locations, which will place additional demands on our resources and operations. Failure to manage our growth and organizational change effectively

20

could lead us to over-invest or under-invest in technology and operations; result in weaknesses in our infrastructure, systems, or controls; give rise to operational mistakes, losses, or loss of productivity or business opportunities; reduce customer or member satisfaction; limit our ability to respond to competitive pressures; and result in loss of team members and reduced productivity of remaining team members. Our growth and organization change could require significant capital expenditures and may divert financial resources and management attention from other projects, such as the development of new or enhanced solutions or the acquisition of suitable businesses or technologies. If our management is unable to effectively manage our growth and organizational change, our expenses may increase more than expected, our revenue could decline or may grow more slowly than expected, and we may be unable to implement our business strategy.

For example, we are in the process of implementing a new enterprise resource planning (ERP) system, which is designed to accurately maintain our financial records and integrate our processes. We may experience difficulties during this implementation which could disrupt our operations and the reporting of our financial results. Our failure to successfully complete such system implementation could harm our business, financial condition, and results of operations. In addition, if the ERP system does not operate as intended, the effectiveness of our internal control over financial reporting could be adversely affected.

20

If we are unable to attract, integrate, and retain additional qualified personnel, especially for Accolade Health Assistants, clinical, including primary care physicians and medical specialists, and various product and technology roles, our business could be adversely affected.

Our future success depends in part on our ability to identify, attract, integrate, and retain empathetic and knowledgeable Accolade Health Assistants and clinicians, as well as highly qualified and motivated product developers and engineers, who embody our mission-driven culture. We seek to employ Accolade Health Assistants and clinicians who demonstrate empathy and problem-solving skills and hire from diverse professional backgrounds, including social work, teaching, customer care, and benefits. 2nd.MD's service relies on the attraction of and engagement with medical specialists to support its business operations, and PlushCare, via the associated medical practices, seeks to engage high quality primary care physicians. We have from time to time in the past experienced, and may in the future experience, difficulty in hiring and retaining employees with appropriate qualifications. In addition, we may experience employee turnover as a result of our organizational changes. Qualified individuals in the regions where we have offices are in high demand, and we may incur significant costs to attract them. For example, the market for software engineers in the Seattle area is particularly competitive. In addition, with a current shortage of certain qualified nurses in many areas of the United States, competition for the hiring of these professionals remains intense. Similarly, with the expansion of adoption of telehealth generally, and specifically virtual primary care, competition remains intense for qualified primary care physicians. We compete for qualified individuals with numerous other companies, many of whom have greater financial and other resources than we do. In addition, in the future, we may experiment with different staffing and scheduling models to help attract and retain qualified personnel, including hiring more individuals that who work remotely, incorporating more flexible work schedules, or deploying a temporary workforce. If we fail to effectively manage our hiring needs or successfully integrate new hires, our employee morale and retention could suffer. Any of these events could also adversely affect our customer and member satisfaction and harm our business.

Attracting, integrating, and retaining personnel will require us to invest in and commit significant financial, operational, and management resources to grow and change in these areas without undermining the mission-driven culture that has been critical to our growth so far. For example, newly hired Accolade Health Assistants and clinicians require significant training and, in many cases, take significant time before they achieve full productivity. We train Accolade Health Assistants and clinicians in our proprietary engagement approach and integrated technology platform to provide data-informed, personalized health and benefit support to members in friendly, straightforward terms. This new hire training process lasts approximately one month, including classroom sessions and supervised live call training. If we do not achieve the benefits anticipated from these investments, or if the realization of these benefits is delayed, our results of operations may be adversely affected and our reputation could suffer.

We may also incur significant costs to attract and retain qualified personnel, including significant expenditures related to salaries and benefits and compensation expenses related to equity awards, and we may lose new employees to our competitors or other companies before we realize the benefit of our investment in recruiting and training them. Additionally, we have granted certain, but not all of, our employees equity-based awards under our equity incentive plans and expect to continue this practice. However, if we do not grant equity awards, or if we reduce the value of the equity awards we grant, we may not be able to attract and retain key personnel. Volatility in the price of our common stock underlying equity awards may adversely affect our ability to attract or retain key personnel. If we grant more equity awards to attract and retain key personnel, the expenses associated with such additional equity awards could affect our results of operations.

21

Further, as of February 28, 2023, approximately 50% of our U.S. based labor force are is hourly employees, including Accolade Health Assistants and certain clinicians, who are paid wage rates that currently are above the applicable U.S. federal and state minimum wage requirements. These employees are classified as non-exempt and overtime eligible under U.S. federal and state law. If we fail to effectively manage these hourly employees, then we may face claims alleging violations of wage and hour employment laws, including claims of back wages, unpaid overtime pay, and missed meal and rest periods. For example, we previously entered into a settlement agreement in early 2019 related to a matter brought by a class of our Accolade Health Assistants employed from August 2014 through August 2017 alleging misclassification of exemption status and a failure to pay appropriate overtime wages. Any such employee litigation could be attempted on a class or representative basis. Such litigation can be expensive and time-consuming regardless of whether the claims against us are valid or whether we are ultimately determined to be liable and could divert management's attention from our business. We also could be adversely affected by negative publicity, litigation costs resulting from the defense of these claims, and the diversion of time and resources from our operations. Although we have historically maintained a good relationship with our Our employees our employees could also unionize or any of our employees could

engage in a strike, work stoppage, or other slowdown that would adversely affect our operations and could result in higher labor costs, which would harm our business.

Our goodwill has been subject to impairment and may be subject to further impairment in the future.

Annually, and upon the identification of a triggering event, management is required to perform an evaluation of the recoverability of goodwill. Triggering events potentially warranting an interim goodwill impairment test include, among other factors, declines in historical or projected revenue, operating income, or cash flows, and sustained declines in our stock price or market capitalization, considered both in absolute terms and relative to peers. As a result of sustained decreases in our stock price and market capitalization, we conducted an impairment test of our goodwill and intangible assets as of May 31, 2022. As a result of this testing, we recorded a non-cash goodwill impairment charge of \$299.7 million during the first quarter of fiscal 2023. We cannot predict if or when additional future goodwill impairments may occur. Additional goodwill impairments could have material adverse effects on our operating income, net assets, or our cost of, or access to, capital, which could harm our business. See Note 5 to our consolidated financial statements for more details.

We may face intense competition, which could limit our ability to maintain or expand market share within our industry, and if we do not maintain or expand our market share our business and operating results will be harmed.

The market for our offerings is underpenetrated, competitive, and characterized by rapidly evolving technology standards, customer and member needs, and the frequent introduction of new products and services. Our competitors range from smaller niche companies to large, well-financed health plans. As costs fall and technology improves, increased market saturation may change the competitive landscape in favor of competitors with greater scale than we currently possess. We compete on the basis of several factors, including level of member engagement, ability to influence members to improve health and financial incomes, customer and member satisfaction, and price. Some of our competitors have greater name recognition, longer operating histories, and significantly greater resources than we do. As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements.

In addition to new niche vendors who offer stand-alone products and services, we also face competition from health plans, which may have existing systems in place at with customers in our target market. These competitors may now or in the future, offer or promise products or services similar to ours and which offer ease of integration with existing systems and which may leverage existing customer and vendor relationships.

In addition, current and potential competitors have established, and may in the future establish, cooperative relationships with vendors of complementary products, our trusted suppliers, Trusted Partner Ecosystem, or other third parties, technologies, or services to increase the availability of their products to the marketplace. For example, our current competitors may persuade our trusted Trusted Partner Ecosystem suppliers to terminate their relationship with us and engage exclusively with our competitors. Accordingly, new competitors or alliances may emerge that have greater market share, larger customer bases, more widely adopted proprietary technologies, greater marketing expertise, greater financial resources, and larger sales forces than we have, which could put us at a competitive disadvantage. Further, in light of these advantages, even if our offerings are more effective than the product or service offerings of our competitors, current or potential customers might accept competitive products and services in lieu of purchasing our solutions.

Our partners, including our trusted suppliers in our Trusted Partner Ecosystem, could become our competitors by offering similar services. Some of our partners may begin to offer services in the same or similar manner as we do. For example, a trusted supplier included in our Trusted Partner Ecosystem may expand their business model from a point solution into an engagement model similar to ours. Although there are many potential opportunities for, and applications of, these services, our partners may seek opportunities or target new customers in areas that may overlap with those that we have chosen to pursue. In such cases, we may potentially compete against our partners. Competition from our partners may adversely affect our business and results from operations. In addition, some of the terms of our partner relationships may include exclusivity or other restrictive clauses. Any agreements with partners that include exclusivity or other restrictive

provisions may limit our ability to partner with or provide services to potential customers or other third parties, which could harm our business.

We also compete on the basis of price. We may be subject to pricing pressures as a result of, among other things, competition within the industry, practices of managed care organizations, government action, and financial stress experienced by our customers. Many customers stage regular request for proposal processes as a matter of procurement policy, which enables competitors to bid aggressively to try to capture such customers' business, and such competitors may submit bids incorporating pricing or other terms that we are unable or unwilling to match. If our pricing experiences significant downward pressure, our business will be less profitable, and our results of operations will be adversely affected. We cannot be certain that we will be able to retain our current customers or expand our customer base in this competitive environment. If we do not retain current customers or expand our customer base, or if we have to renegotiate existing contracts, our business will be harmed.

Moreover, we expect that competition will continue to increase as a result of consolidation in both the healthcare information technology and healthcare industries. If one or more of our competitors or potential competitors were to merge or partner with another of our competitors or one of the suppliers in our trusted suppliers, Trusted Partner Ecosystem, the change in the competitive landscape could also adversely affect our ability to compete effectively and could harm our business. In addition, as the healthcare industry consolidates, competition to provide services to this segment will become more intense. These healthcare industry participants may try to use their market power to negotiate price reductions for our existing and future offerings. If we reduce our prices because of consolidation in the healthcare industry, our revenue would decrease, which could harm our business.

The growth of our business relies, in part, on the growth and success of our customers and the number of members with access to our offerings, which are difficult to predict and are affected by factors outside of our control.

We enter into agreements with our customers under which our fees are generally dependent upon the number of their employees enrolled in in-scope health plans and those employees' enrolled dependents each month. If the number of members covered by one or more of our customers' health and other benefits programs were to decline, such decrease would lead to a decrease in our revenue. Any reductions in headcount for our customers may result in a decrease in our revenue. Some of our fees are also subject to credits if certain performance criteria are not met, which in some cases depend on the behavior of our members, such as their continued engagement with our existing and future offerings, and other factors outside of our control. The recognition of a portion of our revenue is subject to achievement of performance metrics and healthcare cost savings and may not be representative of revenue for future periods. In addition, some of our customers' members may request to opt out of our service, which could cause our customers to only pay for those members that have not opted out, and as a result, may result in utilization-based pricing, which could lead to a decrease in revenue from that customer and harm our business.

We may be unable to successfully execute on our growth initiatives, business strategies, or operating plans.

We are continually executing on growth initiatives, strategies, and operating plans designed to enhance our business and extend our existing and future offerings to address evolving needs. For example, we developed add-on offerings that target specific challenges faced by our customers, including Accolade COVID Response Care, Accolade Boost, the Trusted Supplier Program, and Mental Health Integrated Care, Partner Ecosystem. The anticipated benefits from these efforts are based on several assumptions that may prove to be inaccurate. Moreover, we may not be able to successfully complete these growth initiatives, strategies, and operating plans and realize all of the benefits, including growth targets and cost savings, that we expect to achieve, or it may be more costly to do so than we anticipate. A variety of risks could cause us not to realize some or all of the expected benefits. These risks include, among others, delays in the anticipated timing of activities related to such growth initiatives, strategies, and operating plans, increased difficulty and cost in implementing these efforts, including difficulties in complying with new regulatory requirements, the incurrence of other unexpected costs associated with operating our business, and lack of acceptance by our customers. Moreover, our continued implementation of these programs may disrupt our operations and performance. As a result, we cannot assure you guarantee that we will realize these benefits. If, for any reason, the benefits we realize are less than our estimates or the implementation of these growth initiatives, strategies, and operating plans adversely affect our operations or cost more or take longer to effectuate than we expect, or if our assumptions prove inaccurate, our business may be harmed.

We have and may again in the future acquire other companies or technologies, which could divert our management's attention, result in dilution to our stockholders, and otherwise disrupt our operations, and we may have difficulty integrating any such acquisitions successfully or realizing the anticipated benefits therefrom, any of which could have an adverse effect on our business, financial condition, and results of operations.

We have and may again in the future seek to acquire or invest in businesses, applications, services, or technologies that we believe could complement or expand our existing and future offerings, enhance our technical capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. In addition, we have limited experience in acquiring other businesses and may have difficulty integrating acquired businesses. For example, in March 2021 we acquired 2nd.MD, in June 2021 we acquired PlushCare, and in September 2021 we acquired substantially all the assets of HealthReveal which we are in the process of integrating with our offerings. HealthReveal. If we acquire additional businesses, we may not be able to integrate the acquired operations and technologies successfully, or effectively manage the combined business following the acquisition. Integration may prove to be difficult due to the necessity of integrating personnel with disparate business backgrounds and who are accustomed to different corporate cultures.

We also may not achieve the anticipated benefits from any acquired business due to a number of factors, including:

- inability to integrate or benefit from acquired technologies or services in a profitable manner;
- unanticipated costs or liabilities, including legal liabilities, associated with the acquisition;
- difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;
- difficulty converting the customers of the acquired business into our current and future offerings and contract terms, including disparities in the revenue model of the acquired company;
- diversion of management's attention or resources from other business concerns;
- adverse effects on our existing business relationships with customers, members, or strategic partners as a result of the acquisition;
- the potential loss of key employees; and
- use of substantial portions of our available cash to consummate the acquisition.

We may issue equity securities or incur indebtedness to pay for any such acquisition or investment, which could adversely affect our business, results of operations, or financial condition. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share per-share value of our common stock to decline. In addition, a significant portion of the purchase price of any companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment annually and upon the identification of a triggering event, such as sustained declines in our stock price or market capitalization. In the future, if our acquisitions do not yield expected returns, we may be required to take incur charges to our results of operations based on this impairment assessment process, which could adversely affect our results of operations.

If we do not continue to innovate and provide offerings that are useful to customers and members that achieve and maintain market acceptance, we may not remain competitive, and our revenue and results of operations could suffer.

Our success depends on our ability to keep pace with technological developments, satisfy increasingly sophisticated customer and member requirements, and achieve and maintain market acceptance on our existing and future offerings in the rapidly evolving market for healthcare and benefits in the United States. In addition, market acceptance and adoption of our existing and future offerings depends depend on the acceptance by employers, payors, health plans, and government entities as to the distinct features, cost savings, and other perceived benefits of our existing and future offerings as compared to competitive solutions. Our competitors are constantly developing products and services that may become more efficient or appealing to our customers or members. As a result, we must continue to invest significant resources in research and development in order to enhance our existing offerings and introduce new offerings that customers and members will want, while offering our existing and future offerings at competitive prices. If we are unable to predict customer and member preferences or industry changes, or if we are unable to modify our existing and future offerings on a timely or cost-effective basis, we may lose customers. If we are not successful in demonstrating to existing and potential customers the benefits of our existing and future offerings, or if we are not able to achieve the support of employers, healthcare providers, and insurance carriers for our existing and future offerings, our revenue may decline or we may fail to increase our revenue in line with our forecasts. Our results of operations also would suffer if our innovations are not responsive to the needs of our customers and members, are not timed to match the corresponding market opportunity, or are not effectively brought to market, including as the result of delayed releases or releases that are ineffective or have errors or defects.

The growth of our business and future success relies in part on our partnerships and other relationships with third parties and our business could be harmed if we fail to maintain or expand these relationships.

We selectively form partnerships and engage with a range of numerous third parties, including brokers, agents, benefits consultants, carriers, third-party administrators, trusted suppliers in our Trusted Partner Ecosystem, and co-marketing and co-selling partners to grow our customer base and adoption of our offerings. We may fail to retain and expand these partnerships and other third-party relationships for various reasons, and any such failure could harm our relationship with our customers, our reputation and brand, our prospects, and our business.

In order to grow our business, we anticipate that we will continue to depend on our relationships with our partners. As we seek to form additional partnerships and other third-party relationships, it is uncertain whether these efforts will be successful, or that these relationships will result in increased customer or member use of our solutions or increased revenue. In the event that we are unable to effectively utilize, maintain, and expand these partnerships and other third-party relationships, our revenue growth could slow. Additionally, our partnerships and other third-party relationships may demand, or demand greater, referral fees or commissions.

If the estimates and assumptions we use to determine the size of our total addressable market are inaccurate, our future growth rate may be impacted and our business would be harmed.

Market estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may prove to be inaccurate. Even if the market in which we compete meets our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all. Our market opportunity is based on the assumption that our existing and future offerings will be more attractive to our customers and potential customers than competing solutions. If these assumptions prove inaccurate, our business, financial condition, and results of operations could be adversely affected.

We depend on our senior management team, and the loss of one or more of these employees, or an inability to attract and retain qualified key personnel, could adversely affect our business.

Our success depends, in part, on the skills, working relationships and continued services of Rajeev Singh (Chief Executive Officer), other senior management team members and other key personnel. We do not currently maintain key-person insurance on the lives of any of our key personnel. From time to time, there may be changes in our senior

management team resulting from the hiring or departure of executives, which could disrupt our business. The replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.

While we have entered into offer letters or employment agreements with certain of our executive officers, all of our employees are “at-will” employees, and their employment can be terminated by us or them at any time, for any reason and without notice, subject, in certain cases, to severance payment rights. In order to retain valuable employees, in addition to salary and cash incentives, we may provide equity awards that vest over time or based on performance. The value to employees of equity awards that vest over time or based on performance will be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract offers from other organizations. The departure of key personnel could adversely affect the conduct of our business. In such event, we would be required to hire other personnel to manage and operate our business, and there can be no assurance that we would be able to employ a suitable replacement for the departing individual, or that a replacement could be hired on terms that are favorable to us. In addition, volatility or lack of performance in our stock price may affect our ability to attract and retain replacements should key personnel depart. If we are not able to retain **any of** our key personnel, our business could be harmed.

If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.

We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with our existing customers and partners, including **suppliers in our trusted suppliers, Trusted Partner Ecosystem**, and to our ability to attract new customers and partners. The promotion of our brand may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly difficult and expensive. Brand promotion and marketing activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our results of operations could be harmed. In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of customers, members, and partners, and failure to maintain high-quality support, could harm our reputation and brand and make it substantially more difficult for us to attract new customers and **trusted Trusted Partner Ecosystem** suppliers or form new partnerships. Additionally, the performance of third parties with whom we have a relationship, including **suppliers in our trusted suppliers, Trusted Partner Ecosystem**, may also affect our brand and reputation, particularly if our customers and members do not have a positive experience with **suppliers in our trusted suppliers Trusted Partner Ecosystem** or other third parties. In addition, our sales process is highly dependent on the reputation of our offerings and business and on positive recommendations from our existing customers. If we do not successfully maintain and enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with existing and prospective customers, which would harm our business.

Any failure to offer high-quality customer and member support services could adversely affect our relationships with our customers and partners and our operating results.

Our customers and members depend on our support to assist members with their healthcare and other benefits needs. We may be unable to accurately predict our members' demand for services or respond quickly enough to accommodate short-term increases in customer or member demand for services. Increased customer or member demand for services, without a corresponding increase in productivity or revenue, could increase costs and adversely affect our operating results. Any failure to maintain high-quality support, or a market perception that we do not maintain high-quality support, could adversely affect our reputation, our ability to sell our solutions to existing and prospective customers, our relationships with third parties and our ability to form new partnerships, and our business and operating results.

If our existing customers do not continue to renew their contracts with us, renew at lower fee levels, decline to purchase additional offerings from us, or terminate their contracts for convenience, our business could be harmed.

We expect to derive a significant portion of our revenue from the renewal of existing customers' contracts and sales of additional solutions to existing customers. As part of our growth strategy, for instance, we have recently focused

26

on expanding our solutions among current customers. For example, with the acquisitions of 2nd.MD and PlushCare, we

26

introduced our expert medical opinion and virtual primary care offerings to our customers. In 2020, as the pandemic proliferated, we launched Accolade COVID Response Care, a service that helps employers manage their return to work programs. We also launched Mental Health Integrated Care, which expands our members' access to mental health coaching, virtual therapy, and virtual psychiatry and deeply integrates these services with the physical health support provided by the Accolade care team. Achieving a high customer retention rate and selling additional applications and solutions are critical to our future business, revenue growth, and results of operations. Factors that may affect our retention rate and our ability to sell additional applications and solutions include the following:

- the price, performance, and functionality of our existing and future offerings;
- the availability, price, performance, and functionality of competing solutions;
- our ability to develop and sell complementary applications and solutions;
- changes in healthcare laws, regulations, or trends; and
- the business environment of our customers.

We typically enter into contracts with our customers with a stated initial term of three years and various termination rights, which if invoked may cause such contracts to be terminated before the term expires. For example, after a specified period, certain of these contracts are terminable for convenience by our customers after a notice period has passed, including existing contracts with some of our largest customers. In connection with Macroeconomic factors including the COVID-19 pandemic, macroeconomic factors heightened inflation, recent and potential future bank failures, and geopolitical tension may affect our customers' desire to renew their contracts, or even if they do renew, if they undergo layoffs or reductions in force, then our membership numbers would decrease which would reduce our revenues. If any of our contracts with our customers is terminated, we may not be able to recover all fees due under the terminated contract, which may adversely affect our operating results. Should any of our customers terminate their relationship with us after implementation of our solutions has begun, we not only would lose our time, effort, and resources invested in that implementation, but also we would have lost the opportunity to leverage those resources to build a relationship with other customers over that same period of time. Our customers may negotiate terms less advantageous to us upon renewal, which may reduce our revenue from these customers and may decrease our annual revenue. Mergers and acquisitions involving our customers have in the past and may in the future lead to non-renewal or termination of our contracts with those customers or by the acquiring or combining companies. If our customers fail to renew their contracts, renew their contracts upon less favorable terms or at lower fee levels, or fail to purchase new solutions from us, our revenue may decline or our future revenue growth may be constrained.

The healthcare industry is rapidly evolving and the market for technology-enabled solutions that empower healthcare consumers is relatively immature and unproven. If we are not successful in promoting the benefits of our existing and future offerings, our growth may be limited.

The market for our solutions is subject to rapid and significant changes. The market for technology-enabled solutions that empower healthcare consumers is characterized by rapid technological change, new product and service introductions, increasing consumer financial responsibility, consumerism and engagement, and the entrance of non-traditional competitors. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of this market due in part to the rapidly evolving nature of the healthcare and technology industries and the substantial resources available to our existing and potential competitors. The market for technology-enabled solutions that empower healthcare consumers is relatively new and unproven, and it is uncertain whether this market will achieve and sustain high levels of demand and market adoption. In order to remain competitive, we are continually involved in a number of projects to compete with new market entrants by developing new offerings, growing our customer base, and expanding into adjacent markets. For example, with from the acquisitions of 2nd.MD and PlushCare, we are introducing introduced our expert medical opinion, virtual primary care, and mental health support offerings to our customers, including integrated offerings with our core navigation services referred to as Accolade One (an offering combining navigation, expert medical opinion services, and virtual primary care, and mental health support), and Accolade Care (an offering combining our virtual primary care and mental health support with elements of our navigation capabilities). Further, the Accolade Boost solution and our Trusted Supplier Program Partner Ecosystem are examples of add-on offerings we have deployed to

complement our traditional offerings and generate additional value to our customers. These projects carry risks, such as cost overruns, delays in

delivery, performance problems, and lack of acceptance by our customers. If we cannot adapt to rapidly evolving industry standards, technology, and increasingly sophisticated customers and their employees, our existing technology could become undesirable, obsolete, or harm our reputation.

We must continue to invest significant resources in our personnel and technology in a timely and cost-effective manner in order to enhance our existing offerings and introduce new offerings that existing customers and potential new customers will want. If our new or modified offerings are not responsive to the preferences of customers and their employees, emerging industry standards, or regulatory changes, are not appropriately timed with market opportunity, or are not effectively brought to market, we may lose existing customers or be unable to obtain new customers, and our results of operations may suffer.

Our success also depends, to a substantial extent, on the ability of our existing and future offerings to increase member engagement and our ability to demonstrate the value of our existing and future offerings to customers. If our existing customers do not recognize or acknowledge the benefits of our existing and future offerings or our offerings do not increase member engagement, then the market for our solutions might not develop at all, or it might develop more slowly than we expect, either of which could adversely affect our operating results. In addition, we have limited insight into trends that might develop and affect our business, which could lead to errors in our predicting and reacting to relevant business, legal, and regulatory trends and healthcare reform. If any of these events occur, it could harm our business.

Our marketing efforts for the direct-to-consumer virtual primary care portion of our business may not be successful or may become more expensive, either of which could increase our costs and adversely affect our business, financial condition, results of operations and cash flows.

With the acquisition of PlushCare, direct-to-consumer virtual primary care and mental health support represents a material portion of our overall business. We spend significant resources marketing this service. We rely on relationships for our direct-to-consumer virtual business with a wide variety of third parties, including Internet search providers such as Google, social networking platforms such as Facebook, Internet advertising networks, co-registration partners, retailers, distributors, television advertising agencies and direct marketers, to source new members and to promote or distribute our services and products. In addition, in connection with the launch of new services or products for our direct-to-consumer virtual primary care and mental health support business, we may spend a significant amount of resources on marketing. If our marketing activities are inefficient or unsuccessful, if important third-party relationships or marketing strategies, such as Internet search engine marketing and search engine optimization, become more expensive or unavailable, or are suspended, modified or terminated, for any reason, including, without limitation, resulting from a change in consumer sentiment, or laws, rules or regulations regarding the use of web advertising technologies such as cookies or other tracking technologies, if there is an increase in the proportion of consumers visiting our websites or purchasing our services by way of marketing channels with higher marketing costs as compared to channels that have lower or no associated marketing costs or if our marketing efforts do not result in our services being prominently ranked in Internet search listings, our business, financial condition, results of operations and cash flows could be materially and adversely impacted.

We have been and may in the future become subject to litigation, which could harm our business.

Our business entails the risk of liability claims against us, and we have been and may in the future become subject to litigation. Claims against us may be asserted by or on behalf of a variety of parties, including our customers, our members, vendors of our customers, government agencies, our current or former employees, or our stockholders. Litigation may result related to employer practices and healthcare in connection with the COVID-19 pandemic, including as to one or more of our service offerings. The expansion of Accolade's services to include expert consultations and primary care services, via the acquisition of 2nd.MD and PlushCare, also may increase our risk of litigation related to such services. Some of these claims may result in significant defense costs and potentially significant judgments against us, some of which are not, or cannot be, covered by adequate insurance. Although we carry professional liability insurance in amounts that we believe are appropriate in light of the risks attendant to our business, but successful claims could result in substantial damage awards that exceed the limits of our insurance coverage. In addition, any determination that certain non-medical services are acting in the capacity of a healthcare provider, or exercising

undue influence or control over a healthcare provider, may subject us to claims not covered by our professional liability

insurance coverage, or could result in significant sanctions against us and our clinicians, additional compliance requirements, expense, and liability to us. If our medical care services are found to cause harm to an individual or otherwise constitute malpractice, we may be subject to claims exceeding our coverage limits and cause reputational harm. If we make errors in the billing and the coding for such services, we may be subject to claims exceeding our coverage limits and cause reputational harm. In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as we expand our solutions. As a result, adequate professional liability insurance may not be available to us or to our partners in the future at acceptable costs or at all. We **generally intend to defend ourselves vigorously; however, we** cannot be certain of the ultimate outcomes of any claims that may arise in the future. Resolution of some of these types of matters against us may result in our having to pay significant fines, judgments, or settlements, which, if uninsured, or if the fines, judgments, and settlements exceed insured levels, could adversely impact our earnings and cash flows, thereby harming our business and per share trading price of our common stock. For example, fines or assessments could be levied against us under domestic or foreign data privacy laws (such as **HIPAA**, the **Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act** (collectively, **HIPAA**), the **General Data Protection Regulation (GDPR)**, **GDPR**, or the **California Consumer Privacy Act of 2018 (CCPA)** **CCPA**) or under authority of privacy enforcing governmental entities (such as the **Federal Trade Commission (FTC)**, **FTC**, or the U.S. Department of Health and Human Services (HHS)) or as a result of private actions, such as class actions based on data breaches or based on private rights of action (such as that contained in the CCPA). Certain litigation or the resolution of certain litigation may affect the availability or cost of some of our insurance coverage, which could adversely impact our results of operations and cash flows, expose us to increased risks that would be uninsured and adversely impact our ability to attract directors and officers. In addition, such litigation could result in increased scrutiny by government authorities having authority over our business, such as the FTC, the HHS, Office for Civil Rights (OCR), and state attorneys general.

If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.

In the ordinary course of our business, we may collect, store, use, and disclose or otherwise process (collectively, process) proprietary, confidential, and sensitive information, including personal data (such as health-related data), intellectual property, and trade secrets. We manage and maintain our technology platform and data utilizing a combination of on-site systems, mobile applications, managed data center systems, and cloud-based computing center systems. We are highly dependent on information technology networks, mobile applications, and systems, including the Internet, to securely process, transmit, and store this critical information. We utilize third-party service providers, including business associates as defined under HIPAA, for important aspects of the collection, storage, and transmission of customer and member information, and other confidential and sensitive information, and therefore rely on third parties to manage functions that have material cybersecurity risks. Our technology platform also utilizes artificial intelligence (AI) and machine learning (ML) technology to provide services, and **despite our defense in depth security**, this technology may be susceptible to cybersecurity threats, as PHI, PII, and other confidential and sensitive information may be integrated into the platform. Because of the sensitivity of the PHI, other PII, and other confidential information we and our service providers **collect, store, transmit, and otherwise process**, the security of our technology platform and other aspects of our solutions, including those provided or facilitated by our third-party service providers, are important to our operations and business strategy. While we use various information security techniques and tools **designed** to secure our platforms, and require our third party service providers to adhere to substantially similar standards, our ability to monitor these third parties' cybersecurity practices is limited, and these third parties may not have adequate information security measures in place.

Cyberattacks, malicious **internet-based Internet-based** activity, and online and offline fraud, **are prevalent and continue to increase**, similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology

systems, and those of the third parties upon which we rely. These threats are becoming prevalent, continue to increase, and are increasingly difficult to detect. These threats come from a variety of sources, including traditional computer “hackers,” threat actors, “hacktivists,” organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as computer viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of: denial-of-service attacks

service attacks (such (such as credential stuffing), employee or contractor credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, system disruptions, shutdowns, or unauthorized disclosure or modifications of confidential information, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, and other similar threats.

Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems (including our services) or the third-party information technology systems that support us and our services. The COVID-19 pandemic and our remote Our hybrid workforce poses increased risks to our information technology systems and data, as more many of our employees work from home utilizing on at least a partial schedule and utilize network connections, computers, and devices outside our premises. premises or network, while at home, in transit, or in public locations. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.

Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to data. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services.

We may expend significant resources or modify our business activities in an effort to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry standards or reasonable security measures to protect our information technology systems and data. We take certain administrative, physical, and technological safeguards to address these risks, such as by requiring outsourcing subcontractors and partners, including trusted suppliers in our Trusted Partner Ecosystem, who handle customer and member information for us to enter into agreements that contractually obligate those subcontractors and partners to comply with applicable privacy laws, such as HIPAA, and otherwise use reasonable efforts to safeguard PHI, other PII, and other sensitive information. For those subcontractors and partners who handle PHI on our behalf, we enter into business associate agreements as required by HIPAA. Measures taken to protect our systems, those of our subcontractors and partners, or the PHI, other PII, or other sensitive information we, our subcontractors, or our partners process or maintain, may not adequately protect us from the risks associated with the collection, storage, and transmission of such information.

Although There can be no assurance that the security measures we have implemented security measures designed to protect against security incidents and help protect confidential and other sensitive information (including PHI and PII), there can be no assurance that these measures will be effective. We may be unable to detect vulnerabilities in our information technology systems or remediate them in a timely manner or without adversely impacting or interrupting our operations. Such vulnerabilities could be exploited because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. These vulnerabilities may pose material risks to our business. Further, we may experience delays in developing and deploying remedial measures

designed to address any such identified vulnerabilities. In addition, security incidents and other inappropriate access to, or acquisition or processing of, information can be difficult to detect or may occur outside of our network (such as in our supply chain or at our customers or trusted suppliers) suppliers in our Trusted Partner Ecosystem), and any delay in identifying or responding to such incidents or in providing any notification of such incidents may lead to increased harm. Any such breach or interruption of our systems, or the systems of any of our third-party information technology partners, could compromise our networks or data security processes and sensitive information could be inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost, or stolen. Any such interruption in access, improper access, disclosure, or other loss of information could result in legal claims or

30

proceedings, liability under laws and regulations that protect the privacy govern protections of member information or other personal data, information. Despite our efforts to identify and address vulnerabilities if any, in our information technology systems (including our products), our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.

Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to

30

adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; harm to our reputation; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business.

Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. Although we We maintain insurance covering certain security and privacy damages and claim expenses, we but may not carry insurance or maintain coverage sufficient to compensate for all liability and, in any event, insurance coverage would not address the reputational damage that could result from a security incident. We cannot be sure that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. Additionally, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.

If we fail to provide accurate and timely information, or if our personnel, including Accolade Health Assistants and clinicians, our content, or any other element of our existing and future offerings is associated with faulty administrative or clinical decisions or treatment, we could have liability to customers or members, which could adversely affect our results of operations.

Our Accolade Health Assistants and clinicians, our member web portal, and our mobile application all use our technology platform to support our members in making healthcare and benefits-related decisions. In addition, our Accolade Health Assistants and clinicians use our technology platform to help guide interactions with members. Our technology platform applies artificial intelligence AI and machine learning ML tactics to generate predictive insights about our members, which are then translated into recommended interventions for our Accolade Health Assistants and clinicians and used to enhance our member self-service capabilities. Our services, including personalized recommendations and interventions, center around engagement with our members to provide members with better understanding of their benefits, assist with access to care, and provide options for choosing quality providers and care. For example, our Accolade Health Assistants can leverage our technology platform to provide quotes to a member about that member's healthcare benefits, including in-network services,

balance billing, or claims quotes. If we fail to provide accurate and timely information regarding these benefits or if the data generated by our technology platform (including the artificial intelligence and machine learning components) are inaccurate, fail, or are subject to security incidents, this could lead to claims against us that could result in substantial costs to us or cause demand for our solutions to decline. If our Accolade Health Assistants, clinicians, or technology platform guide people to care settings and providers resulting in faulty clinical decisions or treatment, then our customers or our members could assert claims against us that could result in substantial costs to us, harm our reputation in the industry, and cause demand for our existing and future offerings to decline. For example, our nurses have access to extensive intelligence on provider quality and cost, which allows them to present various options to members when they are selecting a primary care physician or specialist. If the member relies on this provider recommendation, and that provider subsequently makes faulty clinical decisions or treatment recommendations, we could be subject to claims by such member. In addition, if our Accolade Health Assistants or clinicians make recommendations outside of our standard protocol that result in faulty clinical decisions or treatments, then our customers or our members could assert claims against us.

31

In May 2020, we announced Accolade COVID Response Care to provide a comprehensive solution for current and ongoing needs of our customers as they reopen and rebuild their businesses. We may be subject to increased liability exposure from our customers or their members as we assist our customers in managing our customers' return to workplace programs, including programs related to diagnostic and antibody testing. Accordingly, there is the potential for increased liability exposure to Accolade, including as related to an employer's decision not to permit an employee to return to the workplace based on our service or if one of our customers has an outbreak of COVID-19 despite using our solution to plan their reopening.

31

The assertion of such claims and ensuing litigation, regardless of its outcome, could result in substantial cost to us, divert management's attention from operations, damage our reputation, and decrease market acceptance of our existing and future offerings. We maintain general liability and professional liability insurance coverage, but this coverage may not continue to be available on acceptable terms, may not be available in sufficient amounts to cover one or more large claims against us, or may not provide coverage if our Accolade Health Assistants or clinicians were to engage in the unlicensed practice of medicine. In addition, the insurer might disclaim coverage as to any future claim. One or more large claims could exceed our available insurance coverage. Adequate professional liability insurance may not be available to our clinicians or to us in the future at acceptable costs or at all. Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us, and divert the attention of our management and our providers from our operations, which may harm our business. In addition, any claims may adversely affect our business or reputation.

Our technology platform may contain errors or failures that are not detected until after the software is introduced or updates and new versions are released. From time to time, we have discovered defects or errors in our software, and such defects or errors can be expected to appear in the future. Defects and errors that are not timely detected and remedied could expose us to risk of liability to customers and members and cause delays in introduction of new solutions, result in increased costs and diversion of development resources, require design modifications, or decrease market acceptance or customer satisfaction with our solutions. If any of these risks occur, they could harm our business.

In March 2021, we acquired 2nd.MD, which provides a service that allows members to access board-certified national specialists across the country for second opinion consultations in a real-time video call or by phone in order to provide the member with a rapid second opinion on their medical condition enabling the member to better understand a diagnosis and treatment options to help them make more informed decisions on their healthcare regarding significant and high-cost care decisions. While we believe that these specialists do not create a physician-patient relationship with the member and are not practicing medicine in these engagements, if the information provided is not accurate or timely, we could incur liability, which could adversely affect our operations.

In June 2021, we acquired PlushCare, which acts as a managed service provider to several medical practices, including PlushCare of California, Inc. (PlushCare of California), that provide virtual primary care and mental health support to individuals. The physicians employed

by or contracted with PlushCare of California or other PlushCare associated medical practices could misdiagnose or treat a patient, and/or the services and technology provided by PlushCare to the medical practices could malfunction, which could cause us to incur liability, which could adversely affect our operations.

We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties, and our own systems for providing solutions to our customers, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with customers, adversely affecting our brand and our business.

Our ability to deliver our solutions is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. We currently host our technology platform, serve our customers and members, and support our operations primarily using third-party data centers and telecommunications solutions, including cloud infrastructure services such as Amazon Web Services (AWS) and Google Cloud. We also use a third-party call center for off-hours clinical support. We do not have control over the operations of the facilities of our data and call center providers, AWS, or Google Cloud. These facilities are vulnerable to damage or interruption from earthquakes, hurricanes, floods, fires, cyber security attacks, terrorist attacks, power losses, telecommunications failures, and similar events. The occurrence of a natural disaster or an act of terrorism, a decision to close the facilities without adequate notice, or other unanticipated problems could result in lengthy interruptions in our solution. The facilities also could be subject to break-ins, computer viruses, sabotage, intentional acts of vandalism, and other misconduct. Any errors, failures, interruptions, or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with customers and adversely affect our business and could expose us to third-party liabilities.

32

For some of these services, we may not maintain redundant systems or facilities. Our technology platform's continuing and uninterrupted performance is critical to our success. Members may become dissatisfied by any system failure that interrupts our ability to provide our solutions to them. We may not be able to easily switch our AWS and Google Cloud operations to another cloud service provider if there are disruptions or interference with our use of AWS or Google Cloud. Sustained or repeated system failures would reduce the attractiveness of our technology platform to customers and members and result in contract terminations, thereby reducing revenue. Moreover, negative publicity arising from these types of disruptions could damage our reputation and may adversely impact use of our existing and future offerings. We may not carry sufficient business interruption insurance to compensate us for losses that may occur as a result of any events that cause interruptions in our service. Neither our third-party data and call center providers nor AWS or Google Cloud have an obligation to renew their agreements with us on commercially reasonable terms, or at all. If we are unable to renew our agreements with these providers on commercially reasonable terms, if our agreements with our providers are prematurely terminated, or if in the future we add additional data or call center providers or cloud service providers, we may experience costs or downtime in connection with the transfer to, or the addition of, new providers. If these providers were to increase the cost of their services, we may have to increase the price of our existing and future offerings, and our business may be harmed.

The evolving effects of the COVID-19 pandemic and associated global economic instability may have adverse effects on our operations and negatively impact our business, financial condition, and results of operations.

Our business, financial condition, and results of operations could be materially and adversely affected by the effects of a widespread outbreak of a contagious disease, including the COVID-19 pandemic. The COVID-19 pandemic continues to affect various industries, the financial markets globally, which may lead to a further economic downturn and increased market volatility, as well as renewed orders to shelter in place, travel restrictions, and mandated business closures. It has also disrupted the normal operations of many businesses, including ours, and has continued for significantly longer than originally expected, resulting in greater potential impacts on the economy and our business. We have taken measures in response to the COVID-19 pandemic, including permitting employees to work from home, at least in part. If there are resurgences of the COVID-19 pandemic, including, for example, due to existing or new variants, we may experience increased demand on our Accolade Health Assistants and clinical specialists if our members are impacted by a contagious disease in large numbers. This increased demand could result in our failing to meet certain performance metrics set forth in contracts with our customers. Collectively or alone, these conditions could cause (1) increased absenteeism among our workforce (including resulting from sick time or increased use of Family Medical Leave Act and other leave) that could negatively affect our ability to provide our service despite our deployment of business continuity and disaster recovery plans enabling our workforce to work fully remotely from our offices, and/or (2) our customers or prospective customers decreasing headcount, benefits, or budgets, which could decrease corporate spending on our products and services, resulting in delayed sales cycles, a decrease in new customer acquisition, and/or loss of customers. Any layoffs or reductions in employee

headcounts by our employer customers would result in a reduction in our base and variable PMPM fees. If our existing customers do not continue to renew their contracts with us, renew at lower fee levels, decline to purchase additional offerings from us, or terminate their contracts for convenience, our business could be harmed. While these risks may be offset by the value that Accolade can provide to customers and members during a health crisis, the impact on our business is still highly uncertain.

In addition, as we and other businesses consider the return of certain of our employees to our offices, the continued impact of the pandemic may increase employee concern about returning to work, which could lead to increased employee churn, dissatisfaction with our workplace, and potential litigation related to return to office mandates.

The effects of the COVID-19 pandemic continue to rapidly evolve. These effects have increased market volatility and could result in a significant long-term disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, economic instability resulting from the effects of the COVID-19 pandemic could materially affect our business and the value of our common stock.

33

Risks Related to Governmental Regulation

Changes in the health insurance market, ERISA laws, state insurance laws, or other laws could harm our business.

The market for private health insurance in the United States is evolving and, as our customers are primarily employers that deploy our offerings to employees and their families, our future financial performance will depend in part on the growth in this market. Changes and developments in the health insurance system in the United States could reduce demand for our existing and future offerings and harm our business. For example, there has been an ongoing national debate relating to the healthcare reimbursement system in the United States. Some elected officials have introduced proposals that would create a new single payor national health insurance program for all United States residents; others have proposed more incremental approaches, such as creating a new public health insurance plan option as a supplement to private sources of coverage. In the event that laws, regulations or rules that eliminate or reduce private sources of health insurance or require such benefits to be taxable are adopted, the subsequent impact on the workplace benefits provided by our customers may in turn have an adverse effect on our business and results of operations.

In addition, changes in laws or regulations regarding the Employee Retirement Income Security Act of 1974 (ERISA), changes in state insurance laws, or other changes in laws could materially impact the self-insured employer healthcare and benefits markets, or the markets in which our other existing or potential customers procure and provide benefits.

If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business could be harmed.

Our existing and future offerings, as well as our business activities, including our relationships with our commercial partners and customers, are or may be in the future subject to a complex set of regulations and rigorous enforcement, including by the HHS, Office of the Inspector General and Office of Civil Rights, U.S. Food and Drug Administration (FDA), U.S. Department of Justice, and numerous other federal and state governmental authorities. There is also rapidly has been and may continue to be changing COVID-19 guidance from the Centers for Disease Control and Prevention (CDC), state health organizations, the U.S. Equal Employment Opportunity Commission, the Department of Labor, the Occupational Safety and Health Administration, and others, especially as it relates to our new offering, Accolade COVID Response Care. In addition, our employees, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. Certain aspects of our

33

business model may also trigger scrutiny under healthcare and related laws. Federal and state healthcare and related laws and regulations that may now or in the future affect our ability to conduct business include:

□ laws that regulate how businesses operate online, including measures relating to privacy and data security and how such information is communicated to customers (a) under the FTC's unfair and deceptive trade practice authority from the FTC Act, and the FTC breach notification rule, (b) under the OCR's investigative powers regulating HIPAA, and (c) from state attorneys general under state consumer protection laws and data privacy laws; laws, including, without limitation, changes in laws, rules, and regulations related to the use of cookies and tracking technologies on the internet;

□ federal and state laws governing (i) the corporate practice of medicine and other healthcare professions and related fee-splitting laws, including the provision of management or administrative services in connection with practice of medicine and other health care professions, employment of professionals by non-professionals; (ii) professional licensing and standards of professional conduct; (iii) the provision of telemedicine, telehealth or other health care services, including medical record retention requirements; and (iv) the billing, submission, or collection of claims or payments for healthcare services;

□ the federal Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Centers for Medicare and Medicaid Services (CMS) programs, including Medicare and Medicaid;

34

□ the federal civil false claims laws, including the federal False Claims Act, and federal Civil Monetary Penalties Law, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government;

□ federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

□ the federal Physician Payments Sunshine Act, or Open Payments, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the Affordable Care Act), and its implementing regulations, which requires certain manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (e.g. physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and

□ state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

In addition, we are subject to laws that regulate how businesses operate online, including measures relating to privacy and data security and how such information is communicated to customers (a) under the FTC's unfair and deceptive trade practices authority from the FTC Act and (b) from state attorneys general under state consumer protection laws and data privacy laws.

The Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act.

Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our activities could be subject to challenge under one or more of such laws. For example, there is a risk that regulatory authorities in some states may find that certain of our contractual relationships with healthcare providers are in violation of state anti-kickback, corporate practice of health care professions, or fee-splitting laws. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to

34

incur significant legal expenses and divert our management's attention from the operation of our business. We may be subject to private "qui tam" actions brought by individual whistleblowers on behalf of the federal or state governments, with potential liability under the federal False Claims Act including mandatory treble damages and significant per-claim penalties.

Although we have adopted policies and procedures designed to comply with these laws and regulations and conduct internal reviews of our compliance with these laws, our compliance is also subject to governmental review. The growth of our business and sales organization may increase the potential of violating these laws or our internal policies and procedures. The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant criminal, civil and administrative penalties, damages and fines, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, imprisonment for individuals and exclusion from participation in government programs, such as Medicare and Medicaid, as well as contractual damages

and reputational harm. We could also be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.

In our virtual care business, we are dependent on our relationships with affiliated professional entities, which we do not own, to provide physician services, and our business would be adversely affected if those relationships were disrupted or if our arrangements with our providers or our members are found to violate state laws prohibiting the corporate practice of medicine or fee splitting.

The laws of many states, including states in which our members are located, prohibit us from exercising control over the medical judgments or decisions of physicians and from engaging in certain financial arrangements, such as splitting professional fees with physicians. These laws and their interpretations vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion, and are subject to change and to evolving interpretations by state boards of medicine and state attorneys general, among others. We enter into agreements with professional associations, PlushCare of California, Inc. (a California professional corporation) and others, which enter into contracts with our providers pursuant to which they render professional medical services. In addition, we enter into contracts with our members to deliver professional services in exchange for fees. These contracts include management services agreements with our affiliated physician organizations pursuant to which the physician organizations reserve exclusive control and responsibility for all aspects of the practice of medicine and the delivery of medical services. Although we seek to substantially comply with applicable state prohibitions on the corporate practice of medicine and fee splitting, changes in, or subsequent interpretations of, the corporate practice of medicine laws could circumscribe our business operations, and state officials who administer these laws or other third parties may successfully challenge our existing organization and contractual arrangements. If such a claim were successful, we could be subject to civil and criminal penalties and could be required to restructure or terminate the applicable contractual arrangements. A determination that these arrangements violate state statutes, or our inability to successfully restructure our relationships with our providers to comply with these statutes, could eliminate our ability to acquire members located in certain states from the market for our services, which would have a materially adverse effect on our business, financial condition and results of operations. State corporate practice of medicine doctrines also often impose penalties on physician themselves for aiding the corporate practice of medicine, which could discourage physicians from participating in our network of providers.

We do not own PlushCare of California, Inc. (a California professional corporation) or other medical groups with which we contract. These medical groups are 100% physician owned and independent. The professional corporations with which we contract are owned by Dr. James Wantuck, one of our providers, and the professional corporations are owned by physicians licensed in their respective states. While we expect that these relationships will continue, we cannot guarantee that they will. A material change in our relationship with the medical groups that support our virtual care services, whether resulting from a dispute among the entities, a change in government regulation, or the

loss of these affiliations, could impair our ability to provide services to our members and could have a material adverse effect on our business, financial condition and results of operations. In addition, the arrangement in which we have entered to comply with state corporate practice of medicine doctrines could subject us to additional scrutiny by federal and state regulatory bodies regarding federal and state fraud and abuse laws. Any scrutiny, investigation, or litigation with regard to such arrangements with the medical groups could have a material adverse effect on our business, financial condition and results of operations.

We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.

In the ordinary course of business, we process personal data and other sensitive information, including proprietary and confidential business information, trade secrets, intellectual property, sensitive third-party information, primary member demographic information (e.g. name, address, date of birth, etc.), personal data, benefit plan eligibility information, and health information (including medical claims and other health records). Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external

and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and third parties who may process data on our behalf.

In the United States, state, federal, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. Laws (e.g. Section 5 of the Federal Trade Commission Act, and state consumer protection laws regulating unfair or deceptive trade practices) and other applicable laws (e.g., wiretapping laws). These laws and regulations include HIPAA, which establishes a set of national privacy and security standards for the protection of PHI by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and individuals and entities that perform services for them which involve the use, or disclosure of, individually identifiable health information, known as business associates and their subcontractors. As a healthcare technology company, we are considered a business associate under HIPAA, and with the acquisition of PlushCare, our associated medical practices are considered HIPAA covered entities. As such, we execute business associate agreements with our customers, subcontractors, and trusted suppliers. Suppliers in our Trusted Partner Ecosystem. HIPAA requires covered entities and business associates, such as us, and their covered subcontractors to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information.

Some of our business activities require that we or our partners obtain permissions consistent with HIPAA to provide certain marketing and data aggregation services as well as those activities that require the creation and use of de-identified information. Similarly, our new offering, Accolade COVID Response Care requires us to obtain express authorizations from members, which may result in an increased risk of compliance with such authorizations. We may also require large sets of de-identified information to enable us to continue to develop and enhance our data and analytics platform. If we or our partners are unable to secure these rights, or if there is a future change in law, we may face limitations on the use of PHI and our ability to provide marketing services and use de-identified information, which could harm our business or subject us to potential government actions or penalties. Also, there are ongoing public policy discussions regarding whether the standards for de-identified, anonymous or pseudonomized health information are sufficient, and the risk of re-identification sufficiently small, to adequately protect patient privacy. These discussions may lead to further restrictions on the use of such information or create additional regulatory burdens. There can be no assurance that these initiatives or future initiatives will not adversely affect our ability to access and use data or to develop or market current or future services.

Additionally, through our third-party telehealth partners, we provide COVID-19 testing services to consumers on behalf of certain of our employer customers. Such testing services and the related contract tracing activities related to such testing may be subject to the

aforementioned laws, including HIPAA.

In addition, we could be subject to periodic audits for compliance with the HIPAA Privacy and Security Standards by HHS and our customers. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims. HIPAA imposes mandatory penalties for certain violations and a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys' fees

36

related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.

In addition to HIPAA, the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (CAN-SPAM) CAN-SPAM and the Telephone Consumer Protection Act (TCPA) imposes TCPA impose specific requirements on communications with customers. For example, the TCPA imposes various consumer consent requirements and other restrictions on certain telemarketing activity and other communications with consumers by phone, fax, or text message. TCPA violations can result in significant financial penalties, including penalties or criminal fines imposed by the Federal Communications Commission (FCC) or fines of up to \$1,500 per violation imposed through private litigation or by state authorities. Furthermore, the California Consumer Privacy Act CCPA applies to personal information of 2018 (CCPA) imposes obligations on consumers, business representatives, and employees, and requires businesses to which it applies. These obligations include, but are not limited to, providing provide specific disclosures in privacy notices and affording honor requests from California residents to exercise certain rights related to their personal data. privacy rights. The CCPA allows provides for statutory fines for noncompliance (up civil penalties of up to \$7,500 per violation), violation and allows private litigants affected by certain data breaches to recover significant statutory damages. In addition, it is anticipated that the California Privacy Rights Act of 2020 (CPRA), CPRA, effective January 1, 2023, will expand expands the CCPA. For example, the CPRA establishes CCPA by adding a new right for individuals to correct their personal information and establishing a new California Privacy

37

Protection Agency to implement and enforce the CPRA, which could increase the risk of an enforcement action. CPRA. Other states have enacted data privacy laws. For example, laws, including Virginia, passed the Consumer Data Protection Act, Colorado, passed the Colorado Privacy Act, Utah, and Utah passed the Consumer Privacy Act, Connecticut, all of which become effective in 2023. Additionally, several states and localities have enacted measures related to the use of artificial intelligence AI and machine learning ML in products and services. In addition, Additional data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts.

Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, In Canada, the European Union's General Data Personal Information Protection Regulation (EU GDPR) and Electronic Documents Act (PIPEDA) and various related provincial laws, as well as Canada's Anti-Spam Legislation (CASL), may apply to our operations. Additionally, the EU GDPR and the United Kingdom's UK GDPR (UK GDPR) impose strict requirements for processing the personal data of individuals. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. Further, individuals, classes of data subjects or consumer protection organizations authorized at law to represent their interests may initiate private litigation related to our processing of their personal data. Furthermore, in Europe, there is a proposed regulation related to artificial intelligence (AI) AI and ML that, if adopted, could impose onerous obligations related to the use of AI-related systems. We may have to change our business practices to comply with such obligations. In addition to data privacy and security laws, we may be contractually subject to data privacy and security obligations, including industry standards adopted by industry groups and may become subject to new data privacy and security obligations in the future. For example,

certain Certain privacy laws, such as the GDPR and the CCPA, also require our customers to impose specific contractual restrictions on their service providers.

These Additionally, regulators are increasingly scrutinizing companies that process children's data. Numerous laws, regulations, and legally-binding codes, such as the Children's Online Privacy Protection Act (COPPA), California's Age Appropriate Design Code (effective July 2024), the CCPA and CPRA, other U.S. state comprehensive privacy laws, the EU and UK GDPR, and the UK Age Appropriate Design Code, impose various obligations on companies that process children's data, including by requiring certain consents to process such data and extending certain rights to children and their parents with respect to that data. Some of these obligations have wide ranging applications, including for services that do not intentionally target child users (defined in some circumstances as a user under the age of 18 years old). Additionally, under various privacy laws and regulations other obligations, we may also require additional compliance obligations relating be required to obtain certain consents to process personal data. Our inability or failure to do so could result in adverse consequences.

In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the transfer of data between Accolade and its subsidiaries. For example, absent appropriate safeguards United States or other circumstances, the EU GDPR generally restricts countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to countries outside of other countries. In particular, the European Economic Area (EEA), such as the United States, which the European Commission does not consider to provide an adequate level of data privacy and security. The European Commission released a set of "Standard Contractual Clauses" (SCCs) that are designed to be a valid mechanism by which entities can transfer personal data out of the EEA to jurisdictions that the European Commission has not found to provide an adequate level of protection. Currently, these SCCs are a valid mechanism to transfer personal data outside of the EEA but there exists some uncertainty regarding whether the SCCs will remain a valid mechanism. Additionally, the SCCs impose additional compliance burdens, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. In addition, Switzerland and the UK similarly restrict personal data transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection, and certain countries outside Europe (e.g. China) have also passed or are considering laws requiring local data residency or otherwise impeding significantly restricted the transfer of personal data across borders, any to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of which could increase the cost their data localization and complexity of doing business.

If we cannot implement a valid compliance mechanism for cross-border data transfers, transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK's standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.

If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we may face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against processing or transferring personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe or other foreign jurisdictions, for allegedly violating the GDPR's cross-border data transfer limitations. Inability to transfer personal data from the European Union, EEA, Switzerland or United Kingdom UK to the United States or elsewhere, may restrict our activities in those jurisdictions and limit our ability to provide our products and services in those jurisdictions. Our response to these requirements globally may not meet the expectations of individual customers, affected data subjects, or other stakeholders, which could reduce the demand for our services. Some customers or other service providers may respond to these evolving laws and regulations by asking us to make certain privacy or data-related contractual commitments that we are unable or unwilling to make. This could lead to the loss of current or prospective customers or other business relationships.

Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. This complex, dynamic legal landscape regarding data privacy and security creates significant compliance issues for us and our customers and potentially exposes us to additional expense, adverse publicity and liability. Additionally, these obligations may be subject to

differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model.

38

Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to operate our business and proceedings against us by governmental entities or others. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. While we are unaware of regulatory audits, investigations, or actions relating to our privacy practices, various entities in the healthcare technology industry, including the PlushCare medical practices, have received and responded to a "compliance review" from the U.S. Department of Health and Human Services, Office for Civil Rights (OCR) related to the usage of digital website trackers, such as Meta's Pixel. The compliance review is focused on whether the use of such trackers collects and discloses protected health information for visitors to a healthcare-related website to third parties, such as Meta and Google.

In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. For example, if we are subject to the Payment Card Industry Data Security Standard (PCI DSS) the PCI DSS requires companies to adopt certain measures to ensure the security of cardholder information, including using and maintaining firewalls, adopting proper password protections for certain devices and software, and restricting data access. Noncompliance with PCI DSS can result in penalties ranging from \$5,000 to \$100,000 per month by credit card companies, litigation, damage to our reputation, and revenue losses. We also rely on vendors to process payment card data, who may be subject to PCI DSS, and our business may be negatively affected if our vendors are fined or suffer other consequences as a result of PCI DSS noncompliance. We also publish statements to our customers and members that describe how we handle and protect PHI and personal data (for example, through our privacy policies connected with our website, mobile applications and other digital tools). If federal or state regulatory authorities, such as the FTC or state attorneys general, or private litigants consider any portion of

38

these statements to be untrue, deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to claims of deceptive practices, which could lead to significant liabilities and consequences, including costs of responding to investigations, defending against litigation, settling claims, and complying with regulatory or court orders.

Any of the foregoing consequences could have a material adverse effect on our reputation, business and our financial condition, including but not limited to: interruptions or stoppages in our business operations; interruptions or stoppages of data collection needed to train our algorithms; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. Furthermore, the costs of compliance with, and other burdens imposed by, the laws, regulations and policies that are applicable to the businesses of our customers may limit the use and adoption of, and reduce the overall demand for, our existing and future offerings. Any of the foregoing consequences could harm our business.

Our employment and use of nurses, physician medical directors and our other clinicians and our engagement of physicians may subject us to licensing and other regulatory risks.

Our employment and use of nurses, physician medical directors, and our other clinicians and our engagement of physicians may subject us to state and other licensing and regulatory risks. In addition, our subcontracts with clinicians to provide telehealth services related to COVID-19 testing may also subject us to certain licensing and regulatory risks. For example, there may be restrictions on the ability of our employed and contracted clinicians to provide services to our members residing in states outside of the state or states in which such clinicians are licensed or registered. The services provided by our clinicians may be subject to review by state or other regulatory bodies. In addition, any activities conducted by our clinicians that are in violation of practice rules could subject us to fines or other penalties. While we do not believe that we provide medical care or establish patient relationships with our members, our clinicians could be found to be in violation of applicable laws. Further, in March 2021, we acquired 2nd.MD, which provides a service that allows members to access board-certified national specialists across the country for second opinion consultations in a real-time video call or by phone. This provides the member with a rapid second opinion on their medical condition, enabling the member to better understand a diagnosis and treatment options, which helps them make more informed decisions on their healthcare regarding significant and high-cost care decisions. While we believe that these experts do not create a physician-patient relationship with the member and are not practicing medicine, but state medical boards may disagree with our position, which could result in significant liability and may require the restructuring of such operations. As a result of our acquisition of PlushCare, in June 2021, our associated medical practices employ and engage clinicians as permitted under state law, and maintain physician-patient relationships with members. Further, if one of our clinicians is found to be acting outside the scope of their professional license or otherwise violated the applicable state's practice laws, such activity could result in disciplinary action against the clinician by the applicable licensing agency. The definition of what constitutes the practice of medicine, nursing or other health professions varies by state.

In addition, there is a risk that we may be found in violation of the prohibition of the corporate practice of a health profession under certain state laws, which may result in the imposition of civil or criminal penalties. Certain states

39

prevent corporations from being licensed as practitioners and prohibit physicians from practicing medicine in partnership with non-physicians, such as business corporations. Activities other than those directly related to the delivery of healthcare may be considered an element of the practice of medicine in certain states. These laws, which vary by state, may also prevent the sharing of professional services income with non-professional or business interests. Any determination that we are acting in the capacity as a healthcare provider, exercising undue influence or control over a healthcare provider or impermissibly sharing fees with a healthcare provider, may result in significant sanctions against us and our clinicians, including civil and criminal penalties and fines, additional compliance requirements, expense, and liability to us, and require us to change or terminate some portions of our contractual arrangements or business.

Evolving government regulations may require increased costs or adversely affect our results of operations.

In a regulatory climate that is uncertain, our operations may be subject to direct and indirect adoption, expansion, or reinterpretation of various laws and regulations. Compliance with these future laws and regulations may require us to change our practices at an undeterminable and possibly significant initial monetary and annual expense. These additional monetary expenditures may increase future overhead, which could harm our business. For example,

39

since the Affordable Care Act was enacted, there have been executive, judicial and Congressional challenges to certain aspects of the law. For example, President Trump signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. Concurrently, prior sessions of Congress considered legislation to repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017 (Tax Act), included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the "individual mandate."

The Bipartisan Budget Act of 2018, among other things, amended the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole.” In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax that were mandated by the Affordable Care Act and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. **Thus, the Affordable Care Act will remain in effect in its current form.** Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. **In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in the Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.** It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and **the any additional** healthcare reform measures of the Biden administration will impact the Affordable Care Act. We continue to evaluate the potential impact of such healthcare reform measures on our business.

40

Additionally, the introduction of new solutions may require us to comply with additional, yet undetermined, laws and regulations. Compliance may require obtaining appropriate state medical board licenses or certificates, increasing our security measures and expending additional resources to monitor developments in applicable rules and ensure compliance. The failure to adequately comply with these future laws and regulations may delay or possibly prevent our existing and future offerings from being offered to partners, customers and members, which could significantly harm our business. Further, we expect that additional healthcare reform measures will be adopted in the future, which could impact our business. **For example, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.** In addition, Congress is considering additional health reform measures.

40

Individuals may claim our outbound engagement techniques, including outbound telephone calls and digital outreach, are not compliant with HIPAA or federal marketing laws.

Several federal laws are designed to protect consumers from various types and modes of marketing. HIPAA prohibits certain types of marketing to individuals using PHI, except for certain treatment and healthcare operations, including communications made to describe a health-related product or service (or payment for such product or service) that is provided by, or included in, a plan of benefits. Our solutions may be subject to review by OCR and deemed in violation of HIPAA, which could subject us to significant fines or other penalties. In addition, the **Telephone Consumer Protection Act (TCPA), TCPA**, is a federal statute that protects consumers from unwanted telephone calls and faxes.

Since its inception, the TCPA's purview has extended to text messages sent to consumers. We may communicate with and perform outreach to members through multiple modes of communication, including phone, email, and secure messaging. We must ensure that our solutions that leverage telephone and secure messaging comply with TCPA regulations and agency guidance. While we strive to adhere to strict policies and procedures, the **Federal Communications Commission (FCC)**, **FCC**, as the agency that implements and enforces the TCPA, may disagree with our interpretation of the TCPA and subject us to penalties and other consequences for noncompliance. Determination by a court or regulatory agency that our solutions violate the TCPA could subject us to civil penalties, could invalidate all or portions of some of our customer contracts, could require us to change or terminate some portions of our offerings, could require us to refund portions of our fees, and could have an adverse effect on our business. Even an unsuccessful challenge by consumers or regulatory authorities of our activities could result in adverse publicity and could require a costly response from us. Other laws focus on unsolicited email, such as the **Controlling the Assault of Non-Solicited Pornography and Marketing (CAN-SPAM) Act**, of 2003, (**CAN-SPAM Act**), which establishes requirements for the transmission of commercial email messages and specifies penalties for unsolicited commercial email messages that follow a recipient's opt-out request or deceive the receiving consumer.

In addition, some of our marketing activities require that we obtain permissions consistent with HIPAA and applicable state health information privacy laws. If we are unable to secure such permissions, or if there is a future change in law, we may face limitations on the use of such information, which may harm our business.

Our direct-to-consumer virtual care business leverages revenue from member subscriptions, which, if we do not comply with various state and federal laws relating to the collection of auto-renewing subscription fees, could result in significant liability or reputational harm and, in turn, a material adverse effect on our member base and revenue.

Various state and federal laws require disclosures to be made to consumers prior to collecting periodic subscription fees that will automatically renew without further action by the consumer. One such example is the California Automatic Renewal Law (California ARL) pursuant to which PlushCare, Inc. and PlushCare of California were recently sued by a purported class (*Robbins v. PlushCare, Inc. et al.*) in the United States District Court for the Northern District of California alleging, *inter alia*, that PlushCare violated the California ARL by failing to provide adequate disclosures to members. The lawsuit seeks restitution of subscription fees, statutory damages for each violation, subject to trebling, reasonable attorneys' fees, and injunctive relief. We **will vigorously defend** **have tentatively agreed on a settlement and estimate that, excluding the lawsuit and any potential loss is currently deemed amount of our liability eligible to be immaterial, paid through third-party insurance and remaining indemnification from selling shareholders of PlushCare, Inc., the net amount of our liability will be approximately \$1.2 million.**

With the acquisition of PlushCare, direct-to-consumer virtual care represents a material portion of our overall business. If we are required to change our automatically renewing subscription fee practices, our business, financial condition, results of operations and cash flows could be materially and adversely impacted.

41

The FDA may in the future determine that our technology solutions are subject to the Federal Food, Drug, and Cosmetic Act, and we may face additional costs and risks as a result.

There is a risk that our existing and future offerings, including the operational/technical component of our business model, such as our decision support software incorporating machine learning, meet the definition of a medical device under the **Federal Food, Drug, and Cosmetic Act (FDCA)**, **FDCA**. Medical devices are subject to extensive regulation by the FDA under the FDCA. Under the FDCA, medical devices include any instrument, apparatus, machine, contrivance, or other similar or related articles that is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of

41

disease. FDA regulations govern among other things, product development, testing, manufacture, packaging, labeling, storage, clearance or approval, advertising and promotion, sales and distribution, and import and export.

Failure to appropriately seek FDA approval or noncompliance with applicable FDA requirements can result in, among other things, public warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, failure of the FDA to grant marketing approvals, withdrawal of marketing approvals, a recommendation by the FDA to disallow us from entering into government contracts, and criminal prosecutions. The FDA also has the authority to request repair, replace, or refund of the cost of any device.

Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value-added, or similar taxes, and we could be subject to liability with respect to past or future sales, which could adversely affect our results of operations.

We do not collect sales and use, value-added, and similar taxes in all jurisdictions in which we have sales, based on our understanding that such taxes are not applicable. Sales and use, value-added, and similar tax laws and rates vary greatly by jurisdiction. Certain jurisdictions in which we do not collect such taxes may assert that such taxes are applicable, or jurisdictions in which we collect sales tax may assert that we have under-collected sales tax, either of which could result in tax assessments, penalties, and interest, and we may be required to collect such taxes in the future. Although our customer contracts typically provide that our customers must pay all applicable sales and similar taxes, our customers may be reluctant to pay back-taxes and associated interest and penalties, or we may determine that it would not be commercially feasible to seek reimbursement from such customers, in which event any such tax assessments, penalties, and interest, or future requirements may adversely affect our results of operations.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

As of February 28, 2022 February 28, 2023, we had U.S. federal net operating loss carryforwards (NOLs) of \$422.5 million \$453.3 million and state NOLs of \$373.0 million \$422.5 million. Under the Tax Act, as modified by the CARES Coronavirus Aid, Relief, and Economic Security Act (CARES Act), unused NOLs for the tax year ended February 28, 2018 and prior tax years will carry forward to offset future taxable income, if any, until such unused losses expire. Unused losses generated in tax years beginning after December 31, 2017, which would be our tax year ended February 28, 2018 and thereafter, pursuant to the Tax Act, will not expire and may be carried forward indefinitely but will only be deductible in the case of NOLs arising in taxable years ending after 2020 to the extent of 80% of current year taxable income in any given year. It is uncertain if and to what extent various states will conform to the Tax Act, as modified by the CARES Act. As a result, if we earn net taxable income in future years, our NOLs arising in tax years ended February 28, 2018 and earlier may expire prior to being used, and our NOLs generated in later tax years will be subject to a percentage limitation. Under Sections 382 and 383 of the Code, if a corporation undergoes an "ownership change," the corporation's ability to use its pre-change NOLs and other tax attributes and to offset its post-change income and taxes may be limited. In general, an "ownership change" occurs if there is a cumulative change in our ownership by "5% stockholders" that exceed 50 percentage points over a rolling three-year period. Our existing NOLs may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change in connection with or after our initial public offering or as a result of future events, our ability to utilize NOLs could be further limited by Section 382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code. The existing NOLs of one of our subsidiaries may be subject to limitations arising from ownership changes prior to, or in connection with, their acquisition by us. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or

42

other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes. For these reasons, we may not be able to utilize some portion of our NOLs, none of which are currently reflected on our balance sheet, even if we attain profitability.

42

Risks Related to our Intellectual Property

Failure to protect or enforce our intellectual property rights could harm our business and results of operations.

Our intellectual property includes our processes, methodologies, algorithms, applications, technology platform, software code, website content, user interfaces, graphics, registered and unregistered copyrights, trademarks, trade dress, databases, domain names, and patents and patent applications. We believe that our intellectual property is an essential asset of our business. If we do not adequately protect our intellectual property, our brand and reputation could be harmed and competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business, negatively affect our position in the marketplace, limit our ability to commercialize our technology, and delay or render impossible our achievement of profitability. A failure to protect our intellectual property in a cost-effective and meaningful manner could have a material adverse effect on our ability to compete. We regard the protection of our trade secrets, copyrights, trademarks, trade dress, databases, domain names, and patents as critical to our success.

We strive to protect our intellectual property rights by relying on federal, state, and common law rights and other rights provided under foreign laws. These laws are subject to change at any time and could further restrict our ability to protect or enforce our intellectual property rights. In addition, the existing laws of certain foreign countries in which we operate may not protect our intellectual property rights to the same extent as do the laws of the United States.

We generally enter into confidentiality and invention assignment agreements with our employees and contractors, and confidentiality agreements with other parties, with whom we conduct business in order to limit access to, and disclosure and use of, our proprietary information. However, we may not be successful in executing these agreements with every party who has access to our confidential information or contributes to the development of our intellectual property.

The agreements that we execute may be breached, and we may not have adequate remedies for any such breach. These contractual arrangements and the other steps we have taken to protect our intellectual property may not prevent the misappropriation of our intellectual property or deter independent development of similar intellectual property by others.

Obtaining and maintaining effective intellectual property rights is expensive, including the costs of monitoring unauthorized use of our intellectual property and defending our rights. We make business decisions about when to seek patent protection for a particular technology and when to rely upon trade secret protection, and the approach we select may ultimately prove to be inadequate. We strive to protect certain of our intellectual property rights through filing applications for trademarks, patents, and domain names in a number of jurisdictions, a process that is expensive and may not be successful in all jurisdictions. However, there is no assurance that any resulting patents or other intellectual property rights will adequately protect our intellectual property, or provide us with any competitive advantages. Moreover, we cannot guarantee that any of our pending patent or trademark applications will issue or be approved. Even where we have intellectual property rights, they may later be found to be unenforceable or have a limited scope of enforceability. In addition, we may not seek to pursue such protection in every jurisdiction. The United States Patent and Trademark Office also requires compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process and after a patent has issued. Noncompliance with such requirements and processes may result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to develop and commercialize substantially similar and competing applications, which would harm our business.

We believe it is important to maintain, protect and enhance our brands. Accordingly, we pursue the registration of domain names and our trademarks and service marks in the United States. Third parties may challenge our use of our

43

trademarks, oppose our trademark applications, or otherwise impede our efforts to protect our intellectual property in certain jurisdictions. In the event that we are unable to register our trademarks in certain jurisdictions, we could be forced to rebrand our solutions, which would result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors and others could also attempt to capitalize on our brand

43

recognition by using domain names or business names similar to ours. Domain names similar to ours have been registered in the United States and elsewhere. We may be unable to prevent third parties from acquiring or using domain names and other trademarks that infringe on, are similar to, or otherwise decrease the value of, our brands, trademarks, or service marks. We also may incur significant costs in enforcing our trademarks against those who attempt to imitate our brand and other valuable trademarks and service marks.

In order to protect our intellectual property rights, we may be required to spend significant resources to monitor and protect these rights. We may not be able to detect infringement or unauthorized use of our intellectual property rights, and defending or enforcing our intellectual property rights, even if successfully detected, prosecuted, enjoined, or remedied, could result in the expenditure of significant financial and managerial resources. Litigation has in the past and may be necessary in the future to enforce our intellectual property rights, protect our proprietary rights, or determine the validity and scope of proprietary rights claimed by others. Any litigation of this nature, regardless of outcome or merit, could result in substantial costs and diversion of management and technical resources, any of which could harm our business. Furthermore, our efforts to enforce our intellectual property rights may be met with defenses, counterclaims, countersuits, and adversarial proceedings such as oppositions, inter partes review, post-grant review, re-examination, or other post-issuance proceedings, that attack the validity and enforceability of our intellectual property rights. An adverse determination of any litigation proceedings could put our patents at risk of being invalidated or interpreted narrowly and could put our related pending patent applications at risk of not issuing. Further, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course of litigation there could be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. If we fail to maintain, protect, and enhance our intellectual property rights, our business may be harmed and the market price of our common stock could decline.

Our competitors also may independently develop similar technology that does not infringe on or misappropriate our intellectual property rights. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and mechanisms for enforcement of intellectual property rights may be inadequate. Effective patent, trademark, copyright, and trade secret protection may not be available to us in every country in which our solutions or technology are developed. Further, legal standards relating to the validity, enforceability, and scope of protection of intellectual property rights are uncertain. The laws in the United States and elsewhere change rapidly, and any future changes could adversely affect us and our intellectual property. Our failure to meaningfully protect our intellectual property could result in competitors offering solutions that incorporate our most technologically advanced features, which could seriously reduce demand for existing and future offerings.

Third parties may initiate legal proceedings alleging that we are infringing or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could harm our business.

Our success depends in part on our ability to develop and commercialize our offerings and use our proprietary technology without infringing the intellectual property or proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, operating results, and financial condition to suffer. As the market for healthcare in the United States expands and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our offerings and technology of which we are not aware or that we must challenge to continue our operations as currently contemplated. Whether merited or not, we may face allegations that we, our partners, our licensees, or parties indemnified by us have infringed or otherwise violated the patents, trademarks, copyrights, or other intellectual property rights of third parties. Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties.

Additionally, in recent years, individuals and groups have begun purchasing intellectual property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. We may also

face allegations that our employees have misappropriated the intellectual property or proprietary rights of their former employers or other third parties. We have in the past initiated, and it may in the future be necessary for us to initiate, litigation to defend ourselves in order to

determine the scope, enforceability, and validity of third-party intellectual property or proprietary rights, or to establish our respective rights. Regardless of whether claims that we are infringing

patents or other intellectual property rights have merit, such claims can be time-consuming, divert management's attention and financial resources, and can be costly to evaluate and defend. Results of any such litigation are difficult to predict and may require us to stop commercializing or using our solutions or technology, obtain licenses, modify our solutions and technology while we develop non-infringing substitutes, or incur substantial damages, settlement costs, or face a temporary or permanent injunction prohibiting us from marketing or providing the affected solutions. If we require a third-party license, it may not be available on reasonable terms or at all, and we may have to pay substantial royalties, upfront fees, or grant cross-licenses to intellectual property rights for our solutions. We may also have to redesign our solutions so that they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our technology and solutions may not be available for commercialization or use. Even if we have an agreement to indemnify us against such costs, the indemnifying party may be unable to uphold its contractual obligations. If we cannot or do not obtain a third-party license to the infringed technology, license the technology on reasonable terms, or obtain similar technology from another source, our revenue and earnings could be adversely impacted.

From time to time, we have been and may be subject to legal proceedings and claims in the ordinary course of business with respect to intellectual property. Some third parties may be able to sustain the costs of complex litigation more effectively than we can because they have substantially greater resources. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Moreover, any uncertainties resulting from the initiation and continuation of any legal proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our operations. Assertions by third parties that we violate their intellectual property rights could therefore harm our business.

Our use of open source software could adversely affect our ability to offer our solutions and subject us to possible litigation.

We use open source software in connection with our existing and future offerings. Some of these licenses contain requirements that we make available source code for modifications or derivative works we create based upon the open source software, and that we license such modifications or derivative works under the terms of a particular open source license or other license granting third-parties certain rights of further use. By the terms of certain open source licenses, we could be required to release the source code of our proprietary software and to make our proprietary software available under open source licenses, if we combine and/or distribute our proprietary software with open source software in certain manners. Although we monitor our use of open source software, we cannot be sure that all open source software is reviewed prior to use in our proprietary software, that our programmers have not incorporated open source software into our proprietary software, or that they will not do so in the future. Additionally, the terms of many open source licenses to which we are subject have not been interpreted by U.S. or foreign courts.

There is a risk that open source software licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to provide our existing and future offerings to our customers and members. In addition, the terms of open source software licenses may require us to provide software that we develop using such open source software, to others, including our competitors, on unfavorable license terms. As a result of our current or future use of open source software, we may face claims or litigation, be required to release our proprietary source code, pay damages for breach of contract, re-engineer our technology, discontinue sales in the event re-engineering cannot be accomplished on a timely basis, or take other remedial action that may divert resources away from our development efforts, any of which could harm our business.

Any restrictions on our ability to obtain or use data could harm our business.

Our business depends in part on data provided to us by, among other sources, health plans, benefits administrators, data warehouses, electronic data interchange (EDI) transaction data providers, and suppliers in our trusted suppliers. Trusted Partner Ecosystem. Any errors or defects in any third-party data or other technology could result in errors in our existing and future offerings that could harm our business and damage our reputation and cause losses in revenue, and

we could be required to spend significant amounts of additional resources to fix any problems. In addition, certain of our offerings, including Accolade Total Care and Accolade Total Health and Benefits, depend on maintaining our data and analytics technology platform, which is populated with data provided by third parties. While our existing agreements with these data providers have multiple-year terms, these providers could become our competitors in the future. Any loss of the right to use of data provided by any health plan providers, benefits administrators, or other entities that provide us data, could result in delays in producing or delivering our solutions until equivalent data, other technology, or intellectual property is identified and integrated, which delays could harm our business. In this situation we would be required to either redesign our solutions to function with technology, data, or intellectual property available from other parties or to develop these components ourselves, which would result in increased costs. Furthermore, we might be forced to limit the features available in our existing or future offerings. If we fail to maintain or renegotiate any of these technology or intellectual property licenses, we could face significant delays and diversion of resources in attempting to develop similar or replacement offerings or to license and integrate a functional equivalent of the technology or intellectual property. The occurrence of any of these events may harm our business.

In addition, some of our business activities require that we obtain permissions consistent with HIPAA to provide certain marketing and data aggregation solutions as well as those activities that require the creation and use of de-identified information. We also require large sets of de-identified information to enable us to continue to develop and enhance our data and analytics platform. If we are unable to secure these rights, or if there is a future change in law, we may face limitations on the use of PHI and our ability to use de-identified information that could harm our business. There is also a risk that we may fail to properly de-identify PHI and/or PII under applicable state laws, some of which impose different standards for de-identification than those imposed by HIPAA.

Risks Related to Ownership of Our Common Stock

We have in the past experienced a material weakness in our internal controls over financial reporting, and if we experience additional material weaknesses in the future or if we otherwise fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.

In the third quarter of fiscal 2022, we identified a material weakness in internal control over financial reporting in connection with measuring the fair value of contingent consideration related to business combinations. In response, we have implemented additional processes to enhance our review and validation of key inputs to the valuation of contingent consideration arrangements. As such, we remediated this material weakness during the three months ended February 28, 2022.

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the Exchange Act), the Sarbanes-Oxley Act, and the rules and regulations of the applicable listing standards of Nasdaq. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming, and costly and place significant strain on our personnel, systems, and resources. Nasdaq Stock Market (Nasdaq). The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We have developed and refined our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. If any of our controls and systems do not perform as expected, we may experience additional material weaknesses in our controls. Our For example, in the third quarter of fiscal 2022, we identified a material weakness in internal control over financial reporting in connection with measuring the fair value of contingent consideration related to business combinations. We implemented additional processes to enhance our review and validation of key inputs to the valuation of contingent consideration arrangements and remediated this material weakness during the three months ended February 28, 2022. However, it is possible that our current controls and any new controls that we develop may become inadequate in the future because of changes in

conditions in our business. Further, additional material weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future.

46

Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and further ineffective internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative

46

effect on the trading price of our common stock. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on Nasdaq. We are required to comply with the SEC rules that implement Section 404 of the Sarbanes-Oxley Act and are required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. We are required to provide an annual management report on the effectiveness of our internal control over financial reporting, and our independent registered public accounting firm is also required to formally attest to the effectiveness of our internal control over financial reporting, commencing with this Annual Report on Form 10-K. Our independent registered public accounting firm may issue reports that are adverse in the event it is not satisfied with the level at which our internal control over financial reporting is documented, designed, or operating, or if it is not satisfied with our remediation of any identified material weaknesses. Any failure to maintain effective disclosure controls and internal control over financial reporting could have an adverse effect on our business and results of operations and could cause a decline in the price of our common stock.

Sales of substantial amounts of our common stock in the public markets, or the perception that such sales could occur, could reduce the price that our common stock might otherwise attain.

Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could adversely affect the market price of our common stock and may make it more difficult for you to sell your common stock at a time and price that you deem appropriate.

Stockholders owning an aggregate of up to approximately 6.1 million shares are entitled, under our registration rights agreement, to require us to register shares owned by them for public sale in the United States.

Moreover, we have in the past and may in the future grant rights to some of our stockholders that require us to register the resale of our common stock or other securities on behalf of these stockholders and/or facilitate public offerings of our securities held by these stockholders, including in connection with potential future acquisition or capital-raising transactions. For example, in connection with Stockholders owning an aggregate of up to approximately 5.4 million shares are entitled, under our acquisition of PlushCare, we entered into a registration rights agreement, with PlushCare's existing security holders, pursuant to which we agreed that we would require us to register the shares of common stock issued to such security holders owned by them for public sale in the merger. In July 2021, pursuant to this registration rights agreement, we filed a registration statement with the SEC to register for resale up to 7,117,051 shares of our common stock held by PlushCare's existing security holders. United States.

Sales of our shares as restrictions end or pursuant to registration rights, may make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of our common stock to fall and make it more difficult for you stockholders to sell shares of our common stock.

In order to support the growth of our business, we may need to incur additional indebtedness under our current credit facility or seek capital through new equity or debt financings, which sources of additional capital may not be available to us on acceptable terms or at all.

Our operations have consumed substantial amounts of cash since inception, and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new applications and solutions, enhance our existing solutions, enhance our operating infrastructure, and potentially acquire complementary businesses and technologies. Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:

- finance unanticipated working capital requirements;

47

-
- develop or enhance our technological infrastructure and our existing solutions;
 - fund strategic relationships, including joint ventures and co-investments;
 - fund additional implementation engagements;
 - respond to competitive pressures; and
 - acquire complementary businesses, technologies, products, or services.

Accordingly, we may need to engage in equity or debt financings to secure additional funds. Additional financing may not be available on terms favorable to us, or at all. If we raise additional funds through further issuances

47

of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, during times of economic instability, it has been difficult for many companies to obtain financing in the public markets or to obtain debt financing, and we may not be able to obtain additional financing on commercially reasonable terms, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us, it could harm our business.

If securities or industry analysts publish reports that are interpreted negatively by the investment community or publish negative or inaccurate research reports about our business, our share price and trading volume could decline.

The trading market for our common stock depends, to some extent, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts or the information contained in their reports. Securities and industry analysts may cease to publish research on our business or publish negative coverage. If one or more analysts commence coverage of us and publish research reports that are interpreted negatively by the investment community, or have a negative tone regarding our business, financial condition, operating performance, industry, or end-markets, or downgrade our common stock, our share price could decline. In addition, if a significant number of these analysts ceases coverage of our company or fails to regularly publish reports about us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.

We have never declared or paid any cash dividends on our common stock and do not currently intend to do so for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. In addition, the terms of our credit agreement with Comerica Bank and the related collateral documents contain, and any future indebtedness would likely contain, prohibitions on our paying any cash dividends without the consent of the lenders. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future and the success of an investment in shares of our common stock will depend upon any future appreciation in its value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.

48

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult, limit attempts by our stockholders to replace or remove our current management, and may limit the market price of our common stock.

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of rendering more difficult, delaying, or preventing a change of control or changes in our management. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws include provisions:

- creating a classified board of directors whose members serve staggered three-year terms;
- authorizing "blank check" preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend, and other rights superior to our common stock;
- limiting the liability of, and providing indemnification to, our directors and officers;
- specifying that special meetings of our stockholders can be called only by our board of directors, the Chair of our board of directors, or our Chief Executive Officer;

48

-
- requiring advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates for election to our board of directors;
 - prohibiting cumulative voting in the election of directors;
 - providing that our directors may be removed only for cause and by a two-thirds majority vote of the stockholders;
 - providing that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; and
 - requiring the approval of our board of directors or the holders of at least 66% of our outstanding shares of capital stock to amend our amended and restated bylaws and certain provisions of our amended and restated certificate of incorporation.

These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, institutional stockholder representative groups, stockholder activists, and others may disagree with our corporate governance provisions or other practices, including anti-takeover provisions, such as those listed above. We generally will consider recommendations of institutional stockholder representative groups, but we will make decisions based on what our board and management believe to be in the best long-term interests of our company and stockholders; however, these groups could make recommendations to our stockholders against our practices or our board members if they disagree with our positions.

Finally, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any "interested" stockholder for a period of three years following the date on which the stockholder became an "interested" stockholder.

Any of the foregoing provisions could limit the price that investors might be willing to pay in the future for shares of our common stock, and they could deter potential acquirers of our company, thereby reducing the likelihood that you would receive a premium for your shares of our common stock in an acquisition.

49

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America, will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America, will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:

- any derivative action or proceeding brought on our behalf;
- any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders;
- any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws;
- any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws;

49

-
- any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; or
 - any action asserting a claim governed by the internal affairs doctrine.

This provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act or any claim for which the U.S. federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation will provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.

These exclusive-forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If any other court of competent jurisdiction were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. For example, the Court of Chancery of the State of Delaware determined that a provision stating that U.S. federal district courts are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act is not enforceable. However, this decision was recently reviewed and ultimately overturned by the Delaware Supreme Court in March 2020.

Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans, or otherwise will dilute all other stockholders.

We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors, and consultants under our stock incentive plans. We also may raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies, products, or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline.

50

Risks Related to Ownership of Our Debt

Our credit agreement contains certain restrictions that may limit our ability to operate our business.

The terms of our existing credit agreement with Comerica Bank and the related collateral documents contain, and any future indebtedness would likely contain, a number of restrictive covenants that impose significant operating and financial restrictions on us, including restrictions on our ability, and the ability of our subsidiaries, to take actions that may be in our best interests, including, among others, disposing of assets, entering into change of control transactions, mergers or acquisitions, incurring additional indebtedness, granting liens on our assets, declaring and paying dividends, and agreeing to do any of the foregoing. These agreements require us to satisfy a specified minimum liquidity level at all times and to achieve certain minimum covenant revenue, as defined, on a trailing six-month basis. Our ability to meet financial covenants can be affected by events beyond our control, including as a result of economic downturns, and we may not be able to continue to meet these covenants. A breach of any of these covenants or the occurrence of other events (including a material adverse effect) specified in these agreements and/or the related collateral documents would result in an event of default under such agreements. Upon the occurrence of an event of default, Comerica Bank as administrative agent for the revolving lenders could elect to declare all amounts outstanding, if any, under the credit agreement to be immediately due and payable and terminate all commitments to extend further credit. If we were unable to repay those amounts, Comerica Bank as administrative agent for the revolving lenders could proceed against the collateral granted to them to secure such indebtedness. We have pledged substantially all of our assets as collateral under the loan documents. If Comerica Bank as administrative agent for the revolving lenders accelerates the repayment of borrowings, if any, we may not have sufficient funds to repay our existing debt.

50

We have a significant amount of debt and may incur additional debt in the future. We may not have sufficient cash flow from our business to pay our substantial debt when due.

Our ability to pay our debt when due or to refinance our indebtedness, including the 0.50% Convertible Senior Notes due 2026, we issued in March 2021 (the Notes), depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. In most instances it is at our discretion to settle the Notes for cash or the distribution of common stock; however, any required repurchase of the Notes for cash as a result of a fundamental change would lower our current cash on hand such that we would not have those funds available for us in our business. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

We and our subsidiaries may incur substantial additional debt in the future, subject to the restrictions contained in our future debt instruments, some of which may be secured debt. We are not restricted under the terms of the indenture governing the Notes from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that could have the effect of diminishing our ability to make payments on the Notes when due. Furthermore, the indenture prohibits us from engaging in certain mergers or acquisitions unless, among other things, the surviving entity assumes our obligations under the Notes and the indenture. These and other

provisions in the indenture could deter or prevent a third party from acquiring us even when the acquisition may be favorable to holders of the Notes.

Transactions relating to our Notes may affect the value of our common stock.

The conversion of some or all of the Notes would dilute the ownership interests of existing stockholders to the extent we satisfy our conversion obligation by delivering shares of our common stock upon any conversion of such Notes. Our Notes may become in the future convertible at the option of their holders under certain circumstances. If holders of our Notes elect to convert their notes, we may settle our conversion obligation by delivering to them a significant number of shares of our common stock, which would cause dilution to our existing stockholders. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could

51

be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.

In addition, in connection with the issuance of the Notes, we entered into capped call transactions with certain financial institutions (Option Counterparties). The capped call transactions are expected generally to reduce the potential dilution to our common stock upon any conversion or settlement of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. From time to time, the Option Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the Notes. This activity could cause a decrease in the market price of our common stock.

General Risk Factors

Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.

New income, sales, use, or other tax laws, statutes, rules, regulations, or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. For example, the Tax Act, the CARES Act, and the IRA enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act such legislation may affect us, and

51

certain aspects of the Tax Act could be repealed or modified in future legislation. In addition, in response to the COVID-19 pandemic, the CARES Act was signed into law in March 2020, and subsequently in December 2020, the Continued Assistance for Unemployed Workers Act of 2020 (CARES Act II) was signed into law, extending certain provisions of the CARES Act and making other changes to the Tax Act. The CARES Act and CARES Act II modify certain of the changes made by the Tax Act. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, and the deductibility of expenses under the Tax Act as amended by the CARES Act and CARES Act II, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, as amended by the CARES Act, and CARES Act II, the IRA, or any newly enacted federal tax legislation.

Unstable market and economic conditions, including adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, may have serious adverse consequences on our business, financial condition, results of operations, and stock price.

The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, increased interest rates, inflationary pressures, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. The financial markets and global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism, or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by affected countries and others could exacerbate market and economic instability. There can be no assurance that further deterioration in the credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment, or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance, and stock price and could require us to delay or abandon critical development plans. Accordingly, there is a risk that one or more of our customers, current service providers, or other partners may be adversely impacted by, or may not survive, an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.

In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties, or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. If any of our lenders or counterparties to any such instruments were to be placed into receivership, we may be unable to access such funds.

We regularly maintain cash balances at third-party financial institutions in excess of the FDIC insurance limit. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit, or liquidity agreements, or arrangements, disruptions, or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.

In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all

Natural or man-made disasters, events outside our reasonable control, and other similar events may significantly disrupt our operations and negatively impact our business, financial condition, and results of operations.

Our offices, third-party data and call centers, or cloud infrastructure services may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, power outages, fires, floods, nuclear disasters, acts of terrorism or other criminal activities, or other events or business continuity problems outside our reasonable control such as a general and widespread failure of the Internet or telecommunications or outbreaks of public health threats, such as the novel coronavirus, influenza, or other highly communicable diseases or viruses, which may render it difficult or impossible for us to operate our business for some period of time. Any disruptions in our operations related to the repair or replacement of our offices, third-party data and call centers, or cloud infrastructure services could negatively impact our business and results of operations and harm our reputation. Insurance may not be sufficient to compensate for losses that may occur. Any such losses or damages could harm our business.

We have incurred and will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could adversely affect our business, results of operations, and financial condition.

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the Exchange Act), the listing standards of the Nasdaq Stock Market (Nasdaq) and other applicable securities

52

rules and regulations. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources. For example, the Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and results of operations. As a result of the complexity involved in complying with the rules and regulations applicable to public companies, our management's attention may be diverted from other business concerns, which could harm our business, results of operations, and financial condition. Although we have already hired additional employees and engaged outside consultants to assist us in complying with these requirements, we will need to hire more employees in the future or may need to engage additional outside consultants, which will increase our operating expenses. In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time-consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. These factors could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest substantial resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from business operations to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. As a result of disclosure of information in our public company filings, our business and financial condition will become more visible, which may result in pricing pressure from customers or an increased risk of threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business, results of operations, and financial condition.

53

The trading price of our common stock could be volatile, and you could lose all or part of your investment.

Our stock price has been volatile since our initial public offering, and it is likely that the trading price of our common stock may fluctuate substantially, depending on a number of factors, including those described in this "Risk Factors" section, many of which are beyond our control and may not be related to our operating performance. These fluctuations could cause you to lose all or part of your investment in our common stock. Factors that could cause fluctuations in the trading price of our common stock include the following:

- price and volume fluctuations in the overall stock market from time to time;
- volatility in the market prices and trading volumes of healthcare technology company stocks;
- changes in operating performance and stock market valuations of other healthcare technology companies generally, or those in our industry in particular;
- sales of shares of our common stock by us or our stockholders;
- failure of securities analysts to initiate or maintain coverage of us, changes in financial estimates by securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors;

- the financial projections we may provide to the public, any changes in those projections, or our failure to meet those projections;

- new product announcements by us or our competitors;

- the public's reaction to our press releases, other public announcements, and filings with the SEC;

53

- changes in how customers perceive the benefits of our solutions, and future offerings;

- changes in the structure of healthcare provider and payment systems;

- rumors and market speculation involving us, our customers, our competitors, or other companies in our industry;

- actual or anticipated changes in our results of operations or fluctuations in our results of operations;

- actual, rumored, or anticipated developments in our business, our competitors' businesses, or the competitive landscape generally;

- litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;

- developments or disputes concerning our intellectual property or other proprietary rights;

- any significant data breach involving our technology platform or data stored by us or on our behalf;

- announced or completed acquisitions of businesses, commercial relationships, strategic partnerships, products, services, significant contracts or customers, or technologies by us or our competitors;

- new laws or regulations or new interpretations of existing laws or regulations applicable to our business;

54

- changes in accounting standards, policies, guidelines, interpretations, or principles;

- "flash crashes," "freeze flashes," or other glitches that disrupt trading on the securities exchange on which we are listed;

- any significant change in our management; and

- general economic, social, or political conditions and slow or negative growth of our markets.

Accordingly, we cannot assure you of the liquidity of an active trading market, your ability to sell your shares of our common stock when desired, or the prices that you may obtain for your shares of our common stock. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares of our common stock and may impair our ability to acquire or make investments in complementary companies, products, or technologies by using shares of our common stock as consideration.

In addition, if the market for healthcare technology stocks or the stock market in general experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition, or results of operations. The trading price of our common stock might also decline in reaction to events that affect other companies in our industry even if these events do not directly affect us. In the past, following periods of volatility in the trading price of a company's securities, securities class action litigation has often been brought against that company. If our stock price is volatile, we may become the target of securities litigation. Securities litigation could result in substantial costs and divert our management's attention and resources from our business. This could harm our business.

Item 1B. Unresolved Staff Comments

None.

54

Item 2. Properties

We have co-headquarters in Seattle, Washington at 1201 Third Avenue, Suite 1700, Seattle, WA 98101 and Plymouth Meeting, Pennsylvania at 660 West Germantown Pike, Suite 500, Plymouth Meeting, PA 19462. Our Seattle headquarters is leased pursuant to a lease that expires in 2030. Our Plymouth Meeting headquarters space is leased pursuant to a lease that expires in 2027. We also have offices located in Houston, Texas; San Francisco, California; Scottsdale, Arizona; and Prague, Czech Republic, pursuant to leases that expire at various dates through 2027. In the fourth quarter of fiscal 2023, we signed a lease for an additional office in Prague, Czech Republic that is expected to commence in fiscal 2024 for a term of approximately 8 years. We believe that our properties are generally suitable to meet our needs for the foreseeable future. In addition, to the extent we require additional space in the future, we believe that it would be readily available on commercially reasonable terms.

Item 3. Legal Proceedings

We are from time to time subject to, and are presently involved in, litigation and other legal proceedings that arise in the ordinary course of business. Descriptions of certain legal proceedings to which we are a party are contained The information set forth in Note 16, "Commitments and Contingencies," to our consolidated financial statements included in this Form 10-K. 10-K is incorporated by reference to this Item 3.

Item 4. Mine Safety Disclosures

Not applicable.

55

Part II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock is listed on the Nasdaq Global Select Market under the symbol "ACCD." Trading began on our common stock on July 2, 2020. Prior to that time, there was no public market for our common stock. There were 176 153 stockholders of record as of February 28, 2022 February 28, 2023. Certain shares are held in "street" name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Our ability to pay dividends on our common stock is restricted by our credit facility. See "Management's Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources." Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.

Recent Unregistered Sales of Unregistered Equity Securities

None.

and Use of Proceeds from Public Offering of Common Stock



On July 7, 2020 During the year ended February 28, 2023, we closed on our initial public offering (IPO) did not issue or sell any unregistered securities not previously disclosed in which we issued and sold 11,526,134 shares (inclusive of the underwriters' over-allotment option to purchase 1,503,408 shares) of common stock at a price of \$22.00 per share pursuant to a Registration Statement Quarterly Report on Form S-1. The aggregate net proceeds to us from the offering were \$231.2 million, after deducting underwriting discounts and commissions 10-Q or in a Current Report on Form 8-K.

Purchases of \$17.8 million and net offering expenses of approximately \$4.6 million. There has been no material change in the planned use of proceeds from our IPO from those disclosed in the Final Prospectus for our IPO dated as of July 1, 2020 and filed with the SEC pursuant to Rule 424(b)(4) on July 2, 2020. Equity Securities

55 None.

Stock Performance Graph

The following graph shows the cumulative total stockholder return on our common stock compared with the Nasdaq Composite Index, and the Nasdaq Health Care Index (new industry index), and the S&P MidCap 400 Health Care Index (old industry index). We believe the new industry index better reflects companies relevant to our current business. Index. The comparison begins on July 2, 2020, the date on which our common stock first began trading on the Nasdaq Global Select Market, and assumes an initial investment of \$100.



cautions that the stock price performance shown in this graph should not be considered indicative of potential future stock price performance.

The information under “Stock Performance Graph” is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference in any filing of Accolade, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K and irrespective of any general incorporation language in those filings.

Item 6. [Reserved]

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of our operations should be read together with our consolidated financial statements, including the related notes thereto, appearing at the end of this filing. The following discussion contains forward-looking statements. Actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause future results to differ materially from those projected in the forward-looking statements include, but are not limited to, those discussed in the sections titled “Risk Factors” and “Special Note Regarding Forward-Looking Statements” included elsewhere in this Annual Report on Form 10-K.

Discussion and analysis of our fiscal year 2020, 2021, as well as the year-over-year comparison of our 2021 2022 financial performance to 2020, 2021, have been omitted from this section and may be found under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Annual Report on Form 10-K for the fiscal year ended February 28, 2021 February 28, 2022 and filed with the Securities and Exchange Commission (the SEC) on May 7, 2021 May 2, 2022. Our fiscal year ends on the last day of February, and our fiscal quarters end on May 31, August 31, November 30, and the last day of February.

56

Overview

We provide personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. Our customers are primarily employers that deploy Accolade solutions in order to provide employees and their families (our “members”) a single place to turn for their health, healthcare, and benefits needs. We also offer expert medical opinion services to employer commercial customers (which includes employers, health plans, and governmental entities) and virtual primary care, and mental health support, both directly to consumers and to employer commercial customers. Our innovative platform combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. We leverage our integrated capabilities, connectivity with providers and the broader healthcare ecosystem, and longitudinal data to engage across the entire member population, rather than focusing solely on high-cost claimants or those with chronic conditions. Our goal is to build trusted relationships with our members that ultimately position us to deliver personalized recommendations and interventions. We believe that our platform dramatically improves the member experience, encourages better health outcomes, and lowers costs for both our members and our customers.

Accolade Total Health and Benefits has historically been our most comprehensive offering and most closely aligns to our “Premier” solution on which the company was founded and from which the majority of our revenues are derived today. Our technology platform enabled us to unbundle aspects of this comprehensive offering to create two additional standalone offerings: Accolade Total Benefits (focused on member benefits engagement) and Accolade Total Care (focused on guiding members to high-quality, cost-effective providers). Following our acquisition of 2nd.MD in March 2021, we began offering customers expert medical consultation (primarily for high-complexity, high-cost conditions) as a standalone service as well as a capability that can be incorporated into other core offerings. Following our acquisition of PlushCare in June 2021, we began offering virtual primary care and mental health services directly to consumers and commercial customers. We have further leveraged our technology platform to develop add-on offerings and to integrate acquired solutions that target specific challenges faced by our customers.

In September 2021, we announced new solutions and new naming for the solutions described above. The new solutions – Accolade One and Accolade Care – combine the capabilities of Accolade’s historical navigation and

57

advocacy solutions with our acquired primary care, mental health, and expert medical opinion services, augmented by artificial intelligence, machine learning, and data-driven recommendations. The new solutions are in their early stages of implementation, with initial customer implementations beginning in January 2022. Additionally, we announced new solution bundles incorporating all of our existing solutions to reflect the evolution and maturation of our offering portfolio. With these changes, our current offerings include:

- Accolade Expert MD – Expert medical consultations that connect patients to highly qualified condition-specific specialists for both adult and pediatric care
- Accolade Care – Integrated primary care and mental health support
- Core Plus and Plus Connect – A benefits navigation and care solution designed to work with our customers' existing benefits ecosystem, incorporating elements of all Accolade solutions including Advocacy, Accolade Expert MD, Accolade Care, and the Accolade partner ecosystem. Different offering configurations may also include member services, provider services, and an expanded set of clinical programs that address case and disease management to maximize member engagement and return on investment.
- Accolade One – A value-based option that includes all of the Accolade solutions and the Accolade partner ecosystem with a pricing structure that includes a higher portion of revenues associated with outcomes-based measures

We were founded in 2007 and launched our initial offering in 2009. We have seen significant growth in recent years since the changes to our executive management team in 2015 and the subsequent investments we have made in product, technology, sales, and distribution. As of February 28, 2022 February 28, 2023, we had over 600 employer 800 commercial customers comprising

57

more than 10 million 12 million members. Our customers represent a diversified set of industries, including media, technology, financial services, healthcare, manufacturing, transportation, energy, education, retail, and retail, the public sector. Additionally, as of February 28, 2022 February 28, 2023, we had more than 100,000 150,000 consumers subscribed to virtual primary care services through our PlushCare solution.

In March 2021, we acquired 2nd.MD, a leading expert second opinion consultation and health care decision support company based in Houston, Texas. 2nd.MD provides a service that allows members to access board-certified national experts across the country for high-value consultations in a real-time video call or by phone in order to provide the member with a rapid second opinion on their medical condition enabling the member to make more informed decisions regarding significant and high-cost care decisions, such as whether to have surgery or elect to have a specific treatment. Under the terms of the agreement, we provided cash consideration of \$226.1 million and issued 2,822,242 shares of our common stock at closing. We will issue 1,977,343 additional shares of our common stock to the selling shareholders of 2nd.MD subsequent to February 28, 2022 based on the resolution of contingent consideration under the terms of the agreement.

In June 2021, we acquired PlushCare, a provider of virtual primary care and mental health support. The addition of a primary care team extends our ability to improve clinical health outcomes for members and deliver additional cost savings for employers. Under the terms of the agreement, we provided cash consideration of \$33.9 million and issued 7,144,393 shares of our common stock at closing. We will issue 1,327,445 additional shares of our common stock to the selling shareholders of PlushCare subsequent to February 28, 2022 based on the resolution of contingent consideration under the terms of the agreement. An additional 102,111 shares are withheld pending the resolution of a litigation matter.

In September 2021, we acquired substantially all the assets of HealthReveal, Inc. (HealthReveal). HealthReveal is a clinical artificial intelligence company focused on ensuring patients receive optimal, personalized chronic care to preempt adverse outcomes. Under the terms of the agreement, we issued 252,808 shares of common stock as consideration at closing. We may issue up to 28,089 additional shares of common stock that are subject to an indemnity holdback, and these shares will be released 18 months following the closing.

For the fiscal years ended February 28, 2022 February 28, 2023 and 2021, 2022, our total revenue was \$310.0 million \$363.1 million and \$170.4 million \$310.0 million, respectively, representing 82% 17% year-over-year growth for fiscal year 2022 2023 compared to fiscal year 2021, 2022. For the fiscal years ended February 28, 2022 February 28, 2023 and 2021, 2022, our net losses were \$123.1 million \$459.7 million and

\$50.7 million \$123.1 million, respectively. Net loss for the fiscal year ended February 28, 2023 included a goodwill impairment charge of \$299.7 million due to sustained decreases in our stock price and market capitalization in the first quarter of fiscal 2023. Refer to the section below under Critical Accounting Policies and Estimates titled "Accounting for Goodwill and Other Intangible Assets" and Note 5 to our consolidated financial statements for more details.

Our Business Model

We provide our solutions primarily to employers that deploy Accolade offerings to our members and to consumers who directly purchase our PlushCare virtual primary care services. We earn revenue from providing personalized health guidance solutions, expert medical opinion services, and virtual primary care services and mental health support to the members of our employer commercial customers' health plans and to members of fully insured plans offered via health insurance companies. Our advocacy solutions are priced based on a recurring per-member-per-month (PMPM) fee, typically consisting of both a base fee and a performance-based fee component. As a result, generally, a portion of our potential revenue is variable, subject to our achievement of performance metrics and the realization of savings in healthcare spend by our customers resulting from the utilization of our solutions. We typically achieve a substantial portion of the contractual performance metrics and realization in savings of healthcare spend. We also provide expert medical opinion services, which are typically charged on a PMPM or case rate basis, and virtual primary care and mental health support, services which are typically priced on a fee per visit basis for consumers and a visit fee basis or PMPM plus visit fee basis for employer commercial customers.

The primary cost of delivering our service includes the personnel costs of Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers and virtual primary care physicians, as well as software and tools for telephony, workforce management, business analytics, allocated overhead costs, and other

58

expenses related to delivery and implementation of our solutions. As we support more customers with an increasing number of members over time, we expect that our support costs per member will decline due to economies of scale and improved operational efficiencies driven by continued enhancements of our technology platform and capabilities. We

58

have experienced and expect to continue to achieve operational efficiencies realized from continued enhancements of our technology platform and capabilities.

We employ a multipronged go-to-market strategy to increase adoption of our solutions to new and existing customers. We principally sell our solutions through our direct salesforce which is stratified by account size (i.e., strategic (more than 35,000 employees), enterprise (5,000 to 35,000 employees), and mid-market (500 to 5,000 employees)), region, and existing versus prospective customer. Our sales team possesses deep domain expertise in health benefits management and brings substantial experience selling to key decision makers within our current and prospective customer organizations (human resource officers, CFOs, benefits executives, consultants, and brokers). We believe the effectiveness of our sales organization is evidenced by growing adoption of our platform by large strategic customers, recent traction with enterprise and mid-market customers and demonstrated demand for add-on offerings from existing customers.

We have chosen to invest significantly in growing our customer base, and plan to continue both adding new customers and expanding our relationships with existing customers, which we believe will allow us to increase margins over time. When a customer renews their contract or purchases additional solutions or enhancements, the value realized from that customer increases because we generally do not incur significant incremental acquisition or implementation costs for the renewal or expansion. We believe that as our customer base grows and a higher percentage of our revenue is attributable to renewals and upsells or cross-sells to existing customers, relative to acquisition of new customers, associated sales and marketing expenses and other upfront costs will decrease as a percentage of revenue.

In addition, we have strategically curated our offering portfolio to ensure we have a compelling value proposition at an appropriate price point that resonates with each identified customer segment. Based on our experience, the opportunity to cross-sell is meaningfully enhanced once a customer has been on-boarded onto our platform and has benefited from a measurable and compelling return on their investment. Our customer success team provides strategic insights, point solution recommendations, and day-to-day account support to our customers. They are focused on existing customer retention, cross-sell, and upsell.

We maintain relationships with a range of third parties, including brokers, agents, benefits consultants, carriers, third-party administrators, **trusted suppliers in our Trusted Partner Ecosystem**, and co-marketing and co-selling partners. These third parties provide an important source of referrals for our sales organization. We also selectively form strategic alliances to further drive customer acquisition and adoption of our solutions. We believe the breadth of our go-to-market and distribution strategy enables us to reach customers of nearly every size and across markets.

We have demonstrated a consistent track record of product and technology innovation over time as evidenced by continuous improvement of our platform and new offerings. This innovation is driven by feedback we receive from our customers, industry experts, and the market generally. Our technology platform has enabled us to unbundle aspects of our core navigation capability to create various offerings for our customers, while integrating capabilities from our recent acquisitions to deliver our Personalized Healthcare solution that combines our core navigation with expert medical consultations and virtual primary **care and mental health support, care**. Our investments in product and technology have been focused on increasing the value we provide via our personalized member health guidance solutions and expanding the market segments we can serve with a portfolio of offerings and associated price points.

Business Environment and Trends

The healthcare sector continues to recover from the effects of the COVID-19 Update

COVID-19 has created uncertainty for Accolade's employees, members, and customers. We consider **pandemic**. Over the **impact course** of the pandemic, **on our business by evaluating the health of our operations any changes and clinical leaders trained our frontline teams on evidence-based guidelines and continue to equip them with relevant resources to serve our revenue outlook, and the degree to which perceptions of and interest in Accolade solutions have evolved during this unprecedented time, members**. We measure our performance through several key metrics, including but not limited to customer satisfaction, member engagement, and health assistant availability. As gauged by these core performance metrics, service levels have been high, and member engagement and satisfaction have remained strong. **To ensure we could address our members' many COVID-19-related concerns, our operations and clinical leaders trained our frontline teams on evidence-based guidelines and continue to equip them with relevant resources to help them ably serve under these exceptional circumstances.**

59

While **macroeconomic factors including high inflation, the COVID-19 pandemic, has and geopolitical risk** have not had a material adverse impact on our financial condition and results of operations to date, the future impact of **the ongoing COVID-19 pandemic these factors** on our operational and financial performance will depend on certain developments, including **U.S. unemployment and economic growth, changes in interest rates, the duration and spread of the outbreak, potential future COVID-19 outbreaks**, impact on our customers and our sales cycles, impact on our marketing efforts, and any decreases of workforce or benefits spending by our customers, all of which are uncertain and cannot be predicted. **We have a diverse set of Changing macroeconomic factors may affect our customers' desire to renew their contracts. If our customers across a variety of industries, undergo layoffs or reductions in force, our membership numbers would decrease, which would reduce our revenues.** We may experience increased member attrition to the extent our existing customers reduce their respective workforces in response to changes in economic conditions. Any layoffs or reductions in employee headcounts by our **employer commercial** customers would result in a reduction in our base and variable PMPM fees. When customer headcount reductions occur, we may not experience the impact of changes to our customers' headcounts immediately because employees that are on furlough or are receiving continued health coverage pursuant to COBRA may still have access to our services during such periods and would be included in our member count.

We believe our value proposition **now resonates with an a even broader broad** audience of **employers as they turn their focus to safely reopening their workplaces and managing the ongoing health and well-being of employees and their families. To directly address the former, we developed Accolade COVID Response Care, a solution that allows employers of all sizes to leverage Accolade's platform to support employee education, testing, care plans, contact tracing, and return-to-work clearance. On the latter, we believe that**

the current disruptions employers. Disruptions to traditional care consumption ignited by the COVID-19 pandemic have reinforced the need for navigation services, and that projected increases in healthcare costs (due to some combination of COVID-19-related testing and care, complications stemming from neglected non-COVID conditions, pent-up demand for elective services, and strain on individuals' mental health) prompt the need for solutions such as ours that bend the cost curve, and improve health outcomes, by driving good utilization up and wasteful utilization down.

Factors Affecting Our Performance

The following factors have been important to our business and we expect them to impact our business, results of operations, and financial condition in future periods:

Growth and Retention of Our Customer Base

We believe there is a substantial opportunity to further grow our customer base in our large and under-penetrated market through our sales and marketing strategy. Across our existing customer base and as we acquire new customers, we intend to expand and deepen these relationships. As we build trust through our proven model, we seek to cross-sell our add-on offerings, such as Accolade ExpertMD and Accolade Care solutions as Trusted Supplier Program, COVID Response Care and Mental Health Integrated Care, well as Accolade partner ecosystem programs. We plan to continue to invest in sales and marketing in order to grow our customer base and increase sales to existing customers. Any investments we make in our sales and marketing organization will occur in advance of experiencing any benefits from such investments, so it may be difficult for us to determine if we are efficiently allocating our resources in these areas.

Adoption of Current and Future Solutions

We are constantly innovating to enhance our model and develop new offerings. Our ability to act as a trusted advisor to our members and customers positions us to identify new opportunities for additional offerings that can meet their existing and emerging needs. Our open technology platform also allows us to efficiently add and integrate new offerings and applications on top of our existing technology stack which we have demonstrated with the roll-out of Accolade Total Benefits and Accolade Total Care, as well as our add-on offerings, Accolade Boost, our Trusted Supplier Program, Accolade COVID Response Care, and Mental Health Integrated Care that target specific challenges faced by our customers. Our open technology platform is instrumental for integration of the capabilities acquired through our acquisitions of 2nd.MD and PlushCare. We believe that as we expand our customer base and enter into new markets, we will be adept at identifying and deploying innovative new solutions whether developed internally or through acquisitions. In September 2021, we announced two new solutions – Accolade One and Accolade Care – that combine some or all of the elements of Accolade's historical solutions and the acquired capabilities from 2nd.MD and PlushCare. The new solutions are in their early stages of implementation, with initial customer launches in January 2022.

60

Achievement of Performance-Based Revenue

In most of our contracts, a portion of our potential fee is variable, subject to our achievement of performance metrics and the realization of savings in healthcare spend by our customers resulting from the utilization of our solutions,

60

and thus we might record higher revenue in some quarters compared to others. Examples of performance metrics included in our customer contracts are achievement of specified member engagement levels, member satisfaction levels, and various operational metrics. Although we have earned over 90% of the aggregate maximum potential revenue under our contracts (measured on the corresponding calendar year basis) in fiscal years 2022, 2023 and 2021, 2022, our revenue and financial results in the future may vary as a result of our ability to earn this performance-based revenue. In addition, because our customers typically pay both the base PMPM fees and variable PMPM fees in advance

on a periodic basis, any required refund as a result of our failure to earn the performance-based revenue could have a negative impact on cash flows.

Investments in Technology

Significant investments in our technology platform have enhanced our capabilities with respect to how we engage with our members and deliver our solutions and care interventions. By leveraging our technology in areas such as machine learning, predictive analytics, and multimodal communication, we believe we can generate more efficiencies in our operating model while simultaneously improving our ability to deliver better health outcomes and lower costs for both our members and our customers. We will continue to invest in our technology platform to empower our Accolade Health Assistants, our clinicians, and our members to further improve and optimize efficiencies in our operating model. However, our investments in our technology platform may be more expensive or take longer to develop than we expect and may not result in operational efficiencies.

Seasonality

There are seasonal factors that may cause us to record higher revenue in some quarters compared with others. We have historically recorded a disproportionate amount of revenue during the fourth quarter of our fiscal year relative to the first three quarters of our fiscal year. This timing is caused, in part, by the measurement, achievement, and associated revenue recognition of performance metrics and healthcare costs savings components of certain of our customer contracts during the fourth quarter of each fiscal year. Additionally, services launch on January 1 for the majority of our commercial customer contracts which is during our fiscal fourth quarter. While we believe we have visibility into the seasonality of our business, our rapid growth rate and acquisitions over the last several years have made seasonal fluctuations more difficult to detect.

Key Metrics

We regularly monitor a number of financial and operating metrics in order to measure our current performance and estimate our future performance.

| | February 28, | | February 28, | |
|-------------------------------------|--------------|----------|--------------|---------|
| | 2022 | 2021 | 2023 | 2022 |
| Annual Contract Value (in millions) | \$ 286.0 | \$ 211.5 | \$309.1 | \$286.0 |

| | Year Ended February 28, | | Year Ended February 28, | |
|------------------------|----------------------------|------|----------------------------|------|
| | 2022 | 2021 | 2023 | 2022 |
| Gross Dollar Retention | 98 % | 99 % | 87 % | 98 % |

Annual Contract Value (ACV) — We believe ACV provides investors with useful information on period-to-period performance as evaluated by management, comparison with our past financial performance, and a view toward potential future financial performance. To calculate ACV, we treat each type of contract as detailed below.

Advocacy customers

ACV for advocacy customers represents the annualized value of our in-force contracts as of the measurement date, including base contractual revenue and the amount of performance-based variable revenue we expect to realize in the following fiscal year based on the number of members as of the measurement date and using a straight-line averaging of PMPM fees over the lives of the contracts. ACV also includes expert medical opinion and commercial virtual primary care customers. Pricing for these customers is either PMPM or per case/visit. For contracts with PMPM pricing, we calculate ACV as the number of members multiplied by the applicable annualized rate. For contracts with case/visit rate

pricing, we calculate ACV as the expected utilization during the following fiscal year multiplied by the applicable per case/visit rate. We do not include any consumer subscription revenue or consumer virtual primary care visit fees in ACV, as these arrangements are generally terminable

within 30 days by the consumer.

Over the past two complete fiscal years, we have realized in excess of 90% of the maximum contract value across our book of business. The ACV amounts included above for advocacy customers reflect approximately 95% of the total revenue opportunity, consistent with the percentages realized in recent years. We also include the expected revenue share to be earned from ecosystem product partner arrangements. A large customer that indicated it would end its relationship with us following calendar year 2022 was included in advocacy ACV as of February 28, 2022 and 2021 and is not expected to be included

The increase in ACV as of February 28, 2023 compared to February 28, 2022 is primarily due to growth in the number of customers under contract as of February 28, 2023, partially offset by the end of a relationship with a large customer as of December 31, 2022. ACV for this customer was \$27.1 million at February 28, 2022.

61

As required by GAAP, we recognize performance-based revenue over the minimum term of the applicable contract. In some cases, especially with regard to revenue associated with the realization of healthcare cost savings, revenue may be recognized in a fiscal period later than the period in which the required metric was achieved. Conversely, a fiscal period's revenue may include the recognition of revenue related to the achievement in prior periods of performance metrics and healthcare cost savings. For purposes of calculating ACV, we assume that all customer contracts expiring during the following fiscal year will renew on the same terms.

Expert Medical Opinion Customers

As a result of our acquisition of 2nd.MD in March 2021, ACV as of February 28, 2022 includes expert medical opinion customers. Pricing for expert medical opinion customers are either PMPM or per case. For contracts with PMPM pricing, we calculate ACV as the number of members multiplied by the applicable annualized rate. For contracts with case rate pricing, we calculate ACV as the expected utilization during the following fiscal year multiplied by the applicable per case rate.

Direct to Consumer Customers

We do not include any consumer subscription revenue or consumer virtual primary care visit fees in ACV, as these arrangements are generally terminable within 30 days by the consumer.

Gross Dollar Retention Rate (GDR) — Our ability to increase revenue depends in large part on our ability to retain our existing customers and their associated ACV. We typically enjoy a high rate have historically retained the vast majority of customer retention, our customers. For example, our GDR was 98% and 99% for the fiscal years ended February 28, 2022 and 2021, respectively. However, due primarily to the end of a relationship with a large customer as of December 31, 2022, GDR declined for the fiscal year ended February 28, 2023. Excluding the loss of this large customer, GDR would have been 96% for the fiscal year ended February 28, 2023.

We monitor GDR specifically as it relates to our employer customers, as our employer customers represent our primary strategic focus and today account for approximately 98% of our ACV focus. We calculate GDR for a period by starting with the sum of the ACV from all employer customers as of the beginning of such period (beginning of period ACV); we then subtract the ACV associated with terminated employer customers during the period and divide the result by the beginning of period ACV. Due to Absent a recent notice from significant change in our business or a large discrete event, such as the loss of a significant customer, indicating that it would end its relationship with us following calendar year 2022 and a to be negotiated transition services period, we expect a lower GDR in fiscal 2023 as compared 2024 to more closely approximate historical GDR prior to fiscal years 2023.

Basis of Presentation and Components of Revenue and Expenses

We operate our business through a single reportable segment. We operate on a fiscal year ending at the end of February of each year, and our fiscal quarters end on May 31, August 31, November 30, and the last day of February.

Revenue

We earn revenue from providing personalized health guidance solutions (advocacy), expert medical opinion, services, and virtual primary care services, and mental health support services to the members of our employer commercial customers' health plans and to members of fully insured plans offered via health insurance companies. Access fees for these services are priced primarily using a recurring

PMPM fee, typically with a portion of the fee calculated as the product of a fixed rate times the number of members, and a variable PMPM fee calculated as the product of a variable rate times the number of members. The fees associated with variable PMPM charges are earned through the achievement of performance metrics and/or the realization of healthcare cost savings resulting from use of our services. We also earn revenue from providing virtual primary care services and mental health support services directly to consumers, consumers on a monthly or yearly fixed fee subscription basis. Our advocacy solutions are priced expert medical opinion and virtual primary care services typically also include a variable rate charged based on a recurring PMPM fee and frequently include both a base PMPM fee based on eligible members and a performance-based component, utilization for commercial customers (i.e. case rate or fee-per-visit). As a result, a portion of our total potential fee is typically variable, subject to our achievement of performance metrics, the realization of savings in healthcare spend by our customers resulting from the utilization of our solutions, and the number of eligible members during the respective period. Our expert medical opinion services are typically charged on a PMPM or case rate basis, and our virtual primary care and mental health support services are typically priced on a fee per visit basis for consumers and a visit fee basis or PMPM plus visit fee basis for employer customers.

62

Cost of Revenue, Excluding Depreciation and Amortization

Our cost of revenue, excluding depreciation and amortization, consists primarily of personnel costs including salaries, wages, bonuses, stock-based compensation expense and benefits, as well as software and tools for telephony,

62

workforce management, business analytics, allocated overhead costs, and other expenses related to delivery and implementation of our personalized technology-enabled solutions, expert medical opinion services, and virtual primary care services, services. We expect cost of revenue, excluding depreciation and mental health support, amortization, to increase along with revenue growth over time.

Operating Expenses

Product and technology. Product and technology expenses include costs to build new offerings, add new features to our existing solutions, and to manage, operate, and ensure the reliability and scalability of our existing technology platform. Product and technology expenses consist of personnel expenses, including salaries, bonuses, stock-based compensation expense, and benefits for employees and contractors for our engineering, product, and design teams, and allocated overhead costs, as well as costs of software and tools for business analytics, data management, and IT applications that are not directly associated with delivery of our solutions to customers. We In the short-term, we expect product and technology expenses to increase moderate and grow at a lower rate than the rate of growth experienced in absolute dollars but fiscal 2022 and 2023 due to the workforce realignment actions taken by management in fiscal 2023. Over time, we expect product and technology expenses to decrease as a percentage of revenue over time. revenue.

Sales and marketing. Sales and marketing expenses consist of personnel expenses, including sales commissions for our direct sales force and our market and business development workforce, as well as digital marketing costs, promotional costs, customer conferences, public relations, other marketing events, and allocated overhead costs. Personnel expenses include salaries, bonuses, stock-based compensation expense, and benefits for employees and contractors. We expect sales and marketing expense to increase in absolute dollars but remain relatively stable as a percentage of revenue over time.

General and administrative. General and administrative expenses consist of personnel expenses and related expenses for our executive, finance and accounting, human resources, legal, and corporate organizations. Personnel expenses include salaries, bonuses, stock-based compensation expense, and benefits for employees and contractors. In addition, general and administrative expenses include external legal, accounting, and other professional fees, as well as tools for financial and human capital management, and allocated overhead costs. We expect general and administrative expenses to increase but at a lower rate than the rate of growth experienced in absolute dollars as fiscal 2022 and 2023 due to the workforce realignment actions taken by management in fiscal 2023. Over time, we incur costs associated with being a public company, but expect general and administrative expenses to decrease as a percentage of revenue over time. revenue.

Depreciation and amortization. Depreciation and amortization expenses are primarily attributable to our capital investments and consist of fixed asset depreciation, amortization of intangibles considered to have definite lives, and amortization of capitalized internal-use software costs.

Goodwill impairment. Goodwill impairment represents impairment charges incurred as a result of goodwill impairment testing.

63

Results of Operations

The following table presents a summary of our consolidated statements of operations for the periods indicated:

| | Year Ended February 28, | | Year Ended February 28, | |
|---|----------------------------|-------------|----------------------------|--------------|
| | 2022 | 2021 | 2023 | 2022 |
| | (in thousands) | | (in thousands) | |
| Revenue | \$ 310,021 | \$ 170,358 | \$ 363,142 | \$ 310,021 |
| Cost of revenue, excluding depreciation and amortization ⁽¹⁾ | 169,019 | 93,673 | 198,905 | 169,019 |
| Operating expenses: | | | | |
| Product and technology ⁽¹⁾ | 83,664 | 49,955 | 101,347 | 83,664 |
| Sales and marketing ⁽¹⁾ | 86,765 | 33,711 | 99,113 | 86,765 |
| General and administrative ⁽¹⁾ | 99,106 | 31,584 | 81,209 | 99,106 |
| Depreciation and amortization | 42,608 | 8,212 | 46,377 | 42,608 |
| Goodwill impairment | | | 299,705 | — |
| Change in fair value of contingent consideration | (45,416) | — | — | (45,416) |
| Total operating expenses | 266,727 | 123,462 | 627,751 | 266,727 |
| Loss from operations | (125,725) | (46,777) | (463,514) | (125,725) |
| Interest expense, net | (2,905) | (3,724) | | |
| Interest income (expense), net | | | 255 | (2,905) |
| Other expense | (133) | (147) | (15) | (133) |
| Loss before income taxes | (128,763) | (50,648) | (463,274) | (128,763) |
| Income tax benefit (expense) | 5,639 | (4) | | |
| Income tax benefit | | | 3,624 | 5,639 |
| Net loss | \$ (123,124) | \$ (50,652) | \$ (459,650) | \$ (123,124) |

⁽¹⁾ The stock-based compensation expense included above was as follows:

| | Year Ended February 28, | | Year Ended February 28, | |
|--|----------------------------|----------|----------------------------|-----------|
| | 2022 | 2021 | 2023 | 2022 |
| | (in thousands) | | (in thousands) | |
| Cost of revenue, excluding depreciation and amortization | \$ 3,197 | \$ 948 | \$ 4,794 | \$ 3,197 |
| Product and technology | 18,744 | 3,387 | 24,995 | 18,744 |
| Sales and marketing | 12,822 | 2,376 | 17,275 | 12,822 |
| General and administrative | 38,176 | 2,865 | 25,580 | 38,176 |
| Total stock-based compensation | \$ 72,939 | \$ 9,576 | \$ 72,644 | \$ 72,939 |

64

The following table sets forth our consolidated statements of operation data expressed as a percentage of revenue:

| | Year Ended February 28, | | Year Ended February 28, | |
|--|----------------------------|-------|----------------------------|-------|
| | 2022 | 2021 | 2023 | 2022 |
| Revenue | 100 % | 100 % | 100 % | 100 % |
| Cost of revenue, excluding depreciation and amortization | 55 % | 55 % | 55 % | 55 % |
| Operating expenses: | | | | |
| Product and technology | 27 % | 29 % | 28 % | 27 % |
| Sales and marketing | 28 % | 20 % | 27 % | 28 % |
| General and administrative | 32 % | 19 % | 22 % | 32 % |
| Depreciation and amortization | 14 % | 5 % | 13 % | 14 % |
| Goodwill impairment | | | 83 % | — % |
| Change in fair value of contingent consideration | (15)% | | — % | (15)% |
| Total operating expenses | 86 % | 72 % | 173 % | 86 % |
| Loss from operations | (42)% | (28)% | (129)% | (42)% |
| Interest expense, net | (1)% | (2)% | | |
| Interest income (expense), net | | | — % | (1)% |
| Other expense | 0 % | 0 % | — % | — % |
| Loss before income taxes | (42)% | (30)% | (128)% | (42)% |
| Income tax expense | 2 % | 0 % | | |
| Income tax benefit | | | 1 % | 2 % |
| Net loss | (40)% | (30)% | (127)% | (40)% |

Comparison of Fiscal Years Ended February 28, 2022 February 28, 2023 and 2021 2022

Revenue

| | Year Ended February 28, | | | | Year Ended February 28, | | | |
|---------|------------------------------------|------------|------------|------|------------------------------------|-----------|----------|------|
| | 2022 | 2021 | Changes | | 2023 | 2022 | Changes | |
| | | | Amount | % | | | Amount | % |
| | (in thousands, except percentages) | | | | (in thousands, except percentages) | | | |
| Revenue | \$ 310,021 | \$ 170,358 | \$ 139,663 | 82 % | \$363,142 | \$310,021 | \$53,121 | 17 % |

Revenue increased \$139.7 million \$53.1 million, or 82% 17%, to \$363.1 million for the fiscal year ended February 28, 2023, referred to as fiscal 2023, as compared to \$310.0 million for the fiscal year ended February 28, 2022, referred to as fiscal 2022, as compared to \$170.4 million for the fiscal year ended February 28, 2021, referred to as fiscal 2021. 2022. The increase was attributable to growth in the number of customers served during fiscal 2022, 2023 compared to fiscal 2022. Revenue from access fees increased \$19.5 million, or 7%, to \$284.1 million for fiscal 2023 as compared to \$264.6

million for fiscal 2021, driven by both organic growth and growth 2022. Revenue from utilization-based fees increased \$33.6 million, or 74%, to \$79.0 million for fiscal 2023 as compared to \$45.4 million for fiscal 2022. The increase in utilization-based fees was primarily attributable to a full year of fees related to the acquisitions of 2nd.MD and PlushCare, which contributed approximately \$48.8 million and \$44.4 million virtual primary care utilization in revenues during fiscal 2023 compared to fiscal 2022 respectively, when the PlushCare acquisition occurred mid-year.

Cost of revenue, excluding depreciation and amortization

| | Year Ended February 28, | | Changes | | | Year Ended February 28, | | Changes | |
|--|----------------------------|------|---------|--|--|----------------------------|------|---------|--|
| | 2022 | 2021 | | | | 2023 | 2022 | | |

| | 2022 | 2021 | Amount | % | 2023 | 2022 | Amount | % |
|--|------------------------------------|-----------|-----------|------|------------------------------------|-----------|----------|------|
| | (in thousands, except percentages) | | | | (in thousands, except percentages) | | | |
| Cost of revenue, excluding depreciation and amortization | \$ 169,019 | \$ 93,673 | \$ 75,346 | 80 % | \$198,905 | \$169,019 | \$29,886 | 18 % |

Cost of revenue, excluding depreciation and amortization increased \$75.3 million \$29.9 million, or 80% 18%, to \$198.9 million for fiscal 2023, as compared to \$169.0 million for fiscal 2022, as compared to \$93.7 million for fiscal 2021. 2022. The increase was attributable primarily to cost of revenue incurred by 2nd.MD and PlushCare as well as an increase \$23.2 million in increased personnel and related costs to serve the customer base, which grew included \$1.0 million in fiscal 2022 as compared to fiscal 2021, severance costs associated with workforce realignment actions taken by management, \$3.1 million in increased costs associated with third-party services and solutions from trusted suppliers, and \$1.6 million in increased stock-based compensation expense.

65

Operating expenses

| | Year Ended February 28, | | | | Year Ended February 28, | | | |
|--|------------------------------------|------------|------------|-------|------------------------------------|-----------|-----------|-------|
| | 2022 | 2021 | Amount | % | 2023 | 2022 | Amount | % |
| | (in thousands, except percentages) | | | | (in thousands, except percentages) | | | |
| Operating expenses: | | | | | | | | |
| Product and technology | \$ 83,664 | \$ 49,955 | \$ 33,709 | 67 % | \$101,347 | \$ 83,664 | \$ 17,683 | 21 % |
| Sales and marketing | 86,765 | 33,711 | 53,054 | 157 % | 99,113 | 86,765 | 12,348 | 14 % |
| General and administrative | 99,106 | 31,584 | 67,522 | 214 % | 81,209 | 99,106 | (17,897) | (18)% |
| Depreciation and amortization | 42,608 | 8,212 | 34,396 | 419 % | 46,377 | 42,608 | 3,769 | 9 % |
| Goodwill impairment | | | | | 299,705 | — | 299,705 | N/A |
| Change in fair value of contingent consideration | (45,416) | — | (45,416) | N/A | — | (45,416) | 45,416 | N/A |
| Total operating expenses | \$ 266,727 | \$ 123,462 | \$ 143,265 | 116 % | \$627,751 | \$266,727 | \$361,024 | 135 % |

Product and technology. Product and technology expense increased \$33.7 million \$17.7 million, or 67% 21%, to \$83.7 million \$101.3 million for fiscal 2022, 2023, as compared to \$50.0 million \$83.7 million for fiscal 2021. 2022. The increase was primarily driven by increases \$8.9 million in increased personnel added via the 2nd.MD and PlushCare acquisitions, along related costs, which included \$2.1 million in severance costs associated with the addition of personnel workforce realignment actions taken by management, and \$6.3 million in product development, technology, and product management to support the development of new and existing offerings in connection with the expansion of our business. increased stock-based compensation expense.

Sales and marketing. Sales and marketing expense increased \$53.1 million \$12.3 million, or 157% 14%, to \$99.1 million for fiscal 2023, as compared to \$86.8 million for fiscal 2022, as compared to \$33.7 million for fiscal 2021. 2022. The increase was primarily driven by increases \$6.2 million in personnel added via the 2nd.MD and PlushCare acquisitions, increased digital marketing costs, \$4.5 million in increased stock-based compensation expense, and \$1.9 million in severance costs associated with customer acquisition spend related to PlushCare, along with an increase in the size of our direct sales force, account management, marketing, and supporting functions associated with the expansion of our business. workforce realignment actions taken by management.

General and administrative. General and administrative expense increased \$67.5 million decreased (\$17.9) million, or (18)% or 214%, to \$81.2 million for fiscal 2023, as compared to \$99.1 million for fiscal 2022, as compared to \$31.6 million for fiscal 2021. 2022. The increase decrease was primarily due to the addition of general \$12.6 million in decreased stock-based compensation expense and administrative costs from the 2nd.MD and PlushCare businesses, \$13.2 million of \$12.0 million in decreased acquisition and integration-related charges.

66

partially offset by increases in personnel and related costs incurred in fiscal 2022, and of \$4.9 million of which \$1.9 million was severance costs to operate as a public company, associated with workforce realignment actions taken by management.

Depreciation and amortization. Depreciation and amortization expense increased \$34.4 million \$3.8 million, or 419% 9%, to \$46.4 million for fiscal 2023, as compared to \$42.6 million for fiscal 2022, as compared to \$8.2 million for fiscal 2021, 2022. The increase was primarily due to having a full year of amortization of intangible assets in fiscal 2023 related to intangibles acquired from 2nd.MD and in the PlushCare acquisition during fiscal 2022.

Goodwill impairment. This operating expense represents the impairment charge taken as a result of the goodwill impairment test performed during the first quarter of fiscal 2023.

Change in fair value of contingent consideration. This operating expense represents the change in the fair value of the contingent consideration liabilities associated with the 2nd.MD and PlushCare acquisitions. For fiscal 2022, the change in fair value of The contingent consideration decreased primarily due was reclassified to a decrease equity in our stock price, the fourth quarter of fiscal 2022.

Interest expense, income (expense), net

| | Year Ended | | | | Year Ended | | | |
|--------------------------------|------------------------------------|----------|----------|------|------------------------------------|-----------|----------|-------|
| | February 28, | | Changes | | February 28, | | Changes | |
| | 2022 | 2021 | Amount | % | 2023 | 2022 | Amount | % |
| | (in thousands, except percentages) | | | | (in thousands, except percentages) | | | |
| Interest expense, net | \$ 2,905 | \$ 3,724 | \$ (819) | 22 % | | | | |
| Interest income (expense), net | | | | | \$ 255 | \$(2,905) | \$ 3,160 | 109 % |

Interest expense, income (expense), net decreased \$0.8 million increased \$3.2 million, or 22% 109%, to \$2.9 million \$0.3 million for fiscal 2022, 2023, as compared to \$3.7 million \$(2.9) million for fiscal 2021, 2022. The decrease increase was primarily due to an additional \$3.4 million of interest associated with income generated from our term loan cash and revolving credit agreement in cash equivalents during fiscal 2021 that did not exist in fiscal 2022, partially offset by interest associated with the Convertible Senior Notes in 2023 as compared to fiscal 2022.

Certain Non-GAAP Financial Measures

We use the following non-GAAP financial measures to help us evaluate trends, establish budgets, measure the effectiveness and efficiency of our operations, and determine employee incentives.

| | Year Ended | | Year Ended | |
|-----------------------|------------------------------------|-------------|------------------------------------|-------------|
| | February 28, | | February 28, | |
| | 2022 | 2021 | 2023 | 2022 |
| | (in thousands, except percentages) | | (in thousands, except percentages) | |
| Adjusted Gross Profit | \$ 144,199 | \$ 77,633 | \$ 170,056 | \$ 144,199 |
| Adjusted Gross Margin | 46.5 % | 45.6 % | 46.8 % | 46.5 % |
| Adjusted EBITDA | \$ (42,375) | \$ (26,939) | \$ (36,505) | \$ (42,375) |

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation, compensation and severance costs. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We expect Adjusted Gross Margin to continue to improve over time to the extent that we are able to gain efficiencies through technology and successfully cross-sell and upsell our current and future offerings. However, our ability to improve Adjusted Gross Margin over time is not guaranteed and will be impacted by the factors affecting our performance discussed above

and the risks outlined in the section titled “Risk Factors.” We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors, as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other nonrecurring operating expenses.

67

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net **loss income (loss)** adjusted to exclude interest expense **(net) (income), net**, income tax expense (benefit), depreciation and amortization, stock-based compensation, acquisition and integration-related costs, **and goodwill impairment**, change in fair value of contingent **consideration, consideration, severance costs, and other expense (income).** **Severance costs include severance payments related to the realignment of our resources.** Other expense (income) includes foreign exchange **gain or loss.** We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance. We believe Adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry, as this measure generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA have certain limitations, including that they exclude the impact of certain non-cash charges, such as depreciation and amortization, whereas underlying assets may need to be replaced and result in cash capital expenditures, and stock-based compensation expense, which is a recurring charge. These non-GAAP financial measures may also not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner, limiting their usefulness as comparative measures. In evaluating these non-GAAP financial measures, you should be aware that in the future we expect to incur expenses similar to the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or nonrecurring items. When evaluating our performance, you should consider these non-GAAP financial measures alongside other financial performance measures, including the most directly comparable GAAP measures set forth in the reconciliation

67

tables below and our other GAAP results. The following table presents, for the periods indicated, the calculation of our Adjusted Gross Profit and Adjusted Gross Margin:

| | Year Ended | |
|--|------------------------------------|------------|
| | February 28(29), | |
| | 2022 | 2021 |
| | (in thousands, except percentages) | |
| Revenue | \$ 310,021 | \$ 170,358 |
| Less: | | |
| Cost of revenue, excluding depreciation and amortization | (169,019) | (93,673) |
| Gross profit, excluding depreciation and amortization | 141,002 | 76,685 |
| Add: | | |
| Stock-based compensation, cost of revenue | 3,197 | 948 |
| Adjusted Gross Profit | \$ 144,199 | \$ 77,633 |
| Gross margin, excluding depreciation and amortization | 45.5 % | 45.0 % |
| Adjusted Gross Margin | 46.5 % | 45.6 % |

| | Year Ended | |
|--|------------------------------------|------------|
| | February 28(29), | |
| | 2023 | 2022 |
| | (in thousands, except percentages) | |
| Revenue | \$ 363,142 | \$ 310,021 |
| Less: | | |
| Cost of revenue, excluding depreciation and amortization | (198,905) | (169,019) |
| Gross profit, excluding depreciation and amortization | 164,237 | 141,002 |
| Add: | | |
| Stock-based compensation, cost of revenue | 4,794 | 3,197 |
| Severance costs, cost of revenue | 1,025 | — |
| Adjusted Gross Profit | \$ 170,056 | \$ 144,199 |
| Gross margin, excluding depreciation and amortization | 45.2 % | 45.5 % |
| Adjusted Gross Margin | 46.8 % | 46.5 % |

Gross margin, excluding depreciation and amortization, for fiscal 2022 increased 2023 decreased to 45.5% 45.2% from 45.0% 45.5% for fiscal 2021 2022. This decrease was primarily driven by an increase of \$1.6 million in stock-based compensation expense, cost of revenue, and \$1.0 million in severance costs associated with workforce realignment actions taken by management in fiscal 2023 compared to fiscal 2022. Adjusted Gross Margin for fiscal 2022 2023 increased to 46.5% 46.8% from 45.6% 46.5% for fiscal 2021. These increases were 2022. This increase was driven primarily by (i) a higher margin offering mix for the full fiscal year 2023 and (ii) the realization of cost efficiencies realized through enhancements in fiscal 2023, partially offset by the impact of investments in launching new offerings that have not yet reached scale (for example, launching our technology platform and workflows for fiscal 2022 virtual primary care offering to commercial customers), as well as the impact of increased labor costs on our frontline care teams.

68

The following table presents, for the periods indicated, a reconciliation of our Adjusted EBITDA to our net loss:

| | Year Ended | | Year Ended | |
|--|----------------|-------------|----------------|-------------|
| | February 28, | | February 28, | |
| | 2022 | 2021 | 2023 | 2022 |
| | (in thousands) | | (in thousands) | |
| Net Loss | \$ (123,124) | \$ (50,652) | \$(459,650) | \$(123,124) |
| Adjusted for: | | | | |
| Interest expense, net | 2,905 | 3,724 | | |
| Income tax expense (benefit) | (5,639) | 4 | | |
| Interest expense (income), net | | | (255) | 2,905 |
| Income tax benefit | | | (3,624) | (5,639) |
| Depreciation and amortization | 42,608 | 8,212 | 46,377 | 42,608 |
| Stock-based compensation | 72,939 | 9,576 | 72,644 | 72,939 |
| Acquisition and integration-related costs | 13,219 | 2,050 | 1,218 | 13,219 |
| Goodwill impairment | | | 299,705 | — |
| Change in fair value of contingent consideration | (45,416) | — | — | (45,416) |
| Severance costs | | | 7,065 | — |
| Other expense | 133 | 147 | 15 | 133 |
| Adjusted EBITDA | \$ (42,375) | \$ (26,939) | \$ (36,505) | \$ (42,375) |

Liquidity and Capital Resources

We had cash and cash equivalents of \$365.9 million \$321.1 million as of February 28, 2022 February 28, 2023. Our cash equivalents are comprised primarily of cash and money market accounts held at banks and U.S. treasury bills with original maturities of less than three

months.

Our Debt Arrangements

In March 2021, we issued an aggregate of \$287.5 million principal amount of 0.50% Convertible Senior Notes due 2026 (the Notes), including the exercise in full by the initial purchasers of their option to purchase up to an additional \$37.5 million aggregate principal amount of the Notes, pursuant to an Indenture dated as of March 29, 2021 (the Indenture), between us and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of 0.50% per annum, payable semiannually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021. The

68

Notes mature on April 1, 2026, unless earlier converted, redeemed or repurchased. The Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.

We currently have a revolving credit facility (2019 Revolver), which we entered into in July 2019. The 2019 Revolver provides for a senior secured revolving line of credit in the amount of up to \$80.0 million, with borrowing availability subject to certain monthly recurring revenue calculations. The interest rate on any outstanding borrowings is at LIBOR the Bloomberg Short-Term Bank Yield Index rate (BSBY) plus 350 basis points (prior to December 31, 2021) or the lending institution's base rate Base Rate (as defined) plus 250 basis points, with the BSBY rate and Base Rate subject to minimum levels, subject to certain floors, and interest payments are to be made in installments of one, two, or three months as chosen by us. We also have an outstanding letter letters of credit to serve as an office landlord security deposit deposits in the amount of \$1.1 million \$1.2 million. This letter These letters of credit is are secured through the revolving credit facility, thus reducing the capacity of the revolving credit facility to \$78.9 million \$78.8 million.

During March 2020, we borrowed the available capacity of \$48.7 million to increase our cash position given the uncertainty in the overall business environment due to the COVID-19 pandemic. During July 2020, we repaid the 2019 Revolver in full, including all outstanding interest. The 2019 Revolver expires in July 2022.

The 2019 Revolver contains a liquidity covenant calculated based on cash on hand plus available borrowings under the 2019 Revolver, a revenue covenant and certain reporting covenants. On August 21, 2020 July 19, 2022, we entered into an amendment to extend the 2019 Revolver which revised term until July 19, 2024, documented the terms of transition from the revenue covenant and imposed minimum prior LIBOR and Base Rate levels. On September 11, 2020, we entered into another amendment interest rate index to the 2019 Revolver which modified the allocation requirements BSBY rate, and established new minimum covenant revenue targets. The term will automatically be extended to July 19, 2025 if we have at least \$200,000 in consolidated net cash as of our cash to be held at each of the two lenders participating in the 2019 Revolver. On November 6, 2020, we entered into another amendment to the 2019 Revolver which increased the capacity from \$50.0 million to \$80.0 million May 31, 2024. On March 2, 2021, we entered into another amendment to the 2019 Revolver in association with the acquisition of 2nd.MD and amended certain revenue covenants. On March 23, 2021, we entered into another amendment to the 2019 Revolver in association with the convertible senior notes offering. On May 26, 2021, we entered into another amendment to the 2019 Revolver in association with the acquisition of PlushCare which modified certain reporting covenants.

We were in compliance with all such applicable covenants as of February 28, 2022 February 28, 2023, and believe we are in compliance as of the date of this Annual Report on Form 10-K. We do not expect to need to draw on the 2019 Revolver, but our access to draw on the 2019 Revolver could be limited in the future if we do not have enough monthly recurring revenues to cover the borrowing availability calculations.

69

Material Cash Requirements

As of February 28, 2022 February 28, 2023, our material cash requirements from known contractual and other obligations, which we expect to fund through available cash, future cash generated from operations, and our existing financing arrangements, are as follows:

- *Principal and interest obligations on convertible debt* – As discussed in detail above, the \$287.5 million principal amount of the Notes matures on April 1, 2026. See *Our Debt Arrangements* above and Note 10 to our consolidated financial statements for more details.
- *Operating leases* – We have entered into operating leases, primarily for office space. See Note 7 to our consolidated financial statements for more details.
- *Other purchase obligations* – We have entered into certain arrangements that include obligations to make significant future purchases. The majority of these purchases are not expected to be made over the next 12 months. See Note 16 to our consolidated financial statements for more details.
- *Other material cash requirements* – In addition to the above, our material cash requirements also include compensation and benefits expenses for our employees, severance for terminated employees, expenses for software and third-party services, and other miscellaneous expenses.

Cash Flows

The following table summarizes our cash flows for the periods indicated:

| | Year Ended February 28, | | Year Ended February 28, | |
|---|----------------------------|-------------|----------------------------|-------------|
| | 2022 | 2021 | 2023 | 2022 |
| | (in thousands) | | (in thousands) | |
| Net cash used in operating activities | \$ (62,350) | \$ (25,232) | \$(40,705) | \$ (62,350) |
| Net cash used in investing activities | (263,613) | (2,423) | (7,228) | (263,613) |
| Net cash provided by financing activities | 257,932 | 428,384 | 3,163 | 257,932 |

Operating Activities.

Net cash used in operating activities increased decreased by \$37.1 million \$21.6 million to \$40.7 million during fiscal 2023 from \$62.4 million during fiscal 2022, from \$25.2 million during fiscal 2021, primarily due to higher net loss, which included \$13.2 million in lower cash payments for acquisition and integration-related charges as well as changes in accounts receivable fiscal 2023 compared to fiscal 2022 and accrued compensation, partially offset by changes in deferred revenue and due to customers, favorable timing of customer payments.

Investing Activities.

Net cash used in investing activities increased decreased by \$261.2 million \$256.4 million to \$7.2 million during fiscal 2023 from \$263.6 million during fiscal 2022, from \$2.4 million during fiscal 2021, primarily due to \$260.0 million of cash paid for the acquisitions net of cash acquired, of 2nd.MD and PlushCare in fiscal 2022.

Financing Activities.

Net cash provided by financing activities decreased by \$170.5 million \$254.8 million to \$3.2 million during fiscal 2023 from \$257.9 million during fiscal 2022, from \$428.4 million during fiscal 2021, primarily due to the absence of proceeds from our public offerings which occurred in the prior year issuance of the Convertible Notes of \$287.5 million and the payment for purchase of capped calls associated with the Convertible Senior Notes partially offset by the issuance of the Convertible Senior Notes.

Off-Balance Sheet Arrangements

We did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other purposes. We did not have any other off-balance sheet arrangements, except to the extent reflected under “Material Cash Requirements” above and \$(34.4) million in Note 16 to our consolidated financial statements. fiscal 2022.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of

70

assets, liabilities, revenue, and expenses, as well as related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates.

We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. Our significant accounting policies are more fully described in Note 2 to our consolidated financial statements located elsewhere in this Annual Report on Form 10-K. We have listed below our critical accounting estimates that we believe to have the

70

greatest potential impact on our consolidated financial statements. Historically, our assumptions, judgments, and estimates relative to our critical accounting estimates have not differed materially from actual results.

The critical accounting estimates, assumptions and judgments that we believe have the most significant impact on our consolidated financial statements are described below.

Revenue Recognition

We generate revenue by providing customers access to our advocacy, expert medical opinion, and virtual primary care and mental health support services, as well as through utilization of our expert medical opinion and virtual primary care and mental health support services that were acquired through the acquisitions of 2nd.MD and PlushCare. Contracts with customers that include expert medical opinion or virtual primary care and mental health support services may contain either an access fee, a utilization-based fee, or both.

In accordance with Accounting Standards Codification (ASC) 606, *Revenue from Contracts with Customers*, we recognize revenue when control of the promised services is transferred to our customers, in an amount that reflects the consideration to which we expect to be entitled in exchange for those services. Accordingly, we determine revenue recognition through the following steps:

- identification of the contract, or contracts with a customer;
- identification of the performance obligations in the contract;
- determination of the transaction price;
- allocation of the transaction price to the performance obligations in the contracts; and
- recognition of revenue when, or as, the Company satisfies a performance obligation.

At contract inception, we assess the type of services being provided and assess the performance obligations in the contract. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine the standalone selling prices based on overall pricing objectives, taking into consideration market conditions and other factors, using an expected cost plus margin approach. We considered the variable consideration allocation exception in ASC 606 and concluded that such exception for allocating variable consideration to distinct performance obligations or distinct time periods within a series was not met primarily due to variability in per-member-per-month (PMPM) pricing.

The majority of fees earned by us is considered to be variable consideration due to both the uncertainty regarding the total number of members, consultations or visits for which we will invoice the customer, as well as the variable PMPM fees that are dependent upon the achievement of performance metrics and/or healthcare cost savings. Performance metrics are measured monthly, quarterly, or annually, and with respect to the achievement of healthcare cost savings targets, annually (typically measured on a calendar year basis). Accordingly, at contract inception and on an ongoing basis, as part of our estimate of the transaction price, we determine whether any such fees should be constrained, and we include the estimated consideration for those fees to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur (and is therefore considered to be unconstrained). On an

71

ongoing basis, we reassess our estimates for variable consideration, which can change based upon our assessment of the achievement of performance metrics and healthcare cost savings, as well as the number of members, consultations, or visits.

Access Fees

We generate revenue primarily from contracts with customers to access our advocacy, expert medical opinion, and virtual primary care and mental health support services. We price access fees primarily using a recurring PMPM fee,

71

typically with a portion of the fee calculated as the product of a fixed rate times the number of members (fixed PMPM fee), plus a variable PMPM fee calculated as the product of a variable rate times the number of members (variable PMPM fee). The fees associated with the variable PMPM fee can be earned through the achievement of performance metrics and/or the realization of healthcare cost savings resulting from the use of our services. Collectively, the fixed PMPM fee and variable PMPM fee are referred to as the total PMPM fee. Our PMPM pricing varies by contract. In certain contracts, the maximum total PMPM fee varies during the contract term (total PMPM rate increases or decreases annually), while in other contracts, the total PMPM maximum fee is consistent over the term, yet the fixed and variable portions vary. For example, in certain contracts the fixed PMPM fee increases on an annual basis while the variable PMPM fee decreases on an annual basis, resulting in the same total PMPM fee throughout the term of the contract. The PMPM fees for expert medical opinion and virtual primary care and mental health support services may be tiered based upon the customer's utilization.

Access to our services represents a single stand-ready performance obligation. Our contracts include stand-ready services to provide eligible participants with access to our services and to perform an unspecified quantity of interactions with members during the contract period. Accordingly, our services are generally viewed as stand-ready performance obligations comprised of a series of distinct daily services that are substantially the same and have the same pattern of transfer. Generally, we satisfy these performance obligations over time and recognize revenue related to our services as the services are provided using a measure of progress based upon the actual number of members eligible for the service during the respective period as a percentage of the estimated members expected to be eligible for the service over the term of the contract. We believe a measure of progress based on the number of members is the most appropriate measurement of control of the services being transferred to the customer as the amount of internal resources necessary to stand ready is directly correlated to the number of members who can use the services.

For the majority of expert medical opinion services, we satisfy these performance obligations over time and recognize revenue in the amount of consideration for which we have the right to invoice using the as-invoiced practical expedient. Access fees also include access to our virtual primary care and mental health support services sold directly to consumers on a monthly or yearly fixed fee subscription basis. For these services, we satisfy these stand-ready performance obligations over time and recognize revenue ratably over the subscription period.

Utilization-based fees

We also generate revenue when members utilize the expert medical opinion and virtual primary care and mental health support services that are billed based on utilization. Many, but not all, contracts with customers contain utilization-based fees. For any utilization-based fees, we satisfy these performance obligations over time and recognize revenue in the amount of consideration for which we have the

right to invoice using the as-invoiced practical expedient for any consultations or visits sold to enterprise commercial customers as well as any non-insured consultations or visits related to virtual primary care and mental health support services sold directly to consumers. For any consultations or visits that are paid through insurance claims, we recognize revenue as the consultations and visits occur in an amount that reflects the consideration that is expected based upon then-current prices and historical experience from insurance payors.

Stock-Based Compensation

We estimate the fair value of our stock options using the Black-Scholes option pricing model. This requires the input of subjective assumptions, including the fair value of our underlying common stock (prior to our IPO), the expected term of stock options, the expected volatility of the price of our common stock, risk-free interest rates, and the expected dividend yield of our common stock, the most critical of which, prior to our IPO, was the estimated fair value of common stock. The assumptions used in our option pricing model represent our best estimates. These estimates

72

involve inherent uncertainties and the application of management's judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. The resulting fair value, net of actual forfeitures, is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award.

Prior to our IPO, our board of directors periodically estimated the fair value of the Company's common stock considering, among other things, contemporaneous valuations of our preferred and common stock prepared by an

72

unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid, Valuation of Privately-Held-Company Equity Securities Issues as Compensation. Since the closing of the IPO, our board of directors has determined the per share fair value of the Company's common stock based on the closing price as reported by the Nasdaq Global Select Market on the date of grant.

The subjective assumption used in the Black-Scholes option pricing model, other than the fair value of our common stock (prior to our IPO), is estimated as follows:

- *Expected volatility.* Since a public market for our common stock did not exist prior to our IPO in July 2020 and, therefore, we do not have an extensive trading history of our common stock, we estimated the expected volatility based on the volatility of similar publicly-held entities (guideline companies) over a period equivalent to the expected term of the awards. In evaluating the similarity of guideline companies to us, we considered factors such as industry, stage of life cycle, size, and financial leverage. We intend to continue to consistently apply this process using the same or similar guideline companies to estimate the expected volatility until sufficient historical information regarding the volatility of the share price of our common stock becomes available.

We are required to estimate the fair value of the common stock underlying our stock-based awards when performing fair value calculations.

Accounting for Goodwill and Other Intangible Assets

Goodwill. Goodwill represents the excess of the cost of an acquired business over the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. As of February 28, 2022, we had \$577.9 million of goodwill recorded on our consolidated balance sheet. For the purposes of impairment testing, we have determined that we have one reporting unit. We perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If that is the case, we perform a quantitative impairment test. We test our goodwill for impairment on an annual basis in the fourth quarter of each fiscal year, or more frequently whenever an event or change in circumstances indicates that the asset may be impaired.

In performing our evaluation, we assess qualitative factors such as overall financial performance of our reporting unit, anticipated changes in industry and market structure, and the competitive and regulatory environment. **No indicators**

As a result of sustained decreases in our stock price and market capitalization, we conducted an impairment **were identified** test of our goodwill as of May 31, 2022. As a result of this testing, we recorded a \$299.7 million non-cash goodwill impairment charge (equivalent to \$4.20 per basic and diluted share) during the **fiscal** year ended **February 28, 2022** that required us **February 28, 2023**. Our May 31, 2022 goodwill impairment test reflected an allocation of 70% and 30% between the income and market-based approaches, respectively. We believe the 70% weighting to **perform an interim assessment** the income-based approach is appropriate as it more directly reflects our future growth and profitability expectations. Significant inputs into the valuation models included the discount rate, revenue market multiples, and estimated future cash flows. We used a discount rate of 11% and guideline peer group and public transaction revenue multiples between 1.1x and 1.8x current and forward-looking revenues in the goodwill impairment test. Subsequent to the impairment, there was no excess of reporting unit fair value over carrying value.

While we cannot predict if or **recoverability test** when additional future goodwill impairments may occur, additional goodwill impairments could have material adverse effects on our operating income, net assets, and/or our cost of, or access to, capital.

73

Realizability of Long-Lived Assets. We assess the realizability of our long-lived assets and related intangible assets, other than goodwill, quarterly, or sooner should events or changes in circumstances indicate the carrying values of such assets may not be recoverable. We consider the following factors important in determining when to perform an impairment review: significant under-performance of a business or product line relative to budget; shifts in business strategies which affect the continued uses of the assets; significant negative industry or economic trends; and the results of past impairment reviews. When such events or changes in circumstances occur, we assess recoverability of these assets.

We assess recoverability of these assets by comparing the carrying amounts to the future undiscounted cash flows the assets are expected to generate. If impairment indicators were present based on our undiscounted cash flow models, which include assumptions regarding projected cash flows, we would perform a discounted cash flow analysis to assess impairments on long-lived assets. Variances in these assumptions could have a significant impact on our conclusion as to whether an asset is impaired or the amount of any impairment charge. Impairment charges, if any, result in situations where any fair values of these assets are less than their carrying values.

In addition to our recoverability assessments, we routinely review the remaining estimated useful lives of our long-lived assets. Any reduction in the useful life assumption will result in increased depreciation and amortization expense in the quarter when such determinations are made, as well as in subsequent quarters.

73

We will continue to evaluate the values of our long-lived assets in accordance with applicable accounting rules. As changes in business conditions and our assumptions occur, we may be required to record impairment charges.

Business Combinations and Contingent Consideration

We account for acquisitions in a business combination under the U.S. GAAP business combinations guidance. This accounting requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. Any excess purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. The results of acquired businesses are included in our consolidated financial statements from the date of acquisition. Acquisition-related costs are not considered part of the purchase consideration and are accounted for as operating expenses as incurred.

We account for contingent consideration in accordance with applicable guidance provided within the business combination accounting rules. As part of our consideration for the 2nd.MD and PlushCare acquisitions, we are contractually obligated to pay certain

consideration resulting from the outcome of future events. Therefore, we are required to update our assumptions each reporting period, based on new developments, and record such contingent consideration liabilities at fair value until the contingency is resolved. Changes in the fair value of the contingent consideration liabilities are recognized each reporting period and included in our consolidated statements of operations.

Determining the fair value of assets acquired and liabilities assumed in a business combination requires significant management judgment and estimates, including determining appropriate discount rates and useful lives, selecting valuation methodologies, and estimating future revenues, expenses, and cash flows. In valuing the contingent consideration, the probability of the occurrence of future events is a critical estimate. We may engage third-party valuation specialists to assist with determining the fair value of assets acquired, liabilities assumed, and contingent consideration. These estimates are inherently uncertain and unpredictable, and if different estimates were used the purchase price for the acquisition could be allocated to the assets acquired and liabilities assumed differently from the allocation that we have made. In addition, unanticipated events and circumstances may occur, which may affect the accuracy or validity of such estimates, and if such events occur we may be required to record a charge against the value ascribed to an acquired asset or an increase in the amounts recorded for liabilities assumed.

Recently Issued and Adopted Accounting Pronouncements

For more information on recently issued and adopted accounting pronouncements, see Note 2 in the accompanying Notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.

Emerging Growth Company Status

Prior to February 28, 2022, we were an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012. Based on the market value of our common stock held by non-affiliates as of August 31, 2021, we have met the conditions to be deemed a “large accelerated filer” as of February 28, 2022 and are consequently no longer an emerging growth company as of that date and for purposes of filing this Annual Report on Form 10-K.

Item 7A. Quantitative and Qualitative Disclosures about Market Risks

Interest Rate Risk

We had cash and cash equivalents of \$365.9 million \$321.1 million and \$433.9 million \$365.9 million as of February 28, 2022 February 28, 2023 and 2021, 2022, respectively. Our cash equivalents are comprised primarily of cash and money market accounts held at banks and U.S. treasury bills with original maturities of less than three months. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our investment portfolio as a result of changes in interest rates. Declines in interest rates, however, would reduce future interest income.

⁷⁴ In addition, our 2019 Revolver has a variable interest rate which, if drawn upon, would subject us to risks associated with changes in that interest rate. During fiscal 2023, we had no borrowings under the 2019 Revolver.

Foreign Currency Exchange Risk

We have in the past and may in the future be exposed to foreign currency exchange risks in the ordinary course of our business, but that exposure is not currently material to our business or results of operations.

Item 8. Financial Statements and Supplementary Data

The Consolidated Financial Statements are listed in the Index to Consolidated Financial Statements filed as part of this Annual Report on Form 10-K beginning on page F-1.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of external financial statements in accordance with U.S. generally accepted accounting principles.

Our management, including our Chief Executive Officer and our Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of February 28, 2022 February 28, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in *Internal Control-Integrated Framework (2013)*. Based on this assessment, management, including our Chief Executive Officer and our Chief Financial Officer, concluded that we maintained effective internal control over financial reporting as of February 28, 2022 February 28, 2023.

The Company acquired Innovation Specialists LLC d/b/a 2nd.MD (2nd.MD) and PlushCare, Inc. (PlushCare) during the fiscal year ended February 28, 2022, and management excluded from its assessment of the effectiveness of the Company’s internal control over financial reporting as of February 28, 2022, Innovation Specialists LLC d/b/a 2nd.MD and PlushCare, Inc.’s internal controls over financial reporting associated with approximately 23% of total assets and approximately 30% of total revenue included in the consolidated financial statements of the Company as of and for the year ended February 28, 2022. We are in the process of incorporating 2nd.MD and PlushCare into our system of internal control over financial reporting.

KPMG LLP, the Company’s independent registered public accounting firm, was appointed by the Board of Directors and ratified by our Company’s stockholders to render an opinion regarding our internal control over financial reporting, which appears below.

75

Changes in Internal Control Over Financial Reporting

In the third quarter of fiscal 2022, we identified a material weakness in internal control over financial reporting in connection with measuring the fair value of contingent consideration related to business combinations. In response, we have implemented additional measures to enhance our review and validation of key inputs to the valuation of contingent consideration arrangements. As such, this material weakness was remediated as of February 28, 2022.

Except as noted above related to the Company’s acquisitions, and the remediation efforts discussed above, there There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended February 28, 2022 February 28, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors
Accolade, Inc.:

Opinion on Internal Control Over Financial Reporting

We have audited Accolade, Inc. and subsidiaries (the Company) internal control over financial reporting as of February 28, 2022, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of February 28, 2022, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of February 28, 2022 and 2021, the related consolidated statements of operations, convertible preferred stock and stockholders' equity (deficit), and cash flows for each of the years in the three-year period ended February 28, 2022, and the related notes (collectively, the consolidated

75

financial statements), and our report dated May 2, 2022 expressed an unqualified opinion on those consolidated financial statements.

The Company acquired Innovation Specialists LLC d/b/a 2nd.MD and PlushCare, Inc. during fiscal year ended February 28, 2022, and management excluded from its assessment of the effectiveness of the Company's internal control over financial reporting as of February 28, 2022, Innovation Specialists LLC d/b/a 2nd.MD and PlushCare, Inc.'s internal control over financial reporting associated with 23% of total assets and 30% of total revenues included in the consolidated financial statements of the Company as of and for the year ended February 28, 2022. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Innovation Specialists LLC d/b/a 2nd.MD and PlushCare, Inc.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing

76

and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

Philadelphia, Pennsylvania

May 2, 2022 April 27, 2023

Item 9B. Other Information

On April 28, 2022, we entered into Equity Vesting Acceleration Agreements with each of our named executive officers (the Equity Vesting Acceleration Agreements). The Equity Vesting Acceleration Agreements provide that in the event that a named executive officer's employment terminates within 12 months following a Corporate Transaction (as defined in our 2020 Equity Incentive Plan) or two months preceding a Corporate Transaction, in each case resulting from (a) the Company terminating such named executive officer for any reason other than Cause (as defined in our 2020 Equity Incentive Plan) or (b) such named executive officer voluntarily resigns for Good Reason (as defined in the Equity Vesting Acceleration Agreements), then each of such named executive officer's then outstanding unvested equity awards, including awards that otherwise vest only upon satisfaction of performance criteria, shall accelerate and become exercisable with respect to 100% of the then unvested shares subject to such equity awards.

Such severance benefits are conditional on such named executive officer delivering, and not revoking, in the form provided by the Company, a general release of claims against the Company or persons affiliated with the Company and allowing such release to become effective.

The summary of the Equity Vesting Acceleration Agreement is qualified in its entirety by reference to the text of the Equity Vesting Acceleration Agreement which will be filed with the SEC as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended May 31, 2022. None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

None.

77 76

Part III

The information required by Part III is omitted from this report because we will file a definitive proxy statement within 120 days after the end of our fiscal year pursuant to Regulation 14A for our 2022 2023 Annual Meeting of Stockholders, or the 2022 2023 Proxy Statement, and the information to be included in the 2022 2023 Proxy Statement is incorporated herein by reference.

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this item is incorporated by reference to the information set forth in the sections titled "Proposal 1: Election of Directors," "Executive Officers," "Information Regarding the Board of Directors and Corporate Governance," and "Delinquent Section 16(a) Reports," if applicable, in our 2022 2023 Proxy Statement.

Item 11. Executive Compensation

The information required by this item is incorporated by reference to the information set forth in the sections titled "Executive Compensation—Compensation Discussion and Analysis" and "Director Compensation" in our 2022 2023 Proxy Statement.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item is incorporated by reference to the information set forth in the sections titled "Equity Compensation Plan Information" and "Security Ownership of Certain Beneficial Owners and Management" in our 2022 2023 Proxy Statement.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item is incorporated by reference to the information set forth in the sections titled “Transactions With Related Persons” and “Information Regarding the Board and Corporate Governance – Board Independence” in our 2022 2023 Proxy Statement.

Item 14. Principal Accountant Fees and Services

The information required by this item is incorporated by reference to the information set forth in the sections titled “Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm—Principal Accountant Fees and Services” in our 2022 2023 Proxy Statement.

Part IV

Item 15. Exhibit and Financial Statement Schedules

The following documents are filed as part of this report:

1. The consolidated financial statements of Accolade, Inc. and subsidiaries are included beginning from the section titled “Index to Consolidated Financial Statements” commencing on page F-1.
2. All financial statement schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.
3. The list of exhibits filed with this Annual Report on Form 10-K is set forth in the Exhibit Index preceding the signature page and is incorporated herein by reference or filed with this Annual Report on Form 10-K, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).

77

| Exhibit No. | Exhibit Description | Form | File No. | Exhibit | Filing Date | Filed Herewith |
|-------------|--|-------|------------|---------|-------------------|----------------|
| 2.1† | Agreement and Plan of Merger by and among the Registrant, Maestro Merger Sub, LLC, Innovation Specialists LLC D/B/A 2nd.MD and Shareholder Representative Services, LLC dated January 14, 2021 | 8-K | 001-39348 | 2.1 | March 4, 2021 | |
| 2.2† | Agreement and Plan of Merger, dated April 22, 2021, by and among Registrant, Panda Merger Sub, Inc., PlushCare, Inc., and Fortis Advisors LLC, as stockholder representative, as amended | 8-K | 001-39348 | 2.1 | June 10, 2021 | |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-39348 | 3.1 | July 10, 2020 | |
| 3.2 | Amended and Restated Bylaws of the Registrant | S-1/A | 333-236786 | 3.4 | February 28, 2020 | |
| 4.1 | Form of common stock certificate of the Registrant | S-1 | 333-236786 | 4.1 | February 28, 2020 | |
| 4.2 | Fifth Amended and Restated Registration Rights Agreement by and among the Registrant and Certain of Its Stockholders, dated October 2, 2019 | S-1 | 333-236786 | 4.2 | February 28, 2020 | |
| 4.3 | Indenture, dated as of March 29, 2021, by and between the Registrant and U.S. Bank National Association, as Trustee. | 8-K | 001-39348 | 4.1 | March 29, 2021 | |

| | | | | | | |
|-------|--|------|------------|------|-------------------|--|
| 4.4 | Form of Global Note, representing the Registrant's 0.50% Convertible Senior Notes due 2026 (included as Exhibit A to the Indenture filed as Exhibit 4.4 to this 10-K), | 8-K | 001-39348 | 4.2 | March 29, 2021 | |
| 4.5 | Description of the Registrant's Securities | 10-K | 001-39348 | 4.6 | May 7, 2021 | |
| 10.1* | Accolade, Inc. Amended and Restated 2007 Stock Option Plan, and forms of agreements thereunder | S-1 | 333-236786 | 10.1 | June 16, 2020 | |
| 10.2* | Accolade, Inc. 2020 Equity Incentive Plan and forms of agreement thereunder | S-1 | 333-236786 | 10.2 | June 16, 2020 | |
| 10.3* | Accolade, Inc. 2020 Employee Stock Purchase Plan | S-1 | 333-236786 | 10.3 | June 16, 2020 | |
| 10.4* | Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officer | S-1 | 333-236786 | 10.4 | February 28, 2020 | |
| 10.5* | Employment Agreement by and between the Registrant and Rajeev Singh dated October 2015 | S-1 | 333-236786 | 10.5 | February 28, 2020 | |

78

| Exhibit No. | Exhibit Description | Form | File No. | Exhibit | Filing Date | Filed Herewith |
|--------------------|--|-------------|-----------------|----------------|--------------------|-----------------------|
| 2.1† | Agreement and Plan of Merger by and among the Registrant, Maestro Merger Sub, LLC, Innovation Specialists LLC D/B/A 2nd.MD and Shareholder Representative Services, LLC dated January 14, 2021 | 8-K | 001-39348 | 2.1 | March 4, 2021 | |
| 2.2† | Agreement and Plan of Merger, dated April 22, 2021, by and among Registrant, Panda Merger Sub, Inc., PlushCare, Inc., and Fortis Advisors LLC, as stockholder representative, as amended | 8-K | 001-39348 | 2.1 | June 10, 2021 | |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-39348 | 3.1 | July 10, 2020 | |
| 3.2 | Amended and Restated Bylaws of the Registrant | S-1/A | 333-236786 | 3.4 | February 28, 2020 | |
| 4.1 | Form of common stock certificate of the Registrant | S-1 | 333-236786 | 4.1 | February 28, 2020 | |
| 4.2 | Fifth Amended and Restated Registration Rights Agreement by and among the Registrant and Certain of Its Stockholders, dated October 2, 2019 | S-1 | 333-236786 | 4.2 | February 28, 2020 | |
| 4.3 | Registration Rights Agreement by and among the Registrant and certain of its stockholders, dated June 9, 2021 | 8-K | 001-39348 | 4.1 | June 10, 2021 | |
| 4.4 | Indenture, dated as of March 29, 2021, by and between the Registrant and U.S. Bank National Association, as Trustee. | 8-K | 001-39348 | 4.1 | March 29, 2021 | |

| | | | | | | |
|-------|--|------|------------|------|------------------|--|
| 4.5 | Form of Global Note, representing the Registrant's 0.50% Convertible Senior Notes due 2026 (included as Exhibit A to the Indenture filed as Exhibit 4.4 to this 10-K), | 8-K | 001-39348 | 4.2 | March 29, 2021 | |
| 4.6 | Description of the Registrant's Securities | 10-K | 001-39348 | 4.6 | May 7, 2021 | |
| 10.1* | Accolade, Inc. Amended and Restated 2007 Stock Option Plan, and forms of agreements thereunder | S-1 | 333-236786 | 10.1 | June 16, 2020 | |
| 10.2* | Accolade, Inc. 2020 Equity Incentive Plan and forms of agreement thereunder | S-1 | 333-236786 | 10.2 | June 16, 2020 | |
| 10.3* | Accolade, Inc. 2020 Employee Stock Purchase Plan | S-1 | 333-236786 | 10.3 | June 16, 2020 | |
| 10.4* | Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officer | S-1 | 333-236786 | 10.4 | February 28, 202 | |

| | | | | | | |
|--------|--|------|------------|-------|-------------------|--|
| 10.6* | Offer Letter by and between the Registrant and Stephen Barnes dated December 1, 2014 | S-1 | 333-254291 | 10.6 | March 15, 2021 | |
| 10.7* | Offer Letter by and between the Registrant and Robert Cavanaugh dated October 26, 2015 | S-1 | 333-236786 | 10.7 | February 28, 2020 | |
| 10.8* | Form of Vesting Acceleration Agreement | 10-Q | 001-39348 | 10.1 | July 1, 2022 | |
| 10.9 | Credit Agreement by and among the Registrant, Comerica Bank and Western Alliance Bank dated July 19, 2019 | S-1 | 333-236786 | 10.11 | February 28, 2020 | |
| 10.10+ | First Amendment to Credit Agreement dated August 21, 2020 by and among the Registrant, Comerica Bank and Western Alliance Bank | 8-K | 001-39348 | 10.1 | August 25, 2020 | |
| 10.11 | Second Amendment to Credit Agreement dated September 11, 2020 by and among the Registrant, Comerica Bank and Western Alliance Bank | 10-Q | 001-39348 | 10.8 | October 14, 2020 | |
| 10.12 | Third Amendment to Credit Agreement dated November 6, 2020 by and among the Registrant, Comerica Bank and Western Alliance Bank | 8-K | 001-39348 | 10.1 | November 9, 2020 | |
| 10.13+ | Fourth Amendment to Credit Agreement dated March 2, 2021 by and among the Registrant, Comerica Bank and Western Alliance Bank | 8-K | 001-39348 | 10.1 | March 4, 2021 | |
| 10.14 | Fifth Amendment to Credit Agreement dated March 23, 2021 by and among the Registrant, Comerica Bank and Western Alliance Bank | 10-K | 001-39348 | 10.13 | May 7, 2021 | |
| 10.15 | Sixth Amendment to Credit Agreement dated May 26, 2021 by and among the Registrant, Comerica Bank and Western Alliance Bank | 8-K | 001-39348 | 10.1 | June 1, 2021 | |
| 10.16 | Seventh Amendment to Credit Agreement dated May 26, 2021 by and among the Registrant, Comerica Bank and Western Alliance Bank | 10-Q | 001-39348 | 10.1 | October 6, 2023 | |
| 10.17 | Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated February 22, 2007 | S-1 | 333-236786 | 10.14 | February 28, 2020 | |

| | | | | | | |
|-------|---|-----|------------|-------|-------------------|--|
| 10.18 | First Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated July 24, 2008 | S-1 | 333-236786 | 10.15 | February 28, 2020 | |
|-------|---|-----|------------|-------|-------------------|--|

| | | | | | | |
|--------|--|------|------------|-------|-------------------|--|
| 10.5* | Employment Agreement by and between the Registrant and Rajeev Singh dated October 2015 | S-1 | 333-236786 | 10.5 | February 28, 2020 | |
| 10.6* | Offer Letter by and between the Registrant and Stephen Barnes dated December 1, 2014 | S-1 | 333-254291 | 10.6 | March 15, 2021 | |
| 10.7* | Offer Letter by and between the Registrant and Robert Cavanaugh dated October 26, 2015 | S-1 | 333-236786 | 10.7 | February 28, 2020 | |
| 10.8 | Credit Agreement by and among the Registrant, Comerica Bank and Western Alliance Bank dated July 19, 2019 | S-1 | 333-236786 | 10.11 | February 28, 2020 | |
| 10.9+ | First Amendment to Credit Agreement dated August 21, 2020 by and among the Registrant, Comerica Bank and Western Alliance Bank | 8-K | 001-39348 | 10.1 | August 25, 202 | |
| 10.10 | Second Amendment to Credit Agreement dated September 11, 2020 by and among the Registrant, Comerica Bank and Western Alliance Bank | 10-Q | 001-39348 | 10.8 | October 14, 2020 | |
| 10.11 | Third Amendment to Credit Agreement dated November 6, 2020 by and among the Registrant, Comerica Bank and Western Alliance Bank | 8-K | 001-39348 | 10.1 | November 9, 2020 | |
| 10.12+ | Fourth Amendment to Credit Agreement dated March 2, 2021 by and among the Registrant, Comerica Bank and Western Alliance Bank | 8-K | 001-39348 | 10.1 | March 4, 2021 | |
| 10.13 | Fifth Amendment to Credit Agreement dated March 23, 2021 by and among the Registrant, Comerica Bank and Western Alliance Bank | 10-K | 001-39348 | 10.13 | May 7, 2021 | |
| 10.14 | Sixth Amendment to Credit Agreement dated May 26, 2021 by and among the Registrant, Comerica Bank and Western Alliance Bank | 8-K | 001-39348 | 10.1 | June 1, 2021 | |
| 10.15 | Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated February 22, 2007 | S-1 | 333-236786 | 10.14 | February 28, 2020 | |
| 10.16 | First Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated July 24, 2008 | S-1 | 333-236786 | 10.15 | February 28, 2020 | |
| 10.17 | Second Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated March 3, 2009 | S-1 | 333-236786 | 10.16 | February 28, 2020 | |

| | | | | | | |
|--------|---|-------|------------|-------|-------------------|---|
| 10.19 | Second Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated March 3, 2009 | S-1 | 333-236786 | 10.16 | February 28, 2020 | |
| 10.20 | Third Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated August 5, 2010 | S-1 | 333-236786 | 10.17 | February 28, 2020 | |
| 10.21 | Fourth Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated August 10, 2011 | S-1 | 333-236786 | 10.18 | February 28, 2020 | |
| 10.22 | Fifth Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated January 31, 2012 | S-1 | 333-236786 | 10.19 | February 28, 2020 | |
| 10.23 | Sixth Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated March 7, 2012 | S-1 | 333-236786 | 10.20 | February 28, 2020 | |
| 10.24 | Seventh Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated October 23, 2012 | S-1 | 333-236786 | 10.21 | February 28, 2020 | |
| 10.25 | Eighth Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated December 1, 2017 | S-1 | 333-236786 | 10.22 | February 28, 2020 | |
| 10.26 | Office Lease by and Between the Registrant and 1201 Tab Owner, LLC dated May 28, 2019 | S-1 | 333-236786 | 10.31 | February 28, 2020 | |
| 10.27* | Amended and Restated Non-Employee Director Compensation Policy | S-1 | 333-254291 | 10.31 | March 15, 2021 | |
| 10.28* | Master Services Agreement by and between United Healthcare Services, Inc. and Innovation Specialists, LLC d/b/a 2nd.MD dated December 19, 2016 | S-1/A | 333-254291 | 10.32 | April 1, 2021 | |
| 10.29* | Statement of Work No. 3 to the Master Services Agreement by and Between United Healthcare Services, Inc. and Innovation Specialists, LLC d/b/a 2nd.MD dated September 1, 2019 | S-1/A | 333-254291 | 10.33 | March 15, 2021 | |
| 21.1 | Subsidiaries of the Registrant | | | | | X |
| 23.1 | Consent of KPMG LLP, independent registered public accounting firm | | | | | X |
| 24.1 | Power of Attorney (included on signature page) | | | | | X |

| | | | | | | |
|-------|--|-----|------------|-------|-------------------|--|
| 10.18 | Third Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated August 5, 2010 | S-1 | 333-236786 | 10.17 | February 28, 2020 | |
|-------|--|-----|------------|-------|-------------------|--|

| | | | | | | |
|--------|--|-------|------------|-------|-------------------|---|
| 10.19 | Fourth Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated August 10, 2011 | S-1 | 333-236786 | 10.18 | February 28, 2020 | |
| 10.20 | Fifth Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated January 31, 2012 | S-1 | 333-236786 | 10.19 | February 28, 2020 | |
| 10.21 | Sixth Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated March 7, 2012 | S-1 | 333-236786 | 10.20 | February 28, 2020 | |
| 10.22 | Seventh Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated October 23, 2012 | S-1 | 333-236786 | 10.21 | February 28, 2020 | |
| 10.23 | Eighth Amendment to Lease by and between the Registrant and Brandywine Operating Partnership, L.P. dated December 1, 2017 | S-1 | 333-236786 | 10.22 | February 28, 2020 | |
| 10.24 | Office Lease by and Between the Registrant and 1201 Tab Owner, LLC dated May 28, 2019 | S-1 | 333-236786 | 10.31 | February 28, 2020 | |
| 10.25* | Amended and Restated Non-Employee Director Compensation Policy | S-1 | 333-254291 | 10.31 | March 15, 2021 | |
| 10.26* | Master Services Agreement by and between United Healthcare Services, Inc. and Innovation Specialists, LLC d/b/a 2nd.MD dated December 19, 2016 | S-1/A | 333-254291 | 10.32 | April 1, 2021 | |
| 10.27* | Statement of Work No. 3 to the Master Services Agreement by and Between United Healthcare Services, Inc. and Innovation Specialists, LLC d/b/a 2nd.MD dated September 1, 2019 | S-1/A | 333-254291 | 10.33 | March 15, 2021 | |
| 21.1 | Subsidiaries of the Registrant | | | | | X |
| 23.1 | Consent of KPMG LLP, independent registered public accounting firm | | | | | X |
| 24.1 | Power of Attorney (included on signature page) | | | | | X |
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | | X |

81

| | | | | | | |
|------|--|--|--|--|--|---|
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | | X |
|------|--|--|--|--|--|---|

| | | | | | | |
|---------|--|--|--|--|--|---|
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | | X |
| 32.1 | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | | | | | X |
| 101.INS | Inline XBRL Instance Document | | | | | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | | | | | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | | | | X |
| 101.DEF | Inline XBRL Extension Definition Linkbase Document | | | | | X |
| 101.LAB | Inline XBRL Taxonomy Label Linkbase Document | | | | | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | | | | X |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | | | | | X |

* Indicates management contract or compensatory plan.

† We have omitted schedules and similar attachments to the subject agreement pursuant to Item 601 of Regulation S-K. We will furnish a copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request.

+ Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K. We will furnish a copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request.

□ This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.

Item 16. Form 10-K Summary

None.

82 81

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on May 2, 2022 April 27, 2023.

ACCOLADE, INC.

By: _____ /s/ Rajeev Singh

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Rajeev Singh and Stephen Barnes, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.

| <u>Signature</u> | <u>Title</u> | <u>Date</u> |
|---|--|----------------------------|
| <u>/s/ Rajeev Singh</u> Rajeev Singh | Chief Executive Officer and Chairman of the Board (Principal Executive Officer) | May 2, 2022 April 27, 2023 |
| <u>/s/ Stephen Barnes</u> Stephen Barnes | Chief Financial Officer (Principal Financial and Accounting Officer) | May 2, 2022 April 27, 2023 |
| <u>/s/ Elizabeth Nabel</u> Elizabeth Nabel | Director | May 2, 2022 |
| <u>/s/ Jeff Brodsky</u> Jeff Brodsky | Director | May 2, 2022 April 27, 2023 |
| <u>/s/ Michael Hilton</u> Michael Hilton | Director | April 27, 2023 |
| <u>/s/ Jeffrey Jordan</u> Jeffrey Jordan | Director | May 2, 2022 April 27, 2023 |
| <u>/s/ Cindy Kent</u> Cindy Kent | Director | May 2, 2022 April 27, 2023 |
| <u>/s/ Peter Klein</u> Peter Klein | Director | May 2, 2022 April 27, 2023 |

83 82

| | | |
|---|----------|----------------------------|
| <u>/s/ Dawn Lepore</u> Dawn Lepore | Director | May 2, 2022 April 27, 2023 |
| <u>/s/ Thomas Neff Elizabeth Nabel</u> Thomas Neff Elizabeth Nabel | Director | May 2, 2022 April 27, 2023 |
| <u>/s/ Patricia Wadors</u> | Director | May 2, 2022 April 27, 2023 |

ACCOLADE, INC. AND SUBSIDIARIES
Index to Consolidated Financial Statements

| | |
|--|---------|
| Report of Independent Registered Public Accounting Firm (KPMG LLP; Philadelphia, PA; PCAOB ID: 185) | F-2 |
| Consolidated Balance Sheets at February 28, 2022 February 28, 2023 and 2021 2022 | F-3 F-4 |
| Consolidated Statements of Operations for the years ended February 28(29) February 28, 2023, 2022, 2021, and 2020 2021 | F-5 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the years ended February 28(29) February 28, 2023, 2022, 2021, and 2020 2021 | F-6 |
| Consolidated Statements of Cash Flows for the years ended February 28(29) February 28, 2023, 2022, 2021, and 2020 2021 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors
 Accolade, Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Accolade, Inc. and subsidiaries (the Company) as of February 28, 2022 February 28, 2023 and 2021, 2022, the related consolidated statements of operations, convertible preferred stock and stockholders' equity (deficit), and cash flows for each of the years in the three-year period ended February 28, 2022 February 28, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of February 28, 2022 February 28, 2023 and 2021, 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended February 28, 2022 February 28, 2023, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of February 28, 2022 February 28, 2023 based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated May 2, 2022 April 27, 2023 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting.

Change in Accounting Principle

As discussed in Note 2(t) 7 to the consolidated financial statements, the Company has changed its method of accounting for leases as of March 1, 2021 due to the adoption of Accounting Standards Update 2016-02, *Leases*.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit ~~Matters~~ Matter

The critical audit ~~matters~~ ~~matter~~ communicated below ~~are matters~~ ~~is a matter~~ arising from the current period audit of the consolidated financial statements that ~~were~~ ~~was~~ communicated or required to be communicated to the audit committee and that: (1) ~~relate~~ ~~relates~~ to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of ~~a~~ critical audit ~~matters~~ ~~matter~~ does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit ~~matters~~ ~~matter~~ below, providing ~~a~~ ~~separate~~ ~~opinions~~ ~~opinion~~ on the critical audit ~~matters~~ ~~matter~~ or on the accounts or disclosures to which ~~they relate~~ ~~it relates~~.

F-2

Fair value ~~Sufficiency~~ of customer relationships intangible asset

As discussed in Note 4 to the consolidated financial statements, the Company completed the acquisition of Innovation Specialists LLC d/b/a 2nd.MD (2nd.MD) during the year ended February 28, 2022. The fair value of the consideration transferred for the acquired business was \$420,090 thousand, of which \$120,000 thousand was allocated to a customer relationships intangible asset. The fair value of the identified customer relationships intangible asset was estimated using an income approach valuation model, which required the Company to make assumptions regarding estimated future cash flows and the discount rate.

We identified the assessment of the fair value of the customer relationships intangible asset acquired in the 2nd.MD business combination as a critical audit matter. A high degree of subjective auditor judgment was required to evaluate the ~~evidence over~~ revenue projections in the Company's cash flow forecast and the discount rate assumptions used to determine the fair value of the customer relationships intangible asset, as changes to those assumptions could have had a significant effect on the Company's estimate of fair value.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company's acquisition-date valuation process, including a control related to the revenue projections and the discount rate assumptions used to determine the fair value of the customer relationships intangible asset. We evaluated the Company's revenue projections by comparing them to (1) historical results of 2nd.MD and the Company, (2) forecasted growth rates in an industry report, and (3) historical growth rates of comparable companies. We involved valuation professionals with specialized skill and knowledge, who assisted in evaluating the Company's discount rate by performing a parallel analysis and comparing the results used to the Company's calculation.

Revenue recognition – variable consideration related to healthcare cost savings

As discussed in Note ~~2~~ ~~2(m)~~ to the consolidated financial statements, the Company ~~provides advocacy services~~ ~~generates revenue by~~ ~~providing customers access to its~~ ~~customers~~ ~~advocacy~~, expert medical opinion, and ~~earns~~ ~~virtual primary care services~~, as well as through utilization of its expert medical opinion and virtual primary care services. The Company's revenue ~~from the realization of healthcare cost savings resulting from the members' utilization~~ ~~includes multiple revenue streams and certain aspects~~ of the Company's ~~services~~.

The processes and information technology (IT) systems differ among the revenue streams. As discussed in Note 3, the Company prices its services using recurring per-member-per month (PMPM) fees and those fees related to healthcare cost savings are considered to be variable consideration. The Company includes recorded \$363,142 thousand of revenue for the variable consideration related to the realization of healthcare cost savings in its estimate of the transaction price when it is probable that a significant reversal of cumulative revenue will not occur, year ended February 28, 2023.

We identified the evaluation of the variable consideration recognized by the Company related to the achievement sufficiency of healthcare cost savings audit evidence over revenue as a critical audit matter. A Evaluating the sufficiency of audit evidence required a high degree of challenging subjective auditor judgment was required and specialized skills and knowledge due to evaluate the achievement number of healthcare cost savings revenue streams with unique revenue processes and IT applications involved. This included determining the revenue streams over which procedures were performed and evaluating the nature and extent of evidence obtained over each revenue stream.

The following are the primary procedures we performed to address this critical audit matter. We applied auditor judgment to determine the nature and extent of procedures to be performed over revenue. For each revenue stream where procedures were performed, we evaluated the design and tested the operating effectiveness of certain internal controls related to the Company's revenue process, including a control IT related to controls. We involved IT professionals with specialized skills and knowledge, who assisted in testing certain general IT and application controls used by the variable consideration recognized based on the achievement of healthcare cost savings with Company in its customers. We read a selection of contracts to assess the completeness and existence of any variable consideration associated with the achievement of healthcare cost savings revenue processes. For a selection sample of contracts, transactions, we confirmed with assessed the Company's customers or inspected other supporting documentation that recorded revenue by comparing the relevant healthcare cost savings were achieved as amounts recognized to underlying documentation. We evaluated the sufficiency of the fiscal year end audit evidence obtained over revenue by assessing the results of procedures performed.

/s/ KPMG LLP

We have served as the Company's Company's auditor since 2008.

Philadelphia, Pennsylvania

May 2, 2022 April 27, 2023

F-3

ACCOLADE, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(In thousands, except share and per share data)

| | February 28, | | February 28, | |
|--|--------------|------------|--------------|------------|
| | 2022 | 2021 | 2023 | 2022 |
| Assets | | | | |
| Current assets: | | | | |
| Cash and cash equivalents | \$ 365,853 | \$ 433,884 | \$ 321,083 | \$ 365,853 |
| Accounts receivable, net | 21,116 | 9,112 | 23,435 | 21,116 |
| Unbilled revenue | 9,685 | 2,725 | 3,260 | 9,685 |
| Current portion of deferred contract acquisition costs | 3,015 | 2,210 | 4,022 | 3,015 |
| Current portion of deferred financing fees | — | 93 | | |
| Prepaid and other current assets | 9,468 | 5,957 | 14,149 | 9,468 |
| Total current assets | 409,137 | 453,981 | 365,949 | 409,137 |
| Property and equipment, net | 11,797 | 9,227 | 14,763 | 11,797 |

| | | | | |
|---|---------------------|-------------------|-------------------|--------------------|
| Operating lease right-of-use assets | 33,126 | — | 29,525 | 33,126 |
| Goodwill | 577,896 | 4,013 | 278,191 | 577,896 |
| Intangible assets, net | 244,690 | 604 | 203,202 | 244,690 |
| Deferred contract acquisition costs | 7,205 | 6,067 | 9,815 | 7,205 |
| Other assets | 1,678 | 1,618 | 1,624 | 1,678 |
| Total assets | <u>\$ 1,285,529</u> | <u>\$ 475,510</u> | <u>\$ 903,069</u> | <u>\$1,285,529</u> |
| Liabilities and stockholders' equity (deficit) | | | | |
| Liabilities and stockholders' equity | | | | |
| Current liabilities: | | | | |
| Accounts payable | \$ 7,837 | \$ 7,390 | \$ 10,155 | \$ 7,837 |
| Accrued expenses and other current liabilities | 11,000 | 5,412 | 11,744 | 11,000 |
| Accrued compensation | 39,189 | 35,379 | 39,346 | 39,189 |
| Due to customers | 16,263 | 5,015 | 15,694 | 16,263 |
| Current portion of deferred revenue | 30,875 | 25,879 | 35,191 | 30,875 |
| Current portion of operating lease liabilities | 6,589 | — | 7,284 | 6,589 |
| Total current liabilities | 111,753 | 79,075 | 119,414 | 111,753 |
| Loans payable, net of unamortized issuance costs | 280,666 | — | 282,323 | 280,666 |
| Operating lease liabilities | 32,486 | — | 27,189 | 32,486 |
| Deferred rent and other noncurrent liabilities | 4,562 | 5,192 | | |
| Other noncurrent liabilities | | | 203 | 4,562 |
| Deferred revenue | 268 | 395 | 154 | 268 |
| Total liabilities | <u>429,735</u> | <u>84,662</u> | <u>429,283</u> | <u>429,735</u> |
| Commitments and Contingencies (note 16) | | | | |
| Stockholders' equity (deficit) | | | | |
| Common stock par value \$0.0001; 500,000,000 shares authorized; 67,098,477 and 55,699,052 shares issued and outstanding at February 28, 2022 and 2021, respectively | 7 | 6 | | |
| Commitments and contingencies (Note 16) | | | | |
| Stockholders' equity | | | | |
| Common stock par value \$0.0001; 500,000,000 shares authorized; 73,089,075 and 67,098,477 shares issued and outstanding at February 28, 2023 and 2022, respectively | | | 7 | 7 |
| Additional paid-in capital | 1,350,431 | 762,362 | 1,428,073 | 1,350,431 |
| Accumulated deficit | (494,644) | (371,520) | (954,294) | (494,644) |
| Total stockholders' equity (deficit) | 855,794 | 390,848 | | |
| Total liabilities and stockholders' equity (deficit) | <u>\$ 1,285,529</u> | <u>\$ 475,510</u> | | |
| Total stockholders' equity | | | 473,786 | 855,794 |
| Total liabilities and stockholders' equity | | | <u>\$ 903,069</u> | <u>\$1,285,529</u> |

See accompanying notes to consolidated financial statements.

F-4

ACCOLADE, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(In thousands, except share and per share data)

| | Fiscal Year Ended February 28(29), | | |
|--|------------------------------------|------|------|
| | 2022 | 2021 | 2020 |

| | | | |
|---|--------------|-------------|-------------|
| Revenue | \$ 310,021 | \$ 170,358 | \$ 132,507 |
| Cost of revenue, excluding depreciation and amortization | 169,019 | 93,673 | 73,685 |
| Operating expenses: | | | |
| Product and technology | 83,664 | 49,955 | 42,306 |
| Sales and marketing | 86,765 | 33,711 | 30,050 |
| General and administrative | 99,106 | 31,584 | 26,154 |
| Depreciation and amortization | 42,608 | 8,212 | 8,516 |
| Change in fair value of contingent consideration | (45,416) | — | — |
| Total operating expenses | 266,727 | 123,462 | 107,026 |
| Loss from operations | (125,725) | (46,777) | (48,204) |
| Interest expense, net | (2,905) | (3,724) | (2,925) |
| Other expense | (133) | (147) | (107) |
| Loss before income taxes | (128,763) | (50,648) | (51,236) |
| Income tax benefit (expense) | 5,639 | (4) | (129) |
| Net loss | \$ (123,124) | \$ (50,652) | \$ (51,365) |
| Net loss per share, basic and diluted | \$ (1.93) | \$ (1.72) | \$ (9.13) |
| Weighted average common shares outstanding, basic and diluted | 63,823,270 | 29,370,594 | 5,626,713 |

| | Fiscal Year Ended February 28, | | |
|---|--------------------------------|--------------|-------------|
| | 2023 | 2022 | 2021 |
| Revenue | \$ 363,142 | \$ 310,021 | \$ 170,358 |
| Cost of revenue, excluding depreciation and amortization | 198,905 | 169,019 | 93,673 |
| Operating expenses: | | | |
| Product and technology | 101,347 | 83,664 | 49,955 |
| Sales and marketing | 99,113 | 86,765 | 33,711 |
| General and administrative | 81,209 | 99,106 | 31,584 |
| Depreciation and amortization | 46,377 | 42,608 | 8,212 |
| Goodwill impairment | 299,705 | — | — |
| Change in fair value of contingent consideration | — | (45,416) | — |
| Total operating expenses | 627,751 | 266,727 | 123,462 |
| Loss from operations | (463,514) | (125,725) | (46,777) |
| Interest income (expense), net | 255 | (2,905) | (3,724) |
| Other expense | (15) | (133) | (147) |
| Loss before income taxes | (463,274) | (128,763) | (50,648) |
| Income tax benefit (expense) | 3,624 | 5,639 | (4) |
| Net loss | \$ (459,650) | \$ (123,124) | \$ (50,652) |
| Net loss per share, basic and diluted | \$ (6.45) | \$ (1.93) | \$ (1.72) |
| Weighted average common shares outstanding, basic and diluted | 71,279,831 | 63,823,270 | 29,370,594 |

See accompanying notes to consolidated financial statements.

F-5

ACCOLADE, INC. AND SUBSIDIARIES

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)

(In thousands, except shares)

| Convertible | Stockholders' Equity (Deficit) | | Convertible | Stockholders' Equity (Deficit) | |
|-------------|--------------------------------|--|-------------|--------------------------------|--|
| | Additional | | | Additional | |

| | Preferred Stock | | Common stock | | paid-in | Accumulated | | | Preferred Stock | | Common stock | | paid-in | Accumulated | |
|---|-----------------|------------|--------------|--------|-----------|--------------|-------------|--|-----------------|------------|--------------|--------|-----------|--------------|--|
| | Shares | Amount | Shares | Amount | capital | deficit | Total | | Shares | Amount | Shares | Amount | capital | deficit | |
| Balance, March 1, 2019 | 18,640,901 | \$ 214,664 | 3,616,549 | \$ 1 | \$ 38,881 | \$ (269,503) | \$(230,621) | | | | | | | | |
| Sale of Series F preferred stock, net | 873,038 | 18,358 | — | — | — | — | — | | | | | | | | |
| Issuance of common stock warrants in connection with sale of Series F preferred stock | — | — | — | — | 1,585 | — | 1,585 | | | | | | | | |
| Issuance of common stock in connection with acquisition | — | — | 289,320 | — | 6,164 | — | 6,164 | | | | | | | | |
| Issuance of common stock warrants in connection with July 2019 debt | — | — | — | — | 779 | — | 779 | | | | | | | | |
| Issuance of common stock in connection with joint development agreement | — | — | 251,211 | — | 3,869 | — | 3,869 | | | | | | | | |
| Exercise of stock options and common stock warrants | — | — | 1,876,370 | 1 | 6,791 | — | 6,792 | | | | | | | | |
| Stock-based compensation expense | — | — | — | — | 6,002 | — | 6,002 | | | | | | | | |
| Net loss | — | — | — | — | — | (51,365) | (51,365) | | | | | | | | |
| Balance, February 29, 2020 | 19,513,939 | \$ 233,022 | 6,033,450 | \$ 2 | \$ 64,071 | \$ (320,868) | \$(256,795) | | 19,513,939 | \$ 233,022 | 6,033,450 | \$ 2 | \$ 64,071 | \$ (320,868) | |

| | | | | | | | | | | | | | |
|---|--------------|-----------|------------|---|---------|-------|---------|--------------|-----------|------------|-------|---------|---|
| Exercise of stock options and common stock warrants and vesting of restricted stock units | — | — | 1,342,801 | — | 9,272 | 9,272 | — | — | 1,342,801 | — | 9,272 | | |
| Issuance of common stock in initial public offering, net of issuance costs of \$4,596 | — | — | 11,526,134 | 1 | 231,227 | — | 231,228 | — | — | 11,526,134 | 1 | 231,227 | — |
| Conversion of preferred stock into common stock | (19,513,939) | (233,022) | 29,479,521 | 2 | 233,020 | — | 233,022 | (19,513,939) | (233,022) | 29,479,521 | 2 | 233,020 | — |
| Automatic exercise of warrants into common stock in connection with initial public offering | — | — | 1,401,836 | — | — | — | — | — | — | 1,401,836 | — | — | — |
| Issuance of common stock in follow-on public offering, net of issuance costs of \$600 | — | — | 5,750,000 | 1 | 208,046 | — | 208,047 | — | — | 5,750,000 | 1 | 208,046 | — |
| Issuance of stock options to satisfy bonus obligation | — | — | — | — | 5,735 | — | 5,735 | — | — | — | — | 5,735 | — |
| Issuance of common stock in connection with 2019 acquisition | — | — | 97,812 | — | 156 | — | 156 | — | — | 97,812 | — | 156 | — |

| | | | | | | | | | | | | | |
|--|---|------|------------|------|------------|--------------|------------|---|------|------------|------|------------|--------------|
| Issuance of common stock in connection with the employee stock purchase plan | — | — | 67,498 | — | 1,259 | — | 1,259 | — | — | 67,498 | — | 1,259 | — |
| Stock-based compensation expense | — | — | — | — | 9,576 | — | 9,576 | — | — | — | — | 9,576 | — |
| Net loss | — | — | — | — | — | (50,652) | (50,652) | — | — | — | — | — | (50,652) |
| Balance, February 28, 2021 | — | \$ — | 55,699,052 | \$ 6 | \$ 762,362 | \$ (371,520) | \$ 390,848 | — | \$ — | 55,699,052 | \$ 6 | \$ 762,362 | \$ (371,520) |
| Issuance of common stock in connection with acquisitions | — | — | 10,219,443 | 1 | 456,592 | — | 456,593 | — | — | 10,219,443 | 1 | 456,592 | — |
| Issuance of replacement awards in connection with acquisitions | — | — | — | — | 6,729 | — | 6,729 | — | — | — | — | 6,729 | — |
| Contingent share earnout in connection with acquisitions | — | — | — | — | 73,481 | — | 73,481 | — | — | — | — | 73,481 | — |
| Exercise of stock options and vesting of restricted stock units | — | — | 1,039,144 | — | 8,522 | — | 8,522 | — | — | 1,039,144 | — | 8,522 | — |
| Purchase of capped calls | — | — | — | — | (34,503) | — | (34,503) | — | — | — | — | (34,503) | — |
| Issuance of common stock in connection with the employee stock purchase plan | — | — | 140,838 | — | 4,309 | — | 4,309 | — | — | 140,838 | — | 4,309 | — |
| Stock-based compensation expense | — | — | — | — | 72,939 | — | 72,939 | — | — | — | — | 72,939 | — |
| Net loss | — | — | — | — | — | (123,124) | (123,124) | — | — | — | — | — | (123,124) |

| | | | | | | | | | | | | | | | | | | | | |
|--|---|----|---|------------|----|---|-------------|----|-----------|----|---------|---|----|---|------------|----|---|-------------|----|-----------|
| Balance, February 28, 2022 | — | \$ | — | 67,098,477 | \$ | 7 | \$1,350,431 | \$ | (494,644) | \$ | 855,794 | — | \$ | — | 67,098,477 | \$ | 7 | \$1,350,431 | \$ | (494,644) |
| Settlement of acquisition-related contingent consideration | | | | | | | | | | | | — | | — | 3,304,729 | | | — | | — |
| Exercise of stock options and vesting of restricted stock units | | | | | | | | | | | | — | | — | 2,125,524 | | | 2,071 | | — |
| Issuance of common stock in connection with the employee stock purchase plan | | | | | | | | | | | | — | | — | 560,345 | | | 2,927 | | — |
| Stock-based compensation expense | | | | | | | | | | | | — | | — | — | | | 72,644 | | — |
| Net loss | | | | | | | | | | | | — | | — | — | | | — | | (459,650) |
| Balance, February 28, 2023 | | | | | | | | | | | | — | \$ | — | 73,089,075 | \$ | 7 | \$1,428,073 | \$ | (954,294) |

See accompanying notes to consolidated financial statements.

F-6

ACCOLADE, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(In thousands)

| | Fiscal Year Ended February 28(29), | | | Fiscal Year Ended February 28, | | |
|---|------------------------------------|-------------|-------------|--------------------------------|-------------|------------|
| | 2022 | 2021 | 2020 | 2023 | 2022 | 2021 |
| Cash flows from operating activities: | | | | | | |
| Net loss | \$ (123,124) | \$ (50,652) | \$ (51,365) | \$(459,650) | \$(123,124) | \$(50,652) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
| Goodwill impairment | | | | 299,705 | — | — |
| Depreciation and amortization expense | 42,608 | 8,212 | 8,516 | 46,377 | 42,608 | 8,212 |
| Amortization of deferred contract acquisition costs | 2,945 | 1,657 | 985 | 3,698 | 2,945 | 1,657 |
| Change in fair value of contingent consideration | (45,416) | — | — | — | (45,416) | — |
| Deferred income taxes | (6,132) | — | — | (3,997) | (6,132) | — |
| Noncash interest expense | 1,673 | 2,252 | 834 | 1,660 | 1,673 | 2,252 |
| Noncash bonus | — | — | 5,884 | | | |

| | | | | | | |
|---|------------|------------|-----------|------------|------------|------------|
| Loss on disposal of equipment | — | — | 299 | | | |
| Stock-based compensation expense | 72,939 | 9,576 | 6,002 | 72,644 | 72,939 | 9,576 |
| Changes in operating assets and liabilities: | | | | | | |
| Accounts receivable and unbilled revenue | (11,829) | (10,648) | (683) | 4,106 | (11,829) | (10,648) |
| Accounts payable and accrued expenses | (1,899) | 2,991 | 5,838 | 1,131 | (1,899) | 2,991 |
| Deferred contract acquisition costs | (4,148) | (4,690) | (2,399) | (7,314) | (4,148) | (4,690) |
| Deferred revenue and due to customers | 13,986 | (2,700) | 2,286 | 3,634 | 13,986 | (2,700) |
| Accrued compensation | (2,519) | 16,356 | (1,671) | 157 | (2,519) | 16,356 |
| Deferred rent and other liabilities | (106) | (505) | 220 | | | |
| Other liabilities | | | | 1,627 | (106) | (505) |
| Other assets | (1,328) | 2,919 | (8,993) | (4,483) | (1,328) | 2,919 |
| Net cash used in operating activities | (62,350) | (25,232) | (34,247) | (40,705) | (62,350) | (25,232) |
| Cash flows from investing activities: | | | | | | |
| Capitalized software development costs | | | | (5,123) | (1,096) | (374) |
| Purchases of property and equipment | | | | (2,105) | (2,521) | (1,991) |
| Purchase of marketable securities | (99,998) | — | — | — | (99,998) | — |
| Sale of marketable securities | 99,998 | — | — | — | 99,998 | — |
| Capitalized software development costs | (1,096) | (374) | — | | | |
| Purchases of property and equipment | (2,521) | (1,991) | (3,315) | | | |
| Cash paid for acquisitions, net of cash acquired | (259,996) | — | (206) | — | (259,996) | — |
| Earnout payments to MD Insider | — | (58) | — | — | — | (58) |
| Net cash used in investing activities | (263,613) | (2,423) | (3,521) | (7,228) | (263,613) | (2,423) |
| Cash flows from financing activities: | | | | | | |
| Proceeds from public offerings, net of underwriters' discounts and commissions and offering costs | — | 439,410 | — | | | |
| Proceeds from sale of preferred stock, net | — | — | 19,943 | | | |
| Proceeds from stock purchases under employee stock purchase plan | 4,703 | 2,379 | — | | | |
| Proceeds from stock option and warrant exercises | 8,600 | 9,348 | 6,619 | | | |
| Proceeds from employee stock purchase plan | | | | 2,927 | 4,703 | 2,379 |
| Proceeds from stock option exercises | | | | 2,064 | 8,600 | 9,348 |
| Payment of contingent consideration for acquisition | | | | (1,828) | — | — |
| Payments of equity issuance costs | (60) | — | — | — | (60) | — |
| Payment of debt issuance costs | (8,368) | — | — | — | (8,368) | — |
| Payment for purchase of capped calls | (34,443) | — | — | — | (34,443) | — |
| Proceeds from borrowings on debt | 287,500 | 51,166 | 1,660 | — | 287,500 | 51,166 |
| Proceeds from public offerings, net of underwriters' discounts and commissions and offering costs | | | | — | — | 439,410 |
| Repayments of debt principal | — | (73,166) | — | — | — | (73,166) |
| Payments related to debt retirement | — | (753) | — | — | — | (753) |
| Net cash provided by financing activities | 257,932 | 428,384 | 28,222 | 3,163 | 257,932 | 428,384 |
| Net increase (decrease) in cash and cash equivalents | (68,031) | 400,729 | (9,546) | (44,770) | (68,031) | 400,729 |
| Cash and cash equivalents, beginning of period | 433,884 | 33,155 | 42,701 | 365,853 | 433,884 | 33,155 |
| Cash and cash equivalents, end of period | \$ 365,853 | \$ 433,884 | \$ 33,155 | \$ 321,083 | \$ 365,853 | \$ 433,884 |
| Supplemental cash flow information: | | | | | | |
| Interest paid | \$ 930 | \$ 2,296 | \$ 2,391 | \$ 1,640 | \$ 930 | \$ 2,296 |
| Issuance of stock options in lieu of cash bonus | \$ — | \$ 5,735 | \$ — | \$ — | \$ — | \$ 5,735 |
| Fixed assets included in accounts payable | \$ 161 | \$ 232 | \$ 45 | \$ 771 | \$ 161 | \$ 232 |
| Other receivable related to stock option exercises | \$ 4 | \$ 97 | \$ 173 | \$ 13 | \$ 4 | \$ 97 |
| Income taxes paid | \$ 122 | \$ 149 | \$ 55 | \$ 157 | \$ 122 | \$ 149 |
| Common stock issued in connection with acquisitions | \$ 455,586 | \$ 156 | \$ 6,164 | \$ — | \$ 455,586 | \$ 156 |
| Replacement awards issued in connection with acquisitions | \$ 6,729 | \$ — | \$ — | \$ — | \$ 6,729 | \$ — |
| Offering costs included in prepaid assets and accounts payable and accrued expenses | \$ — | \$ — | \$ 3,042 | | | |

| | | | | | | |
|--|----|---|----|---|----|-------|
| Common stock issued in connection with joint development agreement | \$ | — | \$ | — | \$ | 3,869 |
| Common stock warrants issued in connection with debt | \$ | — | \$ | — | \$ | 779 |

See accompanying notes to consolidated financial statements.

F-7

Accolade, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

(Dollar amounts in thousands except share and per share data)

(1) Background

(a) Business

Accolade, Inc. (Accolade or together with its subsidiaries, the Company) provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. The Company's customers are primarily employers that contract with Accolade to provide their employees and their employees' families (the members) a single place to turn for their health, healthcare, and benefits needs. The Company also offers expert medical opinion services to employer commercial customers through the acquisition of Innovation Specialists LLC d/b/a 2nd.MD (2nd.MD). With the acquisition of PlushCare, Inc. (PlushCare), the Company offers (which includes employers, health plans, and governmental entities) and virtual primary care, and mental health support, both directly to consumers and to employer commercial customers. These services are designed to drive better healthcare outcomes and increased satisfaction for the participants while lowering costs for the payor. The Company provides its services to customers throughout the United States. Accolade is co-headquartered in Seattle, Washington and Plymouth Meeting, Pennsylvania.

(b) Liquidity

The Company has incurred net losses and cumulative negative cash flows from operations since inception. To date, the Company's operations have been funded by capital raised from investors, debt facilities, and revenues in the normal course of business. Management believes that the Company's cash and cash equivalents, plus customer revenues and advances and available borrowings under its debt facility, are sufficient to fund its operations through at least the next 12 months from the issuance of these consolidated financial statements. Additional financing may be required for the Company to successfully implement its long-term strategy. There can be no assurance that additional financing, if needed, can be obtained on terms acceptable to the Company.

(c) COVID-19

Due to the government-imposed quarantines and other public health safety measures put into place in March 2020, COVID-19 has caused disruption in the markets where the Company sells its offerings and related services. Although the Company has not experienced any significant financial impact as a result of the COVID-19 pandemic, there continues to be uncertainty as to the extent to which the COVID-19 pandemic may adversely impact its business and operations, and the Company will continue to closely monitor for any changes to the Company's operations and the operations of its customers.

(d) Initial Public Offering

On July 7, 2020, the Company closed its initial public offering of common stock (IPO) in which the Company issued and sold 11,526,134 shares (inclusive of the underwriters' over-allotment option to purchase 1,503,408 shares) of common stock at \$22.00 per share. The Company received net proceeds of \$231,228 after deducting underwriting discounts and commissions, as well as offering costs of \$4,596. Upon the closing of the IPO, all shares of outstanding convertible preferred stock converted into 29,479,521 shares of common stock, and an additional 1,401,836 shares of common stock were issued upon the automatic net exercise of warrants then outstanding.

(e)(d) Follow-on Public Offering

On October 26, 2020, the Company closed a follow-on public offering of common stock in which the Company issued and sold 5,750,000 shares (inclusive of the underwriters' over-allotment option to purchase 750,000 shares) of

F-8

common stock at \$38.50 per share. The Company received net proceeds of \$208,046 after deducting underwriting discounts and commissions, as well as offering costs of \$600, all of which were paid as of February 28, 2021.

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation and Principles of Consolidation

Accolade's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and include the Company's accounts and those of the Company's wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

F-8

Through the acquisition of PlushCare, Inc. (PlushCare), the Company has various administrative service agreements (ASA) with professional medical corporations established in California, Illinois, Wyoming, and New Jersey (PC). The PCs employ or contract with medical providers who provide services via the Company's technology platform. The ASAs are evergreen and are terminable by the parties for breach or bankruptcy. Through the ASAs, the Company provides non-clinical administrative services to the PCs and manages the economic activities that most significantly affect PCs. The PCs retain control over the provision of medical services and the PC's clinical personnel.

The PCs are variable interest entities (VIE) to the Company. Under Accounting Standards Codification Subtopic 810 – *Consolidation*, the Company is considered the PC's primary beneficiary because the Company has the power to direct the activities that most significantly impact the VIE's economic performance and absorbs the residual benefits and losses from the VIE's operations. Consequently, the Company consolidates the operations of the PCs. PC assets were \$17,838, \$29,847 as of February 28, 2022, February 28, 2023. These assets consisted primarily of cash of \$16,137 and accounts receivable of \$1,654, \$25,896, which may only be used to settle the obligations of the PCs. PC liabilities were \$10,490, \$36,377 as of February 28, 2022, February 28, 2023 and consisted primarily of amounts due to Accolade, Inc. of \$30,372.

The PCs and the Company are independent entities, and as such creditors of the PCs do not have recourse against the Company in the event of default by the PC. PCs. Additionally, the PCs' non-cash assets are available to the Company to satisfy obligations or for other corporate purposes.

(b) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including the fair value of assets acquired and liabilities assumed for business combinations, unbilled revenues and deferred revenues, certain accrued expenses, stock-based compensation, assessment of the useful life and recoverability of long-lived assets, income taxes, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, assessment of the recoverability of goodwill, and the reported amounts of revenues and expenses during the reporting period. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, the Company's financial statements will be affected.

(c) Comprehensive Loss

For the fiscal years ended February 28(29), February 28, 2023, 2022, 2021, and 2020, 2021, there was no difference between comprehensive loss and net loss.

(d) Fair Value of Financial Instruments

The carrying value of the Company's financial instruments, including cash equivalents, accounts receivable, unbilled revenue, other current assets, accounts payable, and accrued expenses approximates fair value due to the short-term nature of those instruments.

F-9

The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires the use of observable inputs and minimizes the use of unobservable inputs. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

- Level 1 — Quoted prices in active markets for identical assets or liabilities.
- Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

F-9

- Level 3 — Inputs that are generally unobservable and typically reflect the Company's estimate of assumptions that market participants would use in pricing the asset or liability.

(e) Cash and Cash Equivalents

Cash and cash equivalents is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less. Cash equivalents consist of investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these instruments.

(f) Marketable Securities

The Company classifies its marketable securities as available-for-sale, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair market value. **There were no purchases or sales of marketable securities during the year ended February 28, 2023.** The total unrecognized gain related to the marketable securities was inconsequential during the year ended February 28, 2022.

(g) Accounts Receivable and Unbilled Revenue

Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company does not have any off-balance-sheet credit exposure related to its customers. The Company records unbilled revenue for services performed on contracts for amounts not yet billed to customers.

(h) Property and Equipment

Property and equipment are recorded at cost. Property and equipment are depreciated on a straight-line basis over their estimated useful lives.

Useful lives for property and equipment are as follows:

| Property and Equipment | Estimated Useful Life |
|--------------------------------|-----------------------|
| Office equipment and furniture | 7 years |
| Computer equipment | 3 - 5 years |
| Computer software | 3 - 5 years |

F-10

(i) Capitalized Internal-Use Software Costs

Costs related to software acquired, developed, or modified solely to meet the Company's internal requirements, including for tools that enable the Company's employees to interact with members and their providers, with no substantive plans to market such software at the time of development, are capitalized. Costs incurred during the preliminary planning and evaluation stage of the project and during the post-implementation operational stage are expensed as incurred. Costs related to minor upgrades, minor enhancements, and maintenance activities are expensed as incurred. Costs incurred during the application development stage of the project are capitalized. Internal-use software is included in property and equipment and is amortized on a straight-line basis over 3 years.

For the fiscal years ended February 28(29) February 28, 2023, 2022, 2021, and 2020, 2021, the Company capitalized \$5,709, \$1,096, \$374, and \$3,005, \$374, respectively, for internal-use software. Amortization expense related to capitalized internal-use software during the fiscal years ended February 28(29) February 28, 2023, 2022, and 2021 was \$1,196, \$2,387, and 2020 was \$2,387, \$4,560, and \$4,533, respectively.

F-10

(j) Impairment of Long-Lived Assets

The Company reviews long-lived assets, such as property and equipment and finite-lived intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset. There were no long-lived asset impairment charges recorded during the fiscal years ended February 28(29) February 28, 2023, 2022, 2021, and 2020, 2021.

(k) Intangible Assets

The Company has acquired intangible assets through various acquisitions. Intangible assets are recorded at fair value on the date of acquisition and are subject to amortization over the estimated useful lives of each asset. Estimates of fair value and useful lives are based on historical factors, current circumstances, and the experience and judgment of management. Estimates and assumptions used to value intangible assets are evaluated by management on an ongoing basis.

The caption "Acquired technology, net" included on the balance sheet in previous filings was changed to "Intangible assets, net" during the year ended February 28, 2022.

(l) Goodwill

Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. evaluations of its recoverability annually and upon the identification of a triggering event. The Company has a single reporting unit and all goodwill relates to that reporting unit.

The Company performs its annual an impairment analysis of goodwill impairment test on an annual basis in the fourth quarter of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded.

The Company's annual goodwill impairment test resulted in no loss was recorded during the first quarter of fiscal 2023. See Note 5 for further information. The Company did not recognize a goodwill impairment charges charge in the fiscal years ended February 28(29), 2022, 2021, February 28, 2022 and 2020, 2021.

(m) **Revenue and Deferred Revenue**

Revenue Recognition

The Company generates revenue by providing customers access to its advocacy, expert medical opinion, and virtual primary care and mental health support services, as well as through utilization of its expert medical opinion and

F-11

virtual primary care and mental health support services that were acquired through the acquisitions of 2nd.MD and PlushCare services. Contracts with customers that include expert medical opinion or virtual primary care and mental health support services may contain either an access fee, a utilization-based fee, or both.

In accordance with Accounting Standards Codification (ASC) 606, *Revenue from Contracts with Customers*, the Company recognizes revenue when control of the promised services is transferred to its customers, in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. Accordingly, the Company determines revenue recognition through the following steps:

- identification of the contract, or contracts with a customer;
- identification of the performance obligations in the contract;
- determination of the transaction price;
- allocation of the transaction price to the performance obligations in the contracts; and
- recognition of revenue when, or as, the Company satisfies a performance obligation.

F-11

At contract inception, the Company assesses the type of services being provided and assesses the performance obligations in the contract. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on overall pricing objectives, taking into consideration market conditions and other factors, using an expected cost plus margin approach. The Company considered the variable consideration allocation exception in ASC 606 for its advocacy contracts and concluded that such exception for allocating variable consideration to distinct performance obligations or distinct time periods within a series was not met primarily due to variability in its per-member-per-month (PMPM) pricing.

The majority of fees earned by the Company are considered to be variable consideration due to both the uncertainty regarding the total number of members, consultations or visits for which the Company will invoice the customer, as well as the variable PMPM fees that are dependent upon the achievement of performance metrics and/or healthcare cost savings. Performance metrics are measured monthly, quarterly, or annually, and with respect to the achievement of healthcare cost savings targets, annually (typically measured on a calendar year basis). Accordingly, at contract inception and on an ongoing basis, as part of the Company's estimate of the transaction price, the Company determines whether any such fees should be constrained, and the Company includes the estimated consideration for those fees to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur (and is therefore considered to be unconstrained). Consideration related to the Company's achievement of healthcare cost savings is typically constrained until the end of the applicable calendar year due to uncertainty related to factors outside of the Company's control. Consideration related to other performance metrics is typically not constrained based on the Company's prior success of achieving such metrics. On an ongoing basis, the Company reassesses its estimates for variable consideration, which can change based upon its assessment of the achievement of performance metrics and healthcare cost savings, as well as the number of members, consultations, or visits.

Access Fees

The Company generates revenue primarily from contracts with customers to access the Company's advocacy, expert medical opinion, and virtual primary care and mental health support services. The Company prices access fees primarily using a recurring PMPM fee, typically with a portion of the fee calculated as the product of a fixed rate times the number of members (fixed PMPM fee), plus a variable PMPM fee calculated as the product of a variable rate times the number of members (variable PMPM fee). The fees associated with the variable PMPM fee can be earned through the achievement of performance metrics and/or the realization of healthcare cost savings resulting from use of the Company's services. Collectively, the fixed PMPM fee and variable PMPM fee are referred to as the total PMPM fee. The Company's PMPM pricing varies by contract. In certain contracts, the maximum total PMPM fee varies during the contract term (total PMPM rate increases or decreases annually), while in other contracts, the total PMPM maximum fee is consistent over the term, yet the fixed and variable portions vary. For example, in certain contracts the fixed PMPM

F-12

fee increases on an annual basis while the variable PMPM fee decreases on an annual basis, resulting in the same total PMPM fee throughout the term of the contract. The PMPM fees for expert medical opinion and virtual primary care and mental health support services may be tiered based upon the customer's utilization.

Access to the Company's services represent a single stand-ready performance obligation. The Company's contracts include stand-ready services to provide eligible participants with access to the Company's services and to perform an unspecified quantity of interactions with members during the contract period. Accordingly, the Company's services are generally viewed as stand-ready performance obligations comprised of a series of distinct daily services that are substantially the same and have the same pattern of transfer. For advocacy services, the Company satisfies these performance obligations over time and recognizes revenue related to its services as the services are provided using a measure of progress based upon the actual number of members eligible for the service during the respective period as a percentage of the estimated members expected to be eligible for the service over the term of the contract. The Company believes a measure of progress based on the number of members is the most appropriate measurement of control of the services being transferred to the customer as the amount of internal resources necessary to stand-ready is directly correlated to the number of members who can use the services.

For the majority of expert medical opinion services, the Company satisfies these performance obligations over time and recognizes revenue in the amount of consideration for which it has the right to invoice using the as-invoiced practical expedient. Access fees also include access to the Company's virtual primary care and mental health support services sold directly to

F-12

consumers on a monthly or yearly fixed fee subscription basis. For these services, the Company satisfies these stand-ready performance obligations over time and recognizes revenue ratably over the subscription period.

Utilization-based fees

The Company also generates revenue when members utilize the expert medical opinion and virtual primary care and mental health support services that are billed based on utilization. Many, but not all, contracts with customers contain utilization-based fees. For any utilization-based fees, the Company satisfies these performance obligations over time and recognizes revenue in the amount of consideration for which it has the right to invoice using the as-invoiced practical expedient for any consultations or visits sold to enterprise commercial customers as well as any non-insured consultations or visits related to virtual primary care and mental health support services sold directly to consumers. For any consultations or visits that are paid through insurance claims, the Company recognizes revenue as the consultations and visits occur in an amount that reflects the consideration that is expected based upon then-current prices and historical experience from insurance payors.

Deferred Revenue

The Company typically invoices its customers in advance of the services performed on a monthly or quarterly basis, and the amount invoiced typically represents the maximum total PMPM fee for the estimated number of eligible members over the applicable invoice period. The total PMPM fee covers the stand-ready services in the Company's typical contracts (i.e., the performance obligations are not separately priced or invoiced). The maximum total PMPM fee that is invoiced includes both the fixed PMPM fee and the variable PMPM fee related to the performance metrics and/or the realization of healthcare cost savings that can be achieved during the period. These fees are classified as deferred revenue on the Company's consolidated balance sheet until such time that revenue can be recognized. In the event the Company fails to satisfy any of the performance metrics and/or realization of healthcare cost savings that are billed in advance, the Company will refund the applicable portion of the fee or offset the amount against a future invoice. These amounts are included in due to customers on the Company's consolidated balance sheet. The Company's accounts receivable represent rights to consideration that are unconditional.

(n) Concentration of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and marketable securities. The Company maintains its cash primarily with domestic financial institutions of high credit quality, which may exceed federal deposit insurance corporation limits. The Company invests its cash equivalents in highly rated money market funds and U.S. treasury bills with original maturities of three months or less.

F-13

Marketable securities are comprised of U.S. treasury bills with original maturities greater than three months. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions.

Significant customers are those which represent 10% or more of the Company's revenue during the period. For each significant customer, revenue as a percentage of total revenue was as follows:

| | Year Ended February 28(29), | | | Year Ended February 28, | | |
|------------|-----------------------------|--------|--------|-------------------------|------|--------|
| | 2022 | 2021 | 2020 | 2023 | 2022 | 2021 |
| Customer 1 | * % | 16.0 % | 23.8 % | * % | * % | 16.0 % |
| Customer 2 | * % | 11.8 % | 12.6 % | * % | * % | 11.8 % |
| Customer 3 | * % | 10.2 % | 11.7 % | * % | * % | 10.2 % |
| Customer 4 | * % | 9.8 % | 10.4 % | * % | * % | 9.8 % |
| Total | * % | 47.8 % | 58.5 % | * % | * % | 47.8 % |

*For the year fiscal years ended February 28, 2022, February 28, 2023 and 2022, no customers customer represented 10% or more of the Company's revenue.

Customers representing 10% or more of the Company's revenue in the year ended February 28, 2021 had a total of \$5,592 in accounts receivable outstanding at February 28, 2021. F-13

(o) Stock-Based Compensation

The Company recognizes compensation cost for awards to employees, nonemployee directors, consultants, and advisors based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder is required to provide service in exchange for the award. The Company estimates the fair value of each employee stock option on the date of grant using the Black-Scholes option pricing model.

(p) Cost of Revenue, excluding Depreciation and Amortization

Cost of revenue, excluding depreciation and amortization, consists primarily of personnel costs including salaries, wages, overtime, bonuses, stock-based compensation expense, and benefits, as well as software and tools for telephony, business analytics, allocated overhead costs, and other expenses related to delivery and implementation of the Company's personalized technology-enabled solutions.

(q) Product and Technology

Product and technology expenses consist of personnel expenses, including salaries, bonuses, stock-based compensation expense, and benefits for employees and contractors for engineering, product, and design teams, and allocated overhead costs, as well as costs of software and tools for business analytics, data management, and IT applications that are not directly associated with delivery of the Company's solutions to customers.

(r) Income Taxes

The provision for income taxes was determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company's assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. **In the current year we released a portion of the valuation allowance against the deferred tax assets attributable to our deferred tax assets as the acquired intangibles from the PlushCare acquisition served as a source of income for which we, more likely than not, will be able to realize the benefits of the deferred tax assets.** Deferred tax assets and liabilities are measured using enacted tax rates applicable in the years in

F-14

which they are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax law is recognized in income in the period that includes the enactment date.

In evaluating the ability to realize deferred tax assets, the Company relies on taxable income in prior carryback years, the future reversals of existing taxable temporary differences, future taxable income, and tax planning strategies.

Consistent with the provisions of FASB ASC Topic 740, *Income Taxes*, the Company does not recognize a tax benefit for a tax position in its financial statements unless it has concluded that it is more likely than not that the benefit will be sustained on audit by the taxing authority based solely on the technical merits of the associated tax position; and that the amount of tax benefit recognized is measured at the largest amount of the tax benefit that, in the Company's judgment, is greater than 50% likely to be realized. U.S. GAAP requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions will more likely than not be sustained by the Company upon challenge by the applicable tax authority. Tax positions not deemed to meet the "more likely than not" threshold and that would result in a tax benefit or expense to the Company would be recorded as a tax benefit or expense in the current period. **For the fiscal years ended February 28(29), 2021, 2020, and 2019, the Company did not recognize any amounts for unrecognized tax benefits.** A reconciliation is not provided herein, as the beginning and ending amounts of unrecognized benefits are \$0, with no additions, reductions, or settlements during the year. Tax years 2010 through present remain subject to examination by the U.S. and state taxing authorities.

(s) Segments

The Company's chief operating decision maker, its Chief Executive Officer, reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates in a single reportable segment.

F-14

As of February 28(29) February 28, 2023, 2022, 2021, and 2020, 2021, substantially all of Accolade's long-lived assets were located in the United States, and all revenue was earned in the United States.

(t) Leases

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, *Leases* (Topic 842). The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with terms of more than 12 months.

The Company adopted Topic 842 on February 28, 2022, with an effective date of adoption of March 1, 2021, using the modified retrospective approach. Topic 842 requires the Company to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use (ROU) asset on its consolidated balance sheet for most leases and disclose key information about leasing arrangements. The Company elected to utilize the package of practical expedients available under Topic 842, which allowed it to not reassess: (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases, and (iii) the initial direct costs for existing leases. As a result of the adoption, the Company recorded operating lease right-of-use assets and operating lease liabilities of \$34,739 and \$38,740, respectively, on the consolidated balance sheet as of March 1, 2021.

Whenever the Company enters into a new arrangement, it determines, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the right to direct the use of, and obtain substantially all the economic benefits from, the use of the underlying asset.

If a lease exists, the Company then determines the separate lease and non-lease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the

F-15

Company and (ii) does not significantly affect, and is not significantly affected by, other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered non-lease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and non-lease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and non-lease components.

For each lease, the Company then determines the lease term, the present value of lease payments, and the classification of the lease as either an operating or finance lease. The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise, and (iii) renewal or termination options that are controlled by the lessor.

The present value of lease payments is calculated based on:

- (1) Lease payments – Lease payments included in the measurement of the lease asset or liability comprise the following: fixed payments (including in-substance fixed payments), and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.
- (2) Discount rate – the discount rate is determined based on information available to the Company upon the commencement of the lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company's leases is generally not readily determinable, the Company generally uses the incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term.

In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee's and lessor's rights, obligations, and economic incentives over the term of the lease.

The Company does not recognize leases with an initial term of 12 months or less on its consolidated balance sheets and will recognize recognizes these payments in the consolidated statements of operations on a straight-line basis over the lease term. Certain leases contain variable payments which are based on usage or operating costs, such as utilities and maintenance. These payments are not included in the measurement of the lease liability or corresponding right-of-use asset due to the uncertainty of the payment amount and are recorded as lease expense in the period incurred.

See Note 7, Leases, for additional information.

Prior to the adoption of Topic 842, the Company accounted for leases under FASB ASC Topic 840, *Leases* (Topic 840).

(u) Recently Adopted Issued Accounting Pronouncements

Debt

In August 2020, June 2022, the FASB issued ASU No. 2020-06, 2022-03, *Debt-Debt with Conversion and Other Options* (Subtopic 470-20) and *Derivatives and Hedging-Contracts in Entity's Own Equity* (Subtopic 815-40) *Fair Value Measurement (Topic 820): Accounting for Convertible Instruments and Contracts in Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions*. This ASU clarifies the guidance when measuring the fair value of an Entity's Own Equity (ASU 2020-06), which simplifies equity security subject to contractual sale restrictions that prohibit the accounting for convertible instruments by reducing the number sale of accounting models available for convertible debt instruments. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments an equity security and requires the use of the if converted method. The Company early adopted the ASU effective March 1, 2021 using the modified retrospective method of adoption. The Company applied this ASU to the convertible debt transaction entered into in March 2021 (see Note 10).

F-16 F-15

Credit Losses

In June 2016, certain disclosures for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. This guidance is effective for annual reporting periods, including interim periods, beginning after December 15, 2023, with early adoption permitted. The provisions of ASU 2022-03 are to be applied prospectively with any adjustments made to earnings on the FASB issued ASU No. 2016-13 *Financial Instruments — Credit Losses (Topic 326): Measurement date of Credit Losses on Financial Instruments*. ASU 2016-13 introduces the current expected credit loss (CECL) model, which will require entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings. adoption. The Company adopted ASU 2016-13 is currently evaluating the impact, if any, of this guidance on February 28, 2022 with an effective date of adoption of March 1, 2021. The adoption did not have a material effect on the Company's consolidated its financial statements.

Internal Use Software

In August 2018, the FASB issued ASU No. 2018-15, *Intangibles — Goodwill and Other-Internal-Use Software* (Subtopic 350-40): *Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted ASU 2018-15 on February 28, 2022 with an effective date of adoption of March 1, 2021. The adoption did not have a material effect on the Company's consolidated financial statements.

(3) Revenue

The following table presents the Company's revenues disaggregated by revenue source:

| | Year Ended February 28, | | Year Ended February 28, | |
|-------------|-------------------------|---------|-------------------------|------------|
| | 2022 | | 2023 | 2022 |
| Access fees | \$ | 264,612 | \$ 284,144 | \$ 264,612 |

| | | | |
|------------------------|-------------------|-------------------|-------------------|
| Utilization-based fees | 45,409 | 78,998 | 45,409 |
| Total | \$ 310,021 | \$ 363,142 | \$ 310,021 |

As of February 28, 2022 February 28, 2023, \$260,210 of revenue is expected to be recognized from remaining performance obligations and is expected to be recognized as follows:

| Year Ending February 28(29), | | | |
|-------------------------------------|-----------|----------------|------------------|
| 2023 | \$ | 154,895 | |
| 2024 | | 65,849 | \$152,976 |
| 2025 | | 36,853 | 56,778 |
| 2026 | | 2,613 | 14,888 |
| 2027 | | | 372 |
| 2028 | | | 34 |
| Total | \$ | 260,210 | \$225,048 |

The expected revenue includes variable fee estimates for the non-cancellable term of the Company's contracts. The expected revenue does not include amounts of variable consideration that are constrained.

Significant changes to the contract liability balances during the fiscal years ended February 28, 2022 February 28, 2023 and 2021 2022 were the result of revenue recognized and net cash received. During the fiscal years ended February 28, 2022 February 28, 2023 and 2021, 2022, significant changes in the deferred revenue balances were the result of recognized revenue of \$25,817 \$30,567 and \$28,919, \$25,817, respectively, that were included in deferred revenue. In addition, significant changes to the contract asset balances during the fiscal years ended February 28, 2022 February 28, 2023 and 2021 2022 were the result of revenue recognized and transfers to accounts receivable. Contract assets relating to unbilled revenue are transferred to accounts receivable when the right to consideration becomes unconditional.

Revenue related to performance obligations satisfied in prior periods that was recognized during the years ended February 28, 2022 February 28, 2023 and 2021 2022 was \$4,673 \$3,768 and \$5,473, \$4,673, respectively. These changes in estimates amounts were primarily due to the inclusion of consideration that was previously constrained related to the Company's achievement of healthcare cost savings.

F-17

Cost to obtain and fulfill a contract

The Company capitalizes sales commissions paid to internal sales personnel that are both incremental to the acquisition of customer contracts and recoverable. These costs are recorded as deferred contract acquisition costs in the accompanying consolidated balance sheets. The Company capitalized commission costs of \$3,478 \$6,016 and \$3,501 \$3,478 for the years ended February 28, 2022 February 28, 2023 and 2021, 2022, respectively. During the year ended February 28, 2022, the Company wrote off previously deferred commissions of \$484 related to a revision of the Company's commission plan, which offset the amounts capitalized during the year ended February 28, 2022. The Company defers costs based on its sales compensation plans only if the commissions are incremental and would not have occurred absent the customer contract. Payments to direct sales personnel are typically made upon signature of the contract. The Company does not pay commissions on contract renewals.

F-16

Deferred commissions paid on the initial acquisition of a contract are amortized ratably over an estimated period of benefit of five years, which is the estimated customer life. The Company determined the period of amortization for deferred commissions by taking into consideration current customer contract terms, historical customer retention, and other factors. Amortization is included in sales and marketing expenses in the accompanying consolidated statements of operations and totaled \$2,695, \$2,080, \$1,106, and \$665 \$1,106 for the

fiscal years ended February 28(29) February 28, 2023, 2022, 2021, and 2020, 2021, respectively. The Company periodically reviews deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the estimated period of benefit. There were no impairment losses recorded during the periods presented.

For certain customer contracts, the Company may incur direct and incremental costs related to customer set-up and implementation. The Company recorded deferred implementation costs of \$1,154 \$1,303 and \$1,189 \$1,154 for the fiscal years ended February 28, 2022 February 28, 2023 and 2021, 2022, respectively. These implementation costs are deferred and amortized over the expected useful life of the Company's customers, which is five years. Amortization is included in cost of revenues in the Company's consolidated statements of operations and totaled \$1,002, \$865, \$551, and \$320 \$551 for the fiscal years ended February 28(29) February 28, 2023, 2022, 2021, and 2020, 2021, respectively.

(4) Acquisitions

Acquisition of 2nd.MD

On March 2, 2021 March 3, 2021, the Company acquired all the outstanding equity interests of 2nd.MD. Innovation Specialists LLC d/b/a 2nd.MD (2nd.MD). Based in Houston, Texas, 2nd.MD is a leading expert medical opinion and medical decision support company. The results of operations and financial position of 2nd.MD are included in the Company's consolidated financial statements from the date of acquisition.

The consideration paid was comprised of cash, common stock, and contingent consideration as follows:

| Consideration | |
|--|-------------------|
| Cash consideration, net of cash acquired | \$ 226,135 |
| Fair value of common stock issued | 116,187 |
| Fair value of replacement awards | 1,520 |
| Fair value of contingent consideration | 76,248 |
| Total consideration | <u>\$ 420,090</u> |

The aggregate purchase consideration of \$420,090 was provided through cash of \$226,135 (net of \$205 cash acquired) and the issuance of up to 4,384,882 shares of the Company's common stock, of which 2,822,242 were issued upon closing of the acquisition, of which 2,495,441 were fully vested at the time of issuance with the remaining 326,801 vesting over future service periods. The cash consideration in the above table includes the repayment of 2nd.MD debt of \$13,026. The contingent consideration represented potential obligations for the Company to issue up to 2,170,972 additional shares of its common stock to the selling shareholders of 2nd.MD and was comprised of two earnout scenarios associated with (1) a contract renewal and (2) the achievement of certain future revenue milestones. As a result of the contract renewal and achievement of certain revenue milestones, the Company will issue issued a total of 1,977,343 1,977,321 shares of its common stock

F-18

subsequent to February 28, 2022 during the year ended February 28, 2023. The estimated fair value of the replacement awards issued in the above table is comprised of 120,760 restricted stock units issued to 2nd.MD employees with an estimated fair value of \$5,434 of which \$1,520 was attributable to pre-acquisition services. The remaining estimated value of \$3,914 associated with the replacement awards is attributable to post-acquisition services and will be is being expensed over the future requisite service periods of the awards.

Several key 2nd.MD employees entered into agreements with the Company whereby their pro rata portion of shares to be issued at closing and upon achievement of the contingent consideration milestones are also subject to continuous

F-17

employment with the Company and vest annually over a period of two years following the acquisition date. Upon voluntary termination of employment, any unvested shares will be forfeited. Due to the risk of forfeiture upon termination of employment, the aggregate 326,801 shares issued at closing and the aggregate shares eligible to be issued upon achievement of the contingent consideration milestones of 281,531 shares **have been** **were** excluded from the purchase price and contingent consideration. These shares are accounted for as stock-based compensation expense in the post business combination periods.

The estimated fair value of the contingent consideration associated with future revenue milestones was determined using a Monte Carlo simulation. The Monte Carlo simulation performs numerous simulations utilizing certain assumptions such as (i) projected eligible revenues, (ii) expected term, (iii) risk-free rate, (iv) risk-adjusted discount rate, (v) share volatility and (vi) operational leverage ratio between revenues and earnings before interest, taxes, depreciation and amortization (EBITDA). The fair value measurements for contingent consideration are based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the assumptions used could materially change the estimated fair value of the contingent consideration. The estimated fair value of the contingent consideration was \$37,767 as of January 31, 2022, at which time the contingency was resolved. The estimated fair value of contingent consideration decreased **since** **from** the acquisition date primarily due to a decrease in the Company's stock price. The Company recorded the change in fair value of its contingent consideration liability in the consolidated statements of operations until January 31, 2022. Upon resolution of the contingency and determination of the number of common stock shares to be issued, the Company reclassified the value of the contingent consideration from a liability into stockholders' equity **as of February 28, 2022** in the consolidated balance sheet. **See Note 9 for further details.**

The Company accounted for the acquisition of 2nd.MD under the U.S. GAAP business combinations guidance. This accounting requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The allocation of the purchase price to the assets acquired and liabilities assumed was subject to further adjustment within the measurement period (up to one year from the acquisition date). Measurement period adjustments since initial preliminary estimates reported in the first quarter of fiscal 2022 were primarily related to an updated working capital calculation. The cumulative effect of all measurement period adjustments resulted in a decrease to recognized goodwill of \$1,878. As of February 28, 2022, the purchase price allocation **is** **was** considered complete.

F-19 **F-18**

The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition.

| | |
|--|-------------------|
| Assets acquired: | |
| Accounts receivable | \$ 5,550 |
| Unbilled revenue | 226 |
| Current portion of deferred contract acquisition costs | 176 |
| Prepaid and other current assets | 1,052 |
| Property and equipment | 4,344 |
| Deferred contract acquisition costs | 564 |
| Goodwill | 208,286 |
| Intangible assets⁽¹⁾ | |
| Customer relationships | 120,000 |
| Technology | 58,000 |
| Supplier-based network | 25,000 |
| Trade name | 3,400 |
| Non-compete agreement | 3,100 |
| Total assets acquired | \$ 429,698 |
| Liabilities assumed: | |
| Accounts payable | \$ 1,195 |
| Accrued expenses | 585 |
| Accrued compensation | 3,817 |

| | |
|--|-----------------|
| Deferred rent and other current liabilities | 904 |
| Due to customers | 294 |
| Current portion of deferred revenue | 625 |
| Deferred rent and other noncurrent liabilities | 2,188 |
| Total liabilities assumed | <u>\$ 9,608</u> |

| | |
|---------------------|-------------------|
| Net assets acquired | <u>\$ 420,090</u> |
|---------------------|-------------------|

(1) The weighted-average useful life of intangible assets acquired is approximately 14 years.

The purchase price was allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The identifiable intangible assets included technology, customer relationships, trade name, supplier based network, and non-compete agreements and are being amortized on a straight-line basis ranging from 3 years to 20 years. Customer relationships and trade names were valued using a multiple period excess earnings method (MPEEM) and the relief from royalty method (RFR), respectively. The supplier-based network and non-compete agreement intangible assets were valued using the "With and Without Method." These valuation methods are specific forms of the Income Approach which is a valuation technique that derives value by estimating the fair value of after-tax cash flows attributable to the acquired intangibles. The valuation methods require several judgments and assumptions to determine the fair value of intangible assets, including growth rates, discount rates, customer attrition rates, expected levels of cash flows, and tax rate. Key assumptions used included revenue projections for fiscal years 2022 through 2032, an attrition rate of 8.0%, a tax rate of 24%, a discount rate of 13%, a royalty rate of 1.5% and probability of competition of 33%.

The technology intangible asset was valued using the estimated replacement cost method. This method requires several judgments and assumptions to determine the fair value, including expected profits and opportunity cost.

F-19

Goodwill is attributable to the workforce of 2nd.MD as well as expected future growth into new and existing markets and is deductible for income tax purposes.

For the fiscal year ended February 28, 2022, 2nd.MD contributed approximately \$48,753 of revenue and approximately \$(32,353) of net loss, which includes \$27,211 of equity-based compensation expense related to 2nd.MD employees, to the Company's operating results.

F-20

Acquisition of PlushCare

On June 9, 2021, the Company acquired all the outstanding equity interests of PlushCare. Based in San Francisco, California, PlushCare is a provider of various technology and administrative services to the medical practice PCs, which in turn provide virtual primary care and mental health support services. The results of operations and financial position of PlushCare are included in the Company's consolidated financial statements from the date of acquisition.

The preliminary consideration paid was comprised of cash, common stock, and contingent consideration as follows:

| | |
|--|-------------------|
| Consideration | |
| Fair value of common stock issued | \$ 330,338 |
| Fair value of contingent consideration | 44,618 |
| Cash consideration, net of cash acquired | 33,860 |
| Fair value of replacement awards | <u>5,209</u> |
| Total consideration | <u>\$ 414,025</u> |

The aggregate purchase consideration of \$414,025 was provided through cash of \$33,860 (net of \$17,837 cash acquired and \$1,463 of debt repaid) and the issuance of 7,144,393 shares of the Company's common stock, of which 854,717 are subject to future vesting and excluded from consideration paid. The contingent consideration represented a potential obligation for the Company to issue up to an additional 1,429,556 shares of its common stock and up to approximately \$2,000 in cash upon the achievement of defined revenue milestones following the closing, closing, of which \$1,828 was paid during fiscal 2023. Up to 102,111 shares of this contingent consideration will be withheld from being issued to the selling shareholders of PlushCare until the resolution of a pending litigation matter. The revenue milestone contingency was resolved at December 31, 2021, and as a result the Company will issue 1,327,445 issued 1,327,408 shares of its common stock subsequent to February 28, 2022, during fiscal 2023, excluding the 102,111 shares that are withheld pending the resolution of the litigation matter. See Note 16 for further details.

The estimated fair value of the replacement awards issued in the above table is comprised of 325,992 options to purchase Accolade common stock issued to PlushCare employees as of the acquisition date with an estimated fair value of \$16,663, of which \$5,209 was attributable to pre-acquisition services. The remaining estimated value of \$11,454 associated with the replacement awards is attributable to post-acquisition services and will be is being expensed over the future requisite service periods of the awards.

Certain key PlushCare employees entered into agreements with the Company whereby a portion of their shares issued at closing are subject to continuous employment with the Company and vest annually over a three-year period following the acquisition date. Upon voluntary termination of employment, any unvested shares will be forfeited. Due to the risk of forfeiture upon termination of employment, the 806,161 shares subject to forfeiture have been excluded from the purchase price and are accounted for as stock-based compensation expense in the post-business combination periods. Also, one PlushCare employee received 48,556 shares of unvested common stock. These shares vest on a pro rata basis monthly through May 2023.

The estimated fair value of the contingent consideration associated with future revenue milestones was determined using a Monte Carlo simulation. The Monte Carlo simulation performs numerous simulations utilizing certain assumptions such as (i) projected eligible revenues, (ii) expected term, (iii) risk-free rate, (iv) risk-adjusted discount rate, (v) share volatility, and (vi) operational leverage ratio between revenues and earnings before interest, taxes, depreciation, and amortization (EBITDA). The fair value measurements for contingent consideration are based on significant inputs not observable in the market and thus represent a Level 3 measurement within the fair value hierarchy.

F-20

The estimated fair value of the contingent consideration was \$37,683 as of December 31, 2021 and was subject to remeasurement until at which time the contingency was resolved. The estimated fair value of contingent consideration decreased since the acquisition date primarily due to a decrease in the Company's stock price. The Company recorded the change in fair value of its contingent consideration liability in the consolidated statements of operations through December 31, 2021. Upon resolution of the contingency and determination of the number of common stock shares to be issued, the Company reclassified the value of the contingent consideration from a liability into stockholders' equity as of February 28, 2022 in the consolidated balance sheet. See Note 9 for further details.

F-21

The Company accounted for the acquisition of PlushCare under the U.S. GAAP business combinations guidance. This accounting requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The allocation of the purchase price to the assets acquired and liabilities assumed is based upon preliminary information and is was subject to further adjustment within the measurement period (up to one year from the acquisition date). Measurement period adjustments since initial preliminary estimates reported in the second quarter of fiscal 2022 were primarily related to updated assessments of acquired deferred tax liability and accounts receivable. The cumulative effect of all measurement period adjustments resulted in a decrease to recognized goodwill of \$1,685. As of May 31, 2022, the purchase price allocation was considered complete.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at the date of acquisition.

| | |
|--|-------------------|
| Assets acquired: | |
| Accounts receivable | \$ 1,359 |
| Prepaid and other current assets | 573 |
| Property and equipment | 298 |
| Other noncurrent assets | 932 |
| Goodwill | 365,597 |
| Intangible assets⁽¹⁾ | |
| Customer relationships | 4,050 |
| Technology | 40,650 |
| Trade name | 10,300 |
| Non-compete agreements | 6,200 |
| Total assets acquired | \$ 429,959 |
| Liabilities assumed: | |
| Accounts payable | \$ 1,532 |
| Accrued expenses | 193 |
| Accrued compensation | 2,117 |
| Current portion of deferred revenue | 1,212 |
| Deferred tax liability | 9,992 |
| Other liabilities | 888 |
| Total liabilities assumed | \$ 15,934 |
| Net assets acquired | \$ 414,025 |

(1) The weighted-average useful life of intangible assets acquired is approximately 5 years.

The purchase price was allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their preliminary estimated fair values at the acquisition date. The identifiable intangible assets included customer relationships, technology, trade name, and non-compete agreements and are being amortized on a straight-line basis ranging from 2 years to 10 years. The valuation methods require several judgments and assumptions to determine the fair

F-21

value of intangible assets, including growth rates, discount rates, customer attrition rates, expected levels of cash flows, and tax rate. Key assumptions used included revenue projections for fiscal years 2022 through 2035, an attrition rate of 25% and 50%, a tax rate of 25%, a discount rate of 12.5%, a royalty rate of 3% and probabilities of competition between 70% and 90%.

The technology intangible asset was valued using the estimated replacement cost method. This method requires several judgments and assumptions to determine the fair value, including expected profits and opportunity cost. Goodwill is attributable to the workforce of PlushCare as well as expected future growth into new and existing markets and is not deductible for income tax purposes.

For the year ended February 28, 2022, PlushCare contributed approximately \$44,393 of revenue and approximately \$(15,396) of net loss, which includes \$17,980 of equity-based compensation expense related to PlushCare employees, to the Company's operating results.

F-22

Unaudited Pro Forma Financial Information

The following table reflects the pro forma operating results for the Company which gives effect to the acquisitions of 2nd.MD and PlushCare as if they had occurred on March 1, 2020. The pro forma results are based on assumptions that the Company believes are reasonable under the circumstances. The pro forma results are not necessarily indicative of future results. The pro forma financial information includes the historical results of the Company, 2nd.MD, and PlushCare adjusted for certain items, which are described below, and does not include the effects of any synergies or cost reduction initiatives related to the acquisitions of 2nd.MD or PlushCare.

| | Unaudited Pro Forma | |
|-------------------|-------------------------|--------------|
| | Year ended February 28, | |
| | 2022 | 2021 |
| Revenue | \$ 324,367 | \$ 249,028 |
| Net income (loss) | \$ (137,644) | \$ (142,392) |

Pro forma net income (loss) for the years ended February 28, 2022 and 2021 reflect adjustments primarily related to interest expense, the amortization of intangible assets and stock-based compensation expense. The unaudited pro forma financial information is not necessarily indicative of what the Company's consolidated results actually would have been if the acquisition had been completed at the beginning of the respective periods.

Acquisition of HealthReveal

On September 30, 2021, the Company acquired substantially all the assets of HealthReveal, Inc. (HealthReveal). HealthReveal is a clinical artificial intelligence company focused on ensuring patients receive optimal, personalized chronic care to preempt adverse outcomes. Under the terms of the agreement, the Company issued 252,808 shares of common stock as consideration at closing. The Company will issue up to also issued 28,089 additional shares of common stock that are subject to an indemnity holdback, and these such shares will be were released 18 months following the closing.

The Company accounted for this transaction as an asset acquisition based on an evaluation of the U.S. GAAP guidance for business combinations. The Company concluded that the developed technology acquired from HealthReveal comprised substantially all of the fair value of the gross assets acquired and that the assets acquired did not meet the definition of a business under the guidance for business combinations. The developed technology intangible asset was recorded at \$9,976 on the acquisition date and is being amortized on a straight-line basis over 3 years.

Acquisition of MD Insider (MDI)

On July 31, 2019, the Company acquired the outstanding equity interests of MDI. Based in California, MDI is a provider of machine learning-enabled physician performance transparency. The following table summarizes the purchase consideration paid to MDI:

| | |
|--|----------|
| Consideration Paid | |
| Cash consideration | \$ 324 |
| Fair value of equity issued | 5,114 |
| Fair value of contingent consideration | 1,050 |
| Total consideration paid | \$ 6,488 |

The aggregate purchase price consideration of \$6,488 was paid primarily through the issuance of up to 462,691 shares of the Company's common stock, of which 387,132 were issued as of February 28, 2022, with the remaining shares issuable subject to certain working capital and indemnity adjustments (if applicable). MDI's former shareholders were eligible to receive 100,607 additional shares of the Company's common stock upon the completion of a platform solution, as defined in the purchase agreement (MDI Earnout). During August 2020, the Company issued 96,487 shares of common stock in connection with the MDI Earnout (which shares are included in the 387,132 shares issued as of February 28, 2021). The MDI Earnout was accounted for as an equity classified instrument and was not subject to remeasurement in subsequent periods.

The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition:

| | | |
|--|----|-------|
| Assets acquired: | | |
| Cash and cash equivalents | \$ | 118 |
| Accounts receivable | | 98 |
| Prepaid expenses | | 5 |
| Goodwill | | 4,013 |
| Intangible assets | | 2,900 |
| Other assets | | 17 |
| Total assets acquired | \$ | 7,151 |
| Liabilities assumed: | | |
| Accounts payable | \$ | 321 |
| Accrued expenses and other current liabilities | | 342 |
| Total liabilities assumed | \$ | 663 |
| Net assets acquired | \$ | 6,488 |

The intangible asset was valued using the estimated replacement cost method. This method requires several judgments and assumptions to determine the fair value of the intangible asset, including expected profits and opportunity costs. Goodwill related to the acquisition is attributable to the workforce of MDI as well as the expected future growth into new and existing markets and is not deductible for income tax purposes.

Acquisition and Integration-Related Costs

Acquisition For the year ended February 28, 2023, the Company incurred \$1,218 in acquisition and integration-related costs include banking, legal, accounting, related to litigation inherited through the PlushCare acquisition. Refer to Note 16 for further details. These costs were recorded in general and consulting fees, administrative expenses in the Company's consolidated statements of operations. For the years

F-22

ended February 28(29), 2022, February 28, 2022 and 2021, and 2020, the Company incurred a total of \$13,219 \$2,050, and \$567 \$2,050, respectively, in acquisition and integration-related costs that were expensed immediately and recorded in general and administrative expenses in the Company's consolidated statements of operations. These costs include banking, legal, accounting, and consulting fees related to acquisitions.

(5) Goodwill and Intangible Assets

The following table presents changes in the carrying amount of goodwill for the year ended February 28, 2022: are as follows:

| | | | |
|----------------------------|----|---------|------------|
| Balance, February 28, 2021 | \$ | 4,013 | \$ 4,013 |
| Acquisitions | | 573,883 | 573,883 |
| Balance, February 28, 2022 | \$ | 577,896 | \$ 577,896 |
| Impairment | | | (299,705) |
| Balance, February 28, 2023 | | | \$ 278,191 |

Annually, and upon the identification of a triggering event, management is required to perform an evaluation of the recoverability of goodwill. Triggering events potentially warranting an interim goodwill impairment test include, among other factors, declines in historical or

projected revenue, operating income or cash flows, and sustained declines in the Company's stock price or market capitalization, considered both in absolute terms and relative to peers.

As a result of sustained decreases in the Company's stock price and market capitalization, the Company conducted an impairment test of its goodwill and intangible assets as of May 31, 2022. As a result of this testing, the Company recorded a non-cash goodwill impairment charge of \$299,705 (equivalent to \$4.20 per basic and diluted share for the year ended February 28, 2023) during the first quarter of fiscal 2023. No impairments were recorded to intangible assets during the year ended February 28, 2023.

The Company's May 31, 2022 goodwill impairment test reflected an allocation of 70% and 30% between income and market-based approaches, respectively. The Company believes the 70% weighting to the income-based approach is appropriate as it more directly reflects its future growth and profitability expectations. Significant inputs into the valuation models included the discount rate, revenue market multiples, and estimated future cash flows. Management used a discount rate of 11% and guideline peer group and public transaction revenue multiples between 1.1x and 1.8x current and forward-looking revenues in the goodwill impairment test. Subsequent to the impairment, there was no excess of reporting unit fair value over carrying value.

While management cannot predict if or when additional future goodwill impairments may occur, additional goodwill impairment impairments could have a material adverse effect effects on the Company's operating income, net assets, and/or the Company's cost of, or access to, capital. The Company did not record any goodwill impairment charges

Intangible assets consisted of the following:

| | As of February 28, 2023 | | | | As of February 28, 2022 | | |
|------------------------|-------------------------|-------------------|--------------------|-------------------|-------------------------|--------------------------|--------------------|
| | Weighted Avg. | | | Net | | | |
| | Remaining Useful | Accumulated | Carrying | | | | |
| | Life (years) | Gross Value | Amortization | Value | Gross Value | Accumulated Amortization | Net Carrying Value |
| Customer relationships | 17.9 | \$ 124,050 | \$ (15,353) | \$ 108,697 | \$ 124,050 | \$ (7,444) | \$ 116,606 |
| Technology | 3.0 | 111,526 | (45,046) | 66,480 | 111,526 | (21,971) | 89,555 |
| Supplier-based network | 3.0 | 25,000 | (10,000) | 15,000 | 25,000 | (5,000) | 20,000 |
| Trade name | 8.2 | 13,700 | (2,483) | 11,217 | 13,700 | (1,112) | 12,588 |
| Non-compete agreement | 0.7 | 9,300 | (7,492) | 1,808 | 9,300 | (3,359) | 5,941 |
| | | <u>\$ 283,576</u> | <u>\$ (80,374)</u> | <u>\$ 203,202</u> | <u>\$ 283,576</u> | <u>\$ (38,886)</u> | <u>\$ 244,690</u> |

Amortization expense for intangible assets was \$41,488, \$36,590, and \$1,450 during the years ended February 28(29) February 28, 2023, 2022, and 2021, and 2020. Subsequent to February 28, 2022, the Company experienced a decline in its market capitalization as a result of a decline in the Company's stock price. If this decline continues for a sustained period of time, the Company may be required to perform a goodwill impairment assessment at an interim period and could be required to recognize a non-cash goodwill impairment charge at that time, which could be material, respectively.

F-24 F-23

Intangible assets consisted of the following:

| | As of February 28, 2022 | | | | As of February 28, 2021 | | |
|------------------------|-------------------------|-------------|--------------|------------|-------------------------|--------------|----------|
| | Weighted Avg. | | | Net | | | Net |
| | Remaining Useful | Accumulated | | Carrying | Accumulated | | Carrying |
| | Life (years) | Gross Value | Amortization | Value | Gross Value | Amortization | Value |
| Customer relationships | 18.6 | \$ 124,050 | \$ (7,444) | \$ 116,606 | \$ — | \$ — | \$ — |
| Technology | 4.0 | 111,526 | (21,971) | 89,555 | 2,900 | (2,296) | 604 |
| Supplier-based network | 4.0 | 25,000 | (5,000) | 20,000 | — | — | — |

| | | | | | | | |
|-----------------------|-----|------------|-------------|------------|----------|------------|--------|
| Trade name | 9.2 | 13,700 | (1,112) | 12,588 | — | — | — |
| Non-compete agreement | 1.5 | 9,300 | (3,359) | 5,941 | — | — | — |
| | | \$ 283,576 | \$ (38,886) | \$ 244,690 | \$ 2,900 | \$ (2,296) | \$ 604 |

Amortization expense for intangible assets was \$36,590, \$1,450, and \$846 during the years ended February 28(29), 2022, 2021, and 2020, respectively.

Amortization expense over the remaining life of the intangible assets will be recognized as follows:

| Year Ending February 28(29), | | |
|------------------------------|-----------|-----------|
| 2023 | \$ 41,488 | |
| 2024 | 37,795 | \$ 37,795 |
| 2025 | 34,143 | 34,143 |
| 2026 | 32,125 | 32,125 |
| 2027 | 9,403 | 9,403 |
| 2028 | | 7,370 |
| Thereafter | 89,736 | 82,366 |
| | 244,690 | 203,202 |

(6) Property and Equipment

Property and equipment consisted of the following:

| | February 28, | | February 28, | |
|---|--------------|-----------|--------------|-----------|
| | 2022 | 2021 | 2023 | 2022 |
| Capitalized software development costs | \$ 33,388 | \$ 32,292 | \$ 39,097 | \$ 33,388 |
| Computer software | 6,023 | 5,688 | 6,026 | 6,023 |
| Computer equipment | 10,518 | 8,386 | 12,363 | 10,518 |
| Office equipment, furniture, and leasehold improvements | 11,838 | 7,141 | 12,120 | 11,838 |
| | 61,767 | 53,507 | 69,606 | 61,767 |
| Less accumulated depreciation | (49,970) | (44,280) | (54,843) | (49,970) |
| Total | \$ 11,797 | \$ 9,227 | \$ 14,763 | \$ 11,797 |

Depreciation and amortization expense related to property and equipment was \$4,889, \$6,018, \$6,762, and \$7,670 for the fiscal years ended February 28(29) February 28, 2023, 2022, and 2021, and 2020, respectively.

During the year ended February 28, 2022, the Company wrote off \$328 of fully-depreciated computer equipment. During the year ended February 28, 2021, the Company wrote off \$3,950 of fully-depreciated capitalized software, \$3,236 of fully-depreciated computer software, \$2,206 of fully-depreciated computer equipment, and \$3,699 of fully-depreciated office equipment, furniture, and leasehold improvements. During the year ended February 29, 2020, the Company accelerated depreciation in the amount of \$1,634 related to the retirement of software. Also during 2020, the Company wrote off \$680 of leasehold improvements and furniture/fixtures related to the termination of an office lease, resulting in a loss on disposal of \$299.

F-25

(7) Leases

The Company adopted Topic 842 Accounting Standards Update 2016-02, Leases (Topic 842) on February 28, 2022, with an effective date of adoption of March 1, 2021, using the modified retrospective approach. The Company has operating leases for offices and certain

equipment under non-cancelable leases in the United States and Czech Republic. These leases have remaining terms of up to 87 years. The Company had no finance leases during the year years ended February 28, 2022, February 28, 2023 and 2022.

The components of operating lease cost recorded in the consolidated statements of operations were as follows:

| | Year Ended February 28, | | |
|----------------------|---------------------------------|-------|---------|
| | Year ended February 28, 2022 | 2023 | 2022 |
| Operating lease cost | \$ 7,169 | 7,575 | \$7,169 |
| Variable lease cost | 1,691 | 2,042 | 1,691 |
| Total lease cost | \$ 8,860 | 9,617 | \$8,860 |

F-24

The following table sets forth the cash flows related to the Company's leases:

| Cash Flow Information | Year Ended February 28, | |
|---|-------------------------|----------|
| | 2023 | 2022 |
| Cash paid for amounts included in the measurement of lease liabilities: | | |
| Operating cash flows from operating leases | \$ 8,569 | \$ 8,310 |
| Right-of-use assets obtained in exchange for lease obligations | | |
| Operating leases | \$ 2,170 | \$ 3,564 |

The following table sets forth the cash flows, weighted-average remaining term and weighted-average discount rate for the Company's leases as of February 28, 2022 February 28, 2023:

| Cash Flow Information | Year ended February 28, 2022 |
|---|---------------------------------|
| | |
| Cash paid for amounts included in the measurement of lease liabilities: | |
| Operating cash flows from operating leases | \$ 8,310 |
| Right-of-use assets obtained in exchange for lease obligations | |
| Operating leases | \$ 3,564 |
| Supplemental Information | |
| Weighted-average remaining lease term (years) | 6.1 |
| Weighted-average discount rate | 4.8 % |
| Supplemental Information | February 28, 2023 |
| Weighted-average remaining lease term (years) | 5.3 |
| Weighted-average discount rate | 5.0 % |

As of February 28, 2022 February 28, 2023, the future minimum lease payments under non-cancelable operating leases were as follows:

| Year Ending February 28(29), | |
|------------------------------|----------------|
| 2023 | \$ 8,457 |
| 2024 | 8,238 \$ 8,849 |

| | | | |
|-------------------------|----|---------|----------|
| 2025 | | 6,640 | 7,270 |
| 2026 | | 6,588 | 7,303 |
| 2027 | | 6,093 | 6,420 |
| 2028 | | | 3,665 |
| Thereafter | | 9,402 | 5,732 |
| Total lease payments | | 45,418 | 39,239 |
| Less: Imputed interest | | (6,350) | (4,766) |
| Total lease liabilities | \$ | 39,068 | \$34,473 |

The Company's future minimum In the fourth quarter of fiscal 2023, the Company entered into an office lease payments agreement in Prague, Czech Republic that is expected to be accounted for as an operating lease. This lease is not recorded in the consolidated balance sheets or in the table above as the lease had not commenced as of February 28, 2021 under the previous accounting standard (ASC 840) were as follows: February 28, 2023. The lease has total minimum fixed payments of approximately \$5,700 over a term of approximately 8 years and is expected to commence in fiscal 2024.

| Year Ending February 28(29), | |
|------------------------------|------------------|
| 2022 | \$ 6,587 |
| 2023 | 6,577 |
| 2024 | 6,625 |
| 2025 | 5,664 |
| 2026 | 5,790 |
| Thereafter | 15,726 |
| | <u>\$ 46,969</u> |

F-26

Prior to the adoption of Topic 842, the Company recorded rent expense of \$6,304 and \$5,143 for the fiscal years ended February 28(29), 2021 and 2020, respectively.

(8) Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

| | February 28, | | February 28, | |
|--|------------------|-----------------|-----------------|-----------------|
| | 2022 | 2021 | 2023 | 2022 |
| Current portion of loans payable, net of unamortized issuance cost | \$ 596 | \$ — | \$ 596 | \$ 596 |
| Professional and consulting fees | 2,661 | 2,185 | 1,992 | 2,661 |
| Taxes | 769 | 1,074 | 528 | 769 |
| Marketing | 1,492 | 226 | 347 | 1,492 |
| Accrued litigation(1) | 888 | — | 3,700 | 888 |
| Software, hardware, and communication costs | 600 | 400 | 464 | 600 |
| Payable related to acquisition earnout | 1,969 | — | — | 1,969 |
| Other | 2,025 | 1,527 | 4,117 | 2,025 |
| Total | <u>\$ 11,000</u> | <u>\$ 5,412</u> | <u>\$11,744</u> | <u>\$11,000</u> |

(1) See note 16 for discussion regarding accrued litigation matters.

(9) Fair Value Measurements

The following table sets forth the fair value of the Company's financial assets within the fair value hierarchy:

| | February 28, 2022 | | | | February 28, 2023 | | | |
|------------------------------|-------------------|---------|---------|------------|-------------------|---------|---------|------------|
| | Level 1 | Level 2 | Level 3 | Fair Value | Level 1 | Level 2 | Level 3 | Fair Value |
| Assets | | | | | | | | |
| Cash equivalents: | | | | | | | | |
| Money market funds | \$ 131,527 | \$ — | \$ — | \$ 131,527 | \$99,861 | \$ — | \$ — | \$ 99,861 |
| | | | | | \$39,995 | \$ — | \$ — | \$ 39,995 |
| United States treasury bills | \$ 99,999 | \$ — | \$ — | \$ 99,999 | | | | |
| | | | | | | | | |
| | February 28, 2021 | | | | February 28, 2022 | | | |
| | Level 1 | Level 2 | Level 3 | Fair Value | Level 1 | Level 2 | Level 3 | Fair Value |
| Assets | | | | | | | | |
| Cash equivalents: | | | | | | | | |
| Money market funds | \$ 283,245 | \$ — | \$ — | \$ 283,245 | \$131,527 | \$ — | \$ — | \$131,527 |
| United States treasury bills | | | | | \$ 99,999 | \$ — | \$ — | \$ 99,999 |

In connection with the acquisitions of 2nd.MD and PlushCare, the Company recorded contingent consideration liabilities for the estimated fair value of Accolade common stock issuable to 2nd.MD and PlushCare shareholders upon the achievement of certain defined milestones. The contingent consideration liabilities were measured at fair value and were based on significant inputs not observable in the market, which represent a Level 3 measurement. The valuation of contingent consideration used assumptions the Company believes would be made by a market participant.

The Company recorded the change in fair value of its contingent consideration liabilities in the consolidated statements of operations. The following presents changes in the Company's Level 3 contingent consideration liabilities for the year ended February 28, 2022:

| | |
|---|----------|
| Balance, February 28, 2021 | \$ — |
| Incurred through acquisition | 120,866 |
| Change in fair value | (45,416) |
| Reclassification to equity and accrued expenses and other current liabilities | (75,450) |
| Balance, February 28, 2022 | \$ — |

As of February 28, 2022, \$1,969 of liabilities related to the acquisition earnouts are included in accrued expenses and other current liabilities on the consolidated balance sheet.

The estimated fair value of the convertible senior notes (Note 10) was \$226,751 \$221,346 as of February 28, 2022 February 28, 2023, based on quoted market prices of the Company's instrument in markets that are not active and are classified as Level 2 within the fair value hierarchy. Considerable judgment is necessary to interpret the market data and develop an estimate of the fair value. Accordingly, the estimate is not necessarily indicative of the amount at which this instrument could be purchased, sold, or settled.

(10) Debt

(a) *Convertible Senior Notes and Capped Call Options*

Convertible Senior Notes

In March 2021, the Company completed a private convertible note offering, pursuant to an Indenture dated as of March 29, 2021 between the Company and U.S. Bank National Association, as trustee (the Indenture), and issued \$287,500 of 0.50% Convertible Senior Notes due 2026 (the Notes) that mature in April 2026, unless earlier converted, redeemed or repurchased. The Notes bear interest at a rate of 0.50% per annum, payable semiannually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021 and are convertible into cash, shares of the Company's

F-26

common stock or a combination of cash and shares of common stock, at the Company's election. The Company incurred costs of \$8,428 in connection with the Notes and the capped calls, of which \$8,368 was allocated to the Notes and recorded as a debt discount and \$60 was allocated to the capped call and recorded directly to additional paid-in capital. Net proceeds from the issuance of Notes were \$279,132, and the Company used \$34,443 of the net proceeds to pay the costs of the capped call transactions described below. For the year years ended February 28, 2022, February 28, 2023 and 2022, the Company recorded interest expense of \$3,094 and \$2,857, respectively, of which \$1,657 and \$1,534, respectively, was associated with the amortization of the debt discount.

Pursuant to the terms of the Notes, a holder may convert all or any portion of its Notes at its option at any time prior to October 1, 2025 and only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on August 31, 2021, if the last reported sale price of the Company's common stock for at least 20 trading days during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the "measurement period") in which the trading price (as defined in the Indenture) per \$1 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; or (4) upon the occurrence of specified corporate events. On or after October 1, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances.

F-28

The initial conversion rate is 19.8088 shares of the Company's common stock per \$1 principal amount of Notes (equivalent to an initial conversion price of approximately \$50.48 per share of the Company's common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event or convert its Notes called (or deemed called) for redemption in connection with such notice of redemption, as the case may be.

The Company may not redeem the Notes prior to April 6, 2024. On or after April 6, 2024, the Company may redeem for cash all or any portion of the Notes (subject to the partial redemption limitation set forth in the Indenture), at its option, if the last reported sale price of the Company's common stock has been at least 130% of the conversion price then in effect for at least 20 trading days, including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption

price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.

Upon a fundamental change (as defined in the Indenture), holders may, subject to certain exceptions, require the Company to purchase their Notes in whole or in part for cash at a price equal to the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date (as defined in the Indenture). In addition, upon a Make-Whole Fundamental Change (as defined in the Indenture), the Company will, under certain circumstances, increase the applicable conversion rate for a holder that elects to convert its Notes in connection with such Make-Whole Fundamental Change.

Under the Indenture, the Notes may be accelerated upon the occurrence of certain customary events of default. If certain bankruptcy and insolvency-related events of default with respect to the Company occur, the principal of, and accrued and unpaid interest on, all of the then outstanding Notes shall automatically become due and payable. The Indenture provides that the sole remedy for an event of default relating to certain failures by the Company to comply with reporting covenants, including timely filings, consists exclusively of the right to receive additional interest on the Notes.

As of February 28, 2022 February 28, 2023, none of the conditions of the Notes to early convert had been met. The Notes are the Company's senior, unsecured obligations that rank senior in right of payment to the Company's future indebtedness that

F-27

is expressly subordinated to the Notes, rank equally in right of payment with the Company's future senior unsecured indebtedness that is not so subordinated, effectively subordinated to the Company's existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables and preferred equity (to the extent the Company is not a holder thereof)) of the Company's subsidiaries. The Notes contain both affirmative and negative covenants. As of February 28, 2022 February 28, 2023, the Company was in compliance with all covenants in the Notes.

As discussed in Note 2, the The Company early adopted ASU 2020-06 as of March 1, 2021 and concluded the Notes will be are accounted for as debt, with no bifurcation of the embedded conversion feature. Transaction costs were recorded as a direct deduction from the related debt liability in the consolidated balance sheet and are amortized to interest expense using the effective interest method over the term of the Notes. The effective interest rate for the Notes is 1.1%.

As of February 28, 2022 February 28, 2023, the Notes consisted of the following:

| | February 28, 2022 | February 28, 2023 |
|----------------------------|-------------------|-------------------|
| Principal | \$ 287,500 | \$ 287,500 |
| Unamortized issuance costs | (6,834) | (5,177) |
| Net carrying amount | \$ 280,666 | \$ 282,323 |

F-29

Capped Call

Concurrent with the pricing of the Notes, the Company entered into privately negotiated capped call transactions with two of the initial purchasers and/or their respective affiliates and another financial institution (the Option Counterparties). The capped call transactions are expected to offset the potential dilution to Accolade's common stock as a result of any conversion of Notes, with such offset subject to a cap initially equal to \$76.20 (which represented a premium of 100% over the last reported sale price of the Company's common stock on March 24, 2021). The capped call transactions are separate transactions, entered into by the Company with the Option Counterparties, and are not part of the terms of the Notes.

As the capped call options are both legally detachable and separately exercisable from the Notes, the Company accounts for the capped call options separately from the Notes. The capped call options are indexed to the Company's own common stock and classified in stockholders' equity. As such, the premiums paid for the capped call options have been were included as a net reduction to additional paid-in capital in the consolidated balance sheet

(b) Revolving Credit Facility

During July 2019, the Company entered into a revolving credit facility (the (as amended, the 2019 Revolver) with a syndicate of two banks. Under the 2019 Revolver, the Company has the capacity to borrow up to \$80,000 on a revolving facility. Availability of borrowings on the 2019 Revolver is calculated as a multiple of the Company's eligible monthly recurring revenues (as defined in the 2019 Revolver). As of February 28, 2022 February 28, 2023, the Company had an outstanding letter letters of credit to serve as office landlord security deposit deposits in the amount of \$1,084. This letter \$1,208. These letters of credit is are secured through the revolving credit facility, thus reducing the maximum capacity of the revolving credit facility to \$78,916 \$78,792 as of February 28, 2022 February 28, 2023. No amounts were outstanding as of February 28, 2022 February 28, 2023.

The 2019 Revolver term ends on July 19, 2022 July 19, 2024. The interest rate on the outstanding borrowings is LIBOR are at the Bloomberg Short-Term Bank Yield Index (BSBY) rate plus 350 basis points (prior to December 31, 2021) or Base Rate (as defined) plus 250 basis points, with the LIBOR BSBY rate and Base Rate subject to minimum levels. Interest payments are to be made in installments of one, two, or three months as chosen by the Company.

The Company incurred lender and third-party fees when entering into the 2019 Revolver, all of which were deferred at the onset of the facility. Issuance costs of \$543, including the fair value of warrants issued, were capitalized facility and are being amortized to interest expense over the remainder of the 2019 Revolver term. have been fully amortized. During the years ended February 28(29) February 28, 2023, 2022, 2021, and 2020, 2021, the Company recorded interest expense of \$203, \$296, \$1,106, and \$273, \$1,106, respectively, related to the revolving credit facility of which \$0, \$93, \$279, and \$195, \$279, respectively, related to the amortization of deferred financing fees. As of February 28, 2022 deferred financing fees have been fully amortized.

F-28

On August 21, 2020 July 19, 2022, the Company entered into an amendment to the 2019 Revolver which revised extended the terms of term until July 19, 2024, documented the transition from the LIBOR interest rate index to the BSBY rate, and established new minimum covenant revenue covenant and imposed minimum LIBOR and Base Rate levels. On September 11, 2020, targets. The term will automatically be extended to July 19, 2025 if the Company entered into a second amendment to the 2019 Revolver which modified the allocation requirements has at least \$200,000 in consolidated net cash as of the Company's cash to be held at each of the two lenders participating in the 2019 Revolver. On November 6, 2020, the Company entered into a third amendment to the 2019 Revolver which increased the capacity from a maximum of \$50,000 to a maximum of \$80,000, based on the achievement of certain growth metrics as defined in the amendment. On March 2, 2021, the Company entered into a fourth amendment to the 2019 Revolver in association with the acquisition of 2nd.MD to be completed and amended certain revenue covenants. On March 23, 2021, the Company entered into a fifth amendment to the 2019 Revolver in association with the issuance of the Convertible Senior Notes. On May 26, 2021, the Company entered into a sixth amendment to the 2019 Revolver in association with the acquisition of PlushCare which modified certain reporting covenants. May 31, 2024.

The 2019 Revolver is collateralized by substantially all of the assets of the Company.

F-30

(c) Term Loan

On January 30, 2017, the Company entered into a \$20,000 term loan facility (the Term Loan). Under the terms of the Term Loan, the Company was permitted to borrow up to an aggregate principal amount of \$20,000, with the total amount of available borrowings subject to certain monthly recurring revenue calculations. During July 2019, an amendment was entered into (Amendment 1) which resulted in an

additional \$2,000 of availability and set interest on the outstanding balance payable monthly at a rate of 10.00% per annum and interest payable-in-kind accrued at a rate of 2.00% per annum, compounded monthly, and due at maturity. Additionally, the Company was required to pay an exit fee equal to 1% of the aggregate principal borrowings at the time of maturity (end of term charge).

During May 2020, the Company entered into an additional amendment (Amendment 2), which resulted in an additional \$2,500 of availability, increasing total availability to \$24,500. Pursuant to Amendment 2, interest on the outstanding balance was payable monthly at a rate of 8.00% per annum and interest payable-in-kind accrued at a rate of 4.50% per annum, compounded monthly, and was due at maturity. Additionally, the Company was required to pay a prepayment fee equal to 2% of the aggregate principal borrowings if prepayment occurred on or prior to December 31, 2020, and 0.50% if prepayment occurred after December 31, 2020 but on or prior to maturity (prepayment fee), plus the end of term charge. Amendment 2 was accounted for as a debt modification, and all new lender fees were recorded as additional debt discount and third-party costs incurred in connection with the amendment were expensed as incurred.

During July 2020, the Company terminated the Term Loan. The Company repaid the outstanding balance of \$24,500 in its entirety, along with accrued interest in kind of \$600, the end of term charge of \$251, and the prepayment fee of \$502.

During the fiscal years ended February 28(29), 2021 and 2020, the Company recorded interest expense of \$2,837 and \$2,858, respectively, related to the Term Loan of which \$1,045 and \$280, respectively, related to the amortization of the debt discount. For the year ended February 28, 2021, amortization of the debt discount included \$502 related to the prepayment fee and \$251 related to the end of term charge. The debt discount related to the Term Loan was fully amortized at February 28, 2021.

(11) Stockholders' Equity (Deficit)

(a) Common Stock

Upon completion of the IPO, the Company issued and sold 11,526,134 shares of common stock at an issuance price of \$22.00 per share resulting in net proceeds of \$231,228, after deducting underwriting discounts, commissions, and offering costs. In addition, the Company issued 1,401,836 shares of common stock as a result of the automatic net exercise of warrants.

The Company closed its follow-on public offering on October 26, 2020, during which the Company issued and sold 5,750,000 shares of common stock at an issuance price of \$38.50 per share resulting in net proceeds of \$208,046 after deducting underwriting discounts, commissions, and offering costs.

(b) Convertible Preferred Stock

On July 7, 2020, upon the closing of the Company's IPO, all shares of the Company's outstanding convertible preferred stock converted into 29,479,521 shares of common stock and, as of February 28, 2022 February 28, 2023, 2022 and 2021, there were no shares of convertible preferred stock outstanding.

(c) Change Healthcare

In February 2020, the Company entered into a joint development agreement (JDA) and a data licensing agreement with Change Healthcare Holdings (Change Healthcare) whereby Change Healthcare provides various services to support the Company's product offerings. Concurrent with entering into the JDA, the Company entered into a five-year data licensing agreement with Change Healthcare. Upon entering into the JDA and data licensing agreement, the

F-31

Company issued 251,211 restricted shares of its common stock to Change Healthcare at an estimated fair value of \$15.40 per share, or \$3,869 in aggregate value. Pursuant to the terms of the restricted share agreement, 150,727 of the shares vested immediately and the remaining 100,484 restricted shares vested upon the achievement of certain product development milestones, as defined. During the year ended February 28, 2021, the remaining 100,484 restricted shares vested upon the achievement of those milestones. The aggregate equity value was allocated to the JDA and data licensing agreement based on the relative fair value of the IP and technical know-how contributed by Change Healthcare within the JDA and the discounted pricing received from Change Healthcare within the data licensing agreement. The equity value allocated to the JDA and data licensing agreement in the amount of \$3,005 was capitalized and deferred as internally developed software and other assets within the Company's consolidated balance sheet, respectively, with an offsetting increase to additional paid-in capital during the

year ended February 29, 2020. Costs that are capitalized and classified as internally developed software are being amortizing within depreciation and amortization in the Company's consolidated statement of operations.

(12) Equity-based Compensation

The following table summarizes the amount of stock-based compensation included in the consolidated statements of operations:

| | Year Ended February 28(29), | | | Year Ended February 28, | | |
|--------------------------------|-----------------------------|----------|----------|-------------------------|----------|---------|
| | 2022 | 2021 | 2020 | 2023 | 2022 | 2021 |
| Cost of revenue | \$ 3,197 | \$ 948 | \$ 318 | \$ 4,794 | \$ 3,197 | \$ 948 |
| Product and technology | 18,744 | 3,387 | 1,674 | 24,995 | 18,744 | 3,387 |
| Sales and marketing | 12,822 | 2,376 | 1,482 | 17,275 | 12,822 | 2,376 |
| General and administrative | 38,176 | 2,865 | 2,528 | 25,580 | 38,176 | 2,865 |
| Total stock-based compensation | \$ 72,939 | \$ 9,576 | \$ 6,002 | \$72,644 | \$72,939 | \$9,576 |

(a) Stock Options

In July 2020, the Company adopted the 2020 Equity Incentive Plan (the Incentive Plan), which authorized the Company to grant up to 4,300,000 shares of common stock to eligible employees, directors, and consultants to the Company in the form of stock options, restricted stock units, and other various equity awards, including any shares subject to stock options or other awards granted under the Company's prior stock option plan that expire or terminate for any reason (other than being exercised in full) or are cancelled in accordance with the terms of the prior stock option plan. The Incentive Plan also includes an annual evergreen increase, and the amount, terms of grants, and exercisability provisions are determined by the board of directors. The term of an award may be up to 10 years and options generally vest over four years, with one quarter of an award vesting one year after grant and the remainder vesting on a monthly basis over three years. As of February 28, 2022 February 28, 2023, there was a total of 6,527,962 9,211,901 shares of common stock authorized for issuance under the Incentive Plan, of which 3,682,077 1,488,576 were available for future grants.

F-29

(a) Stock Options

The Company recognizes stock-based compensation based on the grant date fair value of the awards and recognizes that cost using the straight-line method over the requisite service period of the award. The fair value of options, which vest in accordance with service schedules, is estimated on the date of grant using the Black-Scholes option pricing model. Prior to the Company's IPO in July 2020, the absence of an active market for the Company's common stock required it to estimate the fair value of the Company's common stock for purposes of granting stock options and for determining stock-based compensation expense for the periods presented. The Company obtained contemporaneous third-party valuations to assist in determining the estimated fair value of its common stock. These contemporaneous third-party valuations used the methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Practice Guide, *Valuation of Privately-Held-Company Equity Securities Issued as Compensation*. Expected volatilities are based on historical volatilities of comparable companies. The expected term of the options is based on the simplified method outlined in the SEC Staff accounting guidance, under which the Company estimates the term as the average of the option's contractual term and the option's weighted average vesting period. The risk-free rate represents the yield on U.S. Treasury bonds with maturity equal to the expected term of the granted option. The Company accounts for forfeitures as they occur. All stock options outstanding at February 28, 2022 February 28, 2023 are expected to vest according to their specific schedules.

During the years ended February 28, 2023, 2022, and 2021, the Company recognized \$11,798, \$10,374, and \$7,743, respectively, of compensation expense related to stock options. The Company did not capitalize any stock-based compensation expense to deferred costs for the years ended February 28, 2023, 2022 and 2021. The weighted average grant date fair value for stock options granted during the years ended February 28, 2023, 2022, and 2021 was \$5.10, \$28.59, and \$11.42, respectively. The fair value of the Company's option grants is estimated at the grant date using the Black-Scholes option-pricing model based on the following assumptions:

| | Year Ended February 28, | | |
|--------------------------------------|-------------------------|-----------------|-----------------|
| | 2023 | 2022 | 2021 |
| Estimated fair value of common stock | \$5.13-\$8.54 | \$13.59-\$31.95 | \$9.62-\$31.27 |
| Exercise price | \$8.03-\$14.05 | \$23.50-\$53.38 | \$15.40-\$50.88 |
| Expected volatility | 64%-70% | 63%-68% | 68%-78% |
| Expected term (in years) | 6.08 | 6.08 | 5.00-6.25 |
| Risk-free interest rate | 2.71%-4.14% | 1.29%-1.39% | 0.30%-0.64% |
| Dividend yield | — | — | — |

F-32 F-30

During the years ended February 28(29), 2022, 2021 and 2020, the Company recognized \$10,374, \$7,743, and \$6,002, respectively, of compensation expense related to stock options. The Company did not capitalize any stock-based compensation expense to deferred costs for the years ended February 28(29), 2022 and 2021. The weighted average grant date fair value for stock options granted during the years ended February 28(29), 2022, 2021 and 2020, was \$28.59, \$11.42, and \$5.40, respectively. The fair value of the Company's option grants is estimated at the grant date using the Black-Scholes option-pricing model based on the following weighted average assumptions:

| | Year Ended February 28(29), | | |
|--------------------------------------|-----------------------------|-----------------|---------------|
| | 2022 | 2021 | 2020 |
| Estimated fair value of common stock | \$13.59-\$31.95 | \$9.62-\$31.27 | \$2.40-\$3.35 |
| Exercise price | \$23.50-\$53.38 | \$15.40-\$50.88 | \$4.70-\$6.75 |
| Expected volatility | 63%-68% | 68%-78% | 46%-50% |
| Expected term (in years) | 6.08 | 5.00-6.25 | 6.25 |
| Risk-free interest rate | 1.29%-1.39% | 0.30%-0.64% | 2.65%-2.94% |
| Dividend yield | — | — | — |

The following is a summary of stock option activity under the Option Plan and Incentive Plan:

| | Stock Options | Weighted Average Exercise Price | Weighted Remaining Contractual Life In Years | Aggregate Intrinsic Value | Stock Options | Weighted Average Exercise Price | Weighted Remaining Contractual Life In Years | Aggregate Intrinsic Value |
|----------------------------|---------------|---------------------------------|--|---------------------------|---------------|---------------------------------|--|---------------------------|
| | | | | | | | | |
| Balance, February 28, 2019 | 8,147,544 | | | | | | | |
| Granted | 2,084,046 | \$ 10.80 | | | | | | |
| Exercised | (1,843,001) | \$ 3.70 | | | | | | |
| Forfeited | (392,533) | \$ 5.70 | | | | | | |
| Balance, February 29, 2020 | 7,996,056 | | | | 7,996,056 | | | |
| Granted | 2,167,775 | \$ 17.47 | | | 2,167,775 | \$ 17.47 | | |
| Exercised | (1,182,099) | \$ 5.98 | | | (1,182,099) | \$ 5.98 | | |
| Forfeited | (257,963) | \$ | | | (257,963) | \$ | | |
| Balance, February 28, 2021 | 8,723,769 | | | | 8,723,769 | | | |
| Granted | 528,038 | \$ 47.74 | | | 528,038 | \$ 47.74 | | |
| Exercised | (901,064) | \$ 9.37 | | | (901,064) | \$ 9.37 | | |
| Forfeited | (304,951) | \$ 14.87 | | | (304,951) | \$ 14.87 | | |

| | | | | | | |
|---|-----------|----|-------|-----------|--------------|-----------|
| Balance, February 28, 2022 | 8,045,792 | \$ | 11.24 | 5.9 years | \$69,948,109 | 8,045,792 |
| Vested and expected to vest as of February 28, 2022 | 7,918,090 | \$ | 11.17 | 6.0 years | \$53,913,465 | |
| Exercisable as of February 28, 2022 | 5,957,906 | \$ | 7.42 | 5.2 years | \$63,158,165 | |
| Granted | 915,081 | \$ | 8.06 | | | |
| Exercised | (346,518) | \$ | 5.45 | | | |
| Forfeited | (563,836) | \$ | 20.05 | | | |
| Balance, February 28, 2023 | 8,050,519 | | | 5.1 years | \$ 30,430 | |
| Vested and expected to vest as of February 28, 2023 | 7,893,273 | \$ | 10.43 | 5.4 years | \$ 30,106 | |
| Exercisable as of February 28, 2023 | 6,581,769 | \$ | 9.11 | 4.3 years | \$ 27,765 | |

The aggregate intrinsic value of stock options exercised was \$1,801, \$29,964, \$32,972, and \$22,033 \$32,972 for the years ended February 28(29) February 28, 2023, 2022, 2021, and 2020 2021 respectively. As of February 28, 2022 February 28, 2023, approximately \$24,581 \$13,959 of unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.2 1.7 years.

During June 2020, the Company issued 525,907 fully-vested stock options in lieu of cash payments related to the Company's fiscal 2020 bonus with a value of \$5,735. These options are included in the table above.

F-33

(b) PlushCare Stock Options

In connection with the acquisition of PlushCare, the Company assumed all stock options that were awarded under the PlushCare Plan and that were outstanding as of the closing of the acquisition. These options were converted into options to purchase the Company's common stock at a ratio determined in the purchase agreement. The Company has no intent to grant any further options under the PlushCare Plan beyond the options granted and outstanding as of the Company's acquisition of PlushCare. The following is a summary of stock option activity under the PlushCare Plan:

| | Stock Options | Weighted average exercise price | Weighted remaining contractual life in years | Aggregate intrinsic value | Stock Options | Weighted average exercise price | Weighted remaining contractual life in years | Aggregate intrinsic value |
|---|---------------|---------------------------------|--|---------------------------|---------------|---------------------------------|--|---------------------------|
| Assumed, June 9, 2021 | 325,992 | | | | 325,992 | | | |
| Exercised | (50,506) | \$ 1.20 | | | (50,506) | \$ 1.20 | | |
| Forfeited | (7,765) | \$ 2.88 | | | (7,765) | \$ 2.88 | | |
| Balance, February 28, 2022 | 267,721 | \$ 1.65 | 7.7 years | \$4,371,967 | 267,721 | | | |
| Vested and expected to vest as of February 28, 2022 | 250,160 | \$ 1.69 | 7.7 years | \$4,075,039 | | | | |

| | | | | | | |
|---|---------|-----------|-----------|-------------|--|--|
| Exercisable as of February 28, 2022 | 121,117 | \$ 1.37 | 7.4 years | \$2,011,387 | | |
| Exercised | | (111,456) | \$ 1.65 | | | |
| Forfeited | | (2,657) | \$ 2.61 | | | |
| Balance, February 28, 2023 | 153,608 | | 6.7 years | \$ 1,456 | | |
| Vested and expected to vest as of February 28, 2023 | 124,666 | \$ 1.36 | 6.5 years | \$ 1,216 | | |
| Exercisable as of February 28, 2023 | 95,519 | \$ 1.15 | 6.3 years | \$ 951 | | |

There were 48,556 stock options outstanding as of the acquisition date that were exercised prior to being vested. These options are excluded from the table above and vest on a pro rata basis monthly through May 2023. A total of 16,824 options vested during the year ended February 28, 2022. For the year years ended February 28, 2022, February 28, 2023 and 2022, the Company recognized \$4,367 and \$4,161, respectively, in compensation expense related to PlushCare stock options. As of February 28, 2022, February 28, 2023, approximately \$7,325 \$2,707 of unrecognized compensation expense related to PlushCare stock options is expected to be recognized over a weighted

F-31

average period of 1.9 1.4 years. The aggregate intrinsic value of stock options exercised was \$1,127 and \$1,596 for the year years ended February 28, 2022, February 28, 2023 and 2022, respectively.

(c) **Restricted Stock Units**

The Company issued 4,470,526, 2,257,433, and 191,415 time-based restricted stock units during the years ended February 28, 2022, February 28, 2023, 2022 and 2021, respectively. No restricted stock units were issued prior to fiscal year 2021. These time-based restricted stock units are have generally been subject to a four-year vesting period with of one two quarter to four years. For two-year grants, one-eighth of an award vesting one generally vests quarterly for the first year after the grant and with the remainder vesting ratably on a monthly basis over the subsequent year. For three-year grants, one-third of an award generally vests one year after grant with the remainder vesting ratably on a monthly basis over the subsequent two years. For four-year grants, one quarter of an award generally vests one year after grant and the remainder vests ratably on a monthly basis over the subsequent three years.

The following is a summary of activity for the years ended February 28, 2022, February 28, 2023, 2022, and 2021:

| | Restricted Stock Units |
|----------------------------|------------------------|
| Balance, February 29, 2020 | — |
| Granted | 191,415 |
| Vested | (702) |
| Forfeited | — |
| Balance, February 28, 2021 | 190,713 |
| Granted | 2,257,433 |
| Vested | (87,574) |
| Forfeited | (134,515) |
| Balance, February 28, 2022 | 2,226,057 |
| Granted | 4,470,526 |
| Vested | (1,667,550) |
| Forfeited | (762,043) |
| Balance, February 28, 2023 | 4,266,990 |

For the years ended February 28, 2022, February 28, 2023, 2022 and 2021, the Company recognized \$20,646, \$32,356, \$23,309 and \$842, respectively, in restricted stock unit compensation expense, with \$78,973, \$61,274 remaining of total unrecognized compensation costs related to these awards as of February 28, 2022, February 28, 2023. The total unrecognized costs are expected to be recognized over a weighted-average term of 3.2, 2.3 years. The weighted-average grant date fair value of restricted stock units granted during the years ended February 28, 2022, February 28, 2023, 2022 and 2021 was \$8.76, \$44.40, and \$46.52, respectively.

In connection with the PlushCare acquisition, the agreement provides for the issuance of time-based restricted stock units for 64,694 shares of common stock to existing PlushCare shareholders, upon achievement of the contingent consideration revenue milestones. During the second quarter of fiscal 2023, 57,124 of these restricted stock units were issued. These restricted stock units have not yet been issued and are not included in the table above.

F-34

above. For In addition, during fiscal 2023, performance-based restricted stock units were approved to be issued as part of the Company's corporate bonus program. These restricted stock units are expected to vest in full in fiscal 2024 in association with the Company's fiscal 2023 corporate bonus payout. At February 28, 2023, 753,259 of these performance-based restricted stock units were approved. During the year ended February 28, 2022, February 28, 2023, the Company recognized \$2,663, recorded \$4,663 in restricted stock unit stock-based compensation expense related to these performance-based restricted stock units.

(d) **Common Stock Warrants**

On June 29, 2015, the Company issued a warrant to its initial customer to purchase up to 200,000 common shares. Based on the vesting provisions and the remaining period over which the warrant was exercisable, the maximum number of shares that could vest pursuant to the warrant was 160,000 shares of common stock, all of which were exercised in March 2020.

In connection with the Term Loan amendment, the Company issued a warrant to purchase up to 86,600 shares of the Company's common stock (the 2019 Term Loan Warrant) at an exercise price of \$9.60 per share. The 2019 Term Loan Warrant vested 100% upon issuance and has a ten-year term, ending July 19, 2029. The Company calculated the fair value of the 2019 Term Loan Warrant using the Black-Scholes option pricing model, and the fair value of the 2019 Term Loan Warrant was determined to be \$528. This amount was recorded as a debt discount and was amortized ratably over the Term Loan period.

In connection with the 2019 Revolver, the Company issued the lender warrants to purchase up to 36,363 and 12,631 shares of the Company's common stock (the 2019 Revolver Warrants) at an exercise price of \$13.75 and \$23.75 per share, respectively. The 2019 Revolver Warrants vested 100% upon issuance and have a ten-year term, ending July 19, 2029. The Company calculated the fair value of the 2019 Revolver Warrants using the Black-Scholes option pricing model, and the fair value of the 2019 Revolver Warrants was determined to be \$251.

The following table summarizes the activity for the Company's warrants for the periods presented:

| | Common Stock Warrants |
|---|--------------------------|
| Balance, February 28, 2019 | 1,466,043 |
| Issued | 220,594 |
| Exercised | (33,369) |
| Balance, February 29, 2020 | 1,653,268 |
| Issued | — |
| Exercised | (160,000) |
| Automatic exercise of warrants in connection with IPO | (1,493,268) |
| Balance, February 28, 2021 | — |

On July 7, 2020, upon the closing of the Company's IPO, 1,401,836 shares of common stock were issued upon the automatic net exercise of all warrants that were outstanding as of the IPO date. There were no warrants outstanding as of February 28, 2022 or 2021.

(e) Employee Stock Purchase Plan

In July 2020, the Board of Directors adopted the Company's 2020 Employee Stock Purchase Plan (ESPP) (the ESPP), which became effective immediately prior to the effectiveness of the registration statement for the Company's IPO. The

F-32

total shares of common stock initially reserved under the ESPP was limited to 1,100,000 shares. On March 1, 2021 March 1, 2022, there was an automatic annual increase, which increased the total available common shares to 1,656,991.2,327,976.

Under the ESPP, eligible employees can purchase the Company's common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company's common stock at 85% of the lower of the fair market value of the Company's common stock on the first day of the offering period or on the last day of the offering period. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than \$25,000 worth of the Company's common stock for each calendar year in which such right is outstanding.

F-35

Employees who elect to participate in the ESPP commence payroll withholdings that accumulate through the end of the respective period. In accordance with the guidance in ASC 718-50 – *Compensation – Stock Compensation*, the ability to purchase shares of the Company's common stock for 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option's grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of \$1,332, \$1,749, and \$991 during the years ended February 28, 2022 February 28, 2023, 2022 and 2021, respectively, related to the ESPP.

During the year years ended February 28, 2022 February 28, 2023, 2022 and 2021, employees who elected to participate in the ESPP purchased a total of 560,345, 140,838, and 67,498 shares of common stock, respectively, resulting in cash proceeds to the Company of \$2,927, \$4,309, and \$1,259, respectively. An additional \$1,511 1,384 has been withheld via employee payroll deductions who have opted to participate in the next stock purchase plan period ending May 2022, 2023.

(f) (e) Other

In connection with the acquisition of 2nd.MD (Note 4), several 2nd.MD individuals entered into agreements with the Company whereby these individuals are eligible to receive an aggregate of 608,332 shares that required continued employment with the Company. These shares are excluded from the above restricted stock units table. Included in the 608,332 shares are 281,531 shares that were also contingent upon the achievement of the contingent consideration milestones. These shares are considered compensatory in the post business combination periods due to the additional service requirement for these individuals. These shares will vest vested 50% on the first anniversary of the acquisition date and 50% on the second anniversary of acquisition date. As a result of the achievement of certain revenue milestones (the contingent consideration milestones), a total of 256,418 of the eligible 281,531 shares will be issued to such shareholders, subject to the service requirements. As of February 28, 2022 February 28, 2023, there were 583,219 241,614 unvested shares outstanding with a grant date fair value of \$46.56 per share comprised of the 326,801 shares issued as part of the initial consideration and the 256,418 shares subject to be issued related to the contingency. future service periods. The Company recognized stock-based compensation expense of \$4,015 and \$23,138 during the year years ended February 28, 2022 February 28, 2023 and 2022, respectively, including \$8,981 of accelerated expense related to certain separation and transition agreements entered into during fiscal 2022. The As of March 3, 2023, there is no remaining unamortized compensation expense of \$4,015 will be recognized over a weighted average remaining period of 0.3 years. expense.

In connection with the acquisition of PlushCare (Note 4), certain PlushCare individuals entered into agreements with the Company whereby these individuals are eligible to receive an aggregate of 806,161 shares that require continued employment with the Company. These shares are excluded from the above restricted stock units table. These shares are considered compensatory in the post business combination

periods due to the additional service requirement for these individuals. One third of these shares will vest vested on the first anniversary of the acquisition date, one third will vest on the second anniversary of acquisition date, and one third will vest on the third anniversary of the acquisition date. As of February 28, 2022 February 28, 2023, there were 806,161 537,401 unvested shares outstanding with a grant date fair value of \$52.52 per share. The Company recognized stock-based compensation expense of \$14,113 and \$10,208 during the year years ended February 28, 2022, February 28, 2023 and 2022, respectively. The unamortized compensation expense of \$32,132 \$18,018 will be recognized over a weighted average remaining period of 1.3 years.

(13) Defined Contribution Retirement Plan

The Company sponsors a defined contribution retirement plan named the Accolade, Inc. 401(k) Plan (401(k) Plan). Under the 401(k) Plan, eligible employees may contribute up to the maximum allowed by law. Eligible

F-33

employees are eligible for Company matching contributions on the first quarter following their one-year anniversary date, which are dollar for dollar up to 3.0% (increased to 3.5% as of March 1, 2022) of an employee's eligible compensation, up to \$100 in annual compensation. Employer contributions are vested over a period of four years of service. The 401(k) Plan includes an employer discretionary profit-sharing contribution feature to allow the Company to make a contribution to eligible employees' 401(k) Plan accounts. Profit sharing contributions are vested over a period of four years of service. The Company incurred expenses related to matching contributions totaling \$3,231, \$2,278, \$1,599, and \$1,356 \$1,599 for the years ended February 28(29) February 28, 2023, 2022, 2021, and 2020, 2021, respectively, which were funded subsequent to each respective year-end.

F-36

(14) Income Taxes

Loss Income (loss) before income taxes consists of the following components:

| | Year Ended February 28(29), | | | Year Ended February 28, | | |
|----------|-----------------------------|-------------|-------------|-------------------------|-------------|------------|
| | 2022 | 2021 | 2020 | 2023 | 2022 | 2021 |
| Domestic | \$ (129,569) | \$ (50,934) | \$ (51,794) | \$(463,848) | \$(129,569) | \$(50,934) |
| Foreign | 806 | 286 | 558 | 574 | 806 | 286 |
| Total | \$ (128,763) | \$ (50,648) | \$ (51,236) | \$(463,274) | \$(128,763) | \$(50,648) |

Significant components of income taxes are as follows:

| | Year Ended February 28(29), | | | Year Ended February 28, | | |
|-----------------|-----------------------------|------|------|-------------------------|---------|------|
| | 2022 | 2021 | 2019 | 2023 | 2022 | 2021 |
| Current: | | | | | | |
| Federal | \$ 124 | \$ — | \$ — | \$ 156 | \$ 124 | \$ — |
| State and Local | 76 | 37 | — | 90 | 76 | 37 |
| Foreign | 202 | 141 | 129 | 127 | 202 | 141 |
| Total Current | 402 | 178 | 129 | 373 | 402 | 178 |
| Deferred: | | | | | | |
| Federal | (7,935) | — | — | (1,638) | (7,935) | — |
| State and Local | 1,941 | — | — | (2,359) | 1,941 | — |

| | | | | | | |
|--------------------------------------|-------------------|-------------|---------------|------------------|------------------|-------------|
| Foreign | (47) | (174) | — | — | (47) | (174) |
| Total deferred | (6,041) | (174) | — | (3,997) | (6,041) | (174) |
| Provision (benefit) for income taxes | <u>\$ (5,639)</u> | <u>\$ 4</u> | <u>\$ 129</u> | <u>\$(3,624)</u> | <u>\$(5,639)</u> | <u>\$ 4</u> |

A reconciliation of income tax expense at the U.S. Federal statutory income tax rate to actual income tax provision is as follows:

| | Year Ended February 28(29), | | |
|--|-----------------------------|--------------|---------------|
| | 2022 | 2021 | 2020 |
| Federal income tax expense at statutory tax rate | 21.0 % | 21.0 % | 21.0 % |
| State income taxes, net of federal tax benefit | 4.5 | 4.6 | 7.5 |
| Stock-based compensation | 0.8 | (0.2) | 3.9 |
| Transaction costs | (1.1) | — | (0.2) |
| Contingent consideration | 1.1 | — | — |
| Changes in valuation allowances | (21.9) | (25.4) | (31.4) |
| Other | — | — | (1.0) |
| Effective Income Tax Rate | <u>4.4 %</u> | <u>0.0 %</u> | <u>(0.2)%</u> |

Income tax (expense) benefit for the fiscal years ended February 28(29), 2022, 2021, and 2020 differ from the U.S. statutory income tax rate primarily due to changes in valuation allowances, state income taxes and stock-based compensation.

The tax benefit for the year ended February 28, 2022 relates to the partial release of the U.S. valuation allowance due to the acquired intangibles of PlushCare. The decrease in the valuation allowance of \$(9,991) is due to the acquisition of PlushCare's stock, whereby the acquired intangible assets have no tax basis. This required the Company to record a deferred tax liability which serves as a source of taxable income to realize the existing deferred tax assets of the Company.

The tax benefit associated with the partial valuation allowance release was offset by a tax expense of \$3,999 that was recorded in the year ended February 28, 2022 related to tax amortization of 2nd.MD goodwill and the change in fair value of contingent consideration associated with the 2nd.MD acquisition. The tax amortization and decrease in the

F-37 F-34

contingent consideration created a A reconciliation of income tax expense at the U.S. Federal statutory income tax rate to actual income tax provision is as follows:

| | Year Ended February 28, | | |
|--|-------------------------|--------------|--------------|
| | 2023 | 2022 | 2021 |
| Federal income tax expense at statutory tax rate | 21.0 % | 21.0 % | 21.0 % |
| State income taxes, net of federal tax benefit | 2.8 | 4.5 | 4.6 |
| Change in state rate | (2.1) | — | — |
| Stock-based compensation | (0.3) | 0.8 | (0.2) |
| Transaction costs | — | (1.1) | 0.0 |
| Contingent consideration | — | 1.1 | — |
| Goodwill impairment | (8.6) | — | — |
| Changes in valuation allowances | (11.9) | (21.9) | (25.4) |
| Other | (0.1) | — | — |
| Effective Income Tax Rate | <u>0.8 %</u> | <u>4.4 %</u> | <u>0.0 %</u> |

Income tax (expense) benefit for the fiscal years ended February 28, 2023, 2022, and 2021 differ from the U.S. statutory income tax rate primarily due to changes in valuation allowances, state income taxes, goodwill impairment, and stock based compensation.

The tax benefit for the year ended February 28, 2023 relates to the partial release of the reversal of the deferred tax liability associated with the basis difference in book and tax goodwill. Accordingly, a goodwill from the 2nd.MD acquisition. The goodwill impairment recorded in the first quarter of fiscal 2023 required the Company to reverse that deferred tax liability was recorded with in the related income amount of \$3,899 and recognize a tax expense reflected in earnings, benefit during the year ended February 28, 2023.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. The Company makes significant judgments regarding the realizability of its deferred tax assets (principally net operating losses). The carrying value of deferred tax assets is based on the Company's assessment that it is more likely than not that the Company will

F-35

realize these assets after consideration of all available positive and negative evidence. Significant components of the Company's deferred tax assets and liabilities at February 28, 2022 February 28, 2023 and 2021 2022 are as follows:

| | February 28, | | February 28, | |
|--|--------------|-----------|--------------|------------|
| | 2022 | 2021 | 2023 | 2022 |
| Deferred tax assets: | | | | |
| Net operating loss and tax credit carryforwards | \$ 114,272 | \$ 84,879 | \$ 113,740 | \$ 114,272 |
| Other accruals and reserves | 5,210 | 6,107 | 5,599 | 5,210 |
| Stock-based compensation | 16,353 | 871 | 32,741 | 16,353 |
| Deferred rent | — | 1,181 | | |
| Interest expense deduction limitation carryforward | 3,082 | 2,312 | 3,092 | 3,082 |
| Intangibles | | | 6,248 | — |
| Property, plant & equipment | 578 | 523 | 869 | 578 |
| Capitalized research and development | | | 10,931 | — |
| Lease liability | | | 10,086 | 10,027 |
| Other | 94 | 820 | — | 94 |
| Lease liability | 10,027 | — | | |
| Valuation allowance | (125,810) | (96,516) | (175,610) | (125,810) |
| Deferred tax assets | 23,806 | 177 | 7,696 | 23,806 |
| Deferred tax liabilities: | | | | |
| Operating lease right-of-use assets | (8,494) | — | (7,478) | (8,494) |
| Intangibles | (19,091) | (3) | — | (19,091) |
| Deferred tax liabilities | (27,585) | (3) | (7,478) | (27,585) |
| Net deferred taxes | \$ (3,779) | \$ 174 | \$ 218 | \$ (3,779) |

Deferred tax liabilities are included in deferred rent and other noncurrent liabilities on the consolidated balance sheet. Net operating loss (NOL) carryforwards amounted to \$422,481 \$453,323 and \$307,398 \$422,481 for U.S. federal and \$372,975 \$402,376 and \$283,377 \$372,975 for U.S. states at February 28, 2022 February 28, 2023 and 2021, 2022, respectively. These operating loss NOL carryforwards related to the 2010 through current 2021 2022 tax periods. At February 28, 2022 February 28, 2023, none of the operating loss NOL carryforwards were subject to expiration until 2030. The operating loss NOL carryforwards expiring in years 2030 through 2037 make up \$53,184 \$59,213 of the recorded deferred tax asset. The remaining deferred tax asset relating to operating loss NOL carryforwards of \$61,088 \$54,101 have an indefinite expiration. In addition to operating loss NOL carryforwards, research and development tax credit carryforwards amounted to \$432 for U.S. federal and U.S. states at February 28, 2022 February 28, 2023. These tax credit carryforwards will expire in 2036. Under Section 382 of the Internal Revenue Code, the yearly utilization of a corporation's net operating loss NOL carryforwards may be limited following a change in ownership of greater than 50% (by value) over a three-year period. The yearly limitation is based on the value of the corporation immediately before the ownership change multiplied by the federal long-term tax-exempt rate. If a loss is not utilized in a year after an ownership change that yearly limit is carried forward to future years for the balance of the net operating loss NOL carryforward period. As of February 28, 2022 February 28, 2023, the Company did not incorporate a yearly limitation under Section 382 as a recent study has not been completed.

Management assesses the available positive and negative evidence to estimate if a valuation allowance is required to be recorded against existing deferred tax assets. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon the Company's brief operating history and the net losses incurred since inception, management does not believe that it is more likely than not that the Company will realize the benefits of these deductible differences in the U.S. As a result, a full valuation allowance has been provided at February 28, 2022 February 28, 2023 and 2021 2022 for U.S. Federal and state tax purposes. The Company had previously maintained a full valuation allowance associated with its Czech Republic entity that was released in the prior year.

F-38 F-36

| | Year Ending February 28, | |
|--|--------------------------|------------------|
| | 2022 | 2021 |
| Balance at the beginning of the period | \$ 96,516 | \$ 83,640 |
| Increase due to NOLs and temporary differences | 35,287 | 12,876 |
| Increase due to acquisitions | (5,993) | — |
| Balance at the end of the period | <u>\$ 125,810</u> | <u>\$ 96,516</u> |

The following is a summary of NOL activity:

| | Year Ending February 28, | |
|--|--------------------------|-------------------|
| | 2023 | 2022 |
| Balance at the beginning of the period | \$ 125,810 | \$ 96,516 |
| Increase due to NOLs and temporary differences | 54,937 | 35,287 |
| Decrease due to acquisitions | (5,137) | (5,993) |
| Balance at the end of the period | <u>\$ 175,610</u> | <u>\$ 125,810</u> |

The Company has recorded a deferred tax asset of \$3,082 \$3,092 for interest expense limited under the Tax Act at February 28, 2022 February 28, 2023. The interest expense limited has an unlimited carryforward period.

U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over tax basis of the investments in foreign subsidiaries that is indefinitely reinvested outside the U.S. The foreign subsidiary is identified as a branch for U.S. tax purposes, and therefore, a gross temporary difference for investment basis differences is not applicable.

The Company had no material accrual for uncertain tax positions or interest or penalties related to income taxes on the Company's consolidated balance sheets at February 28, 2022 February 28, 2023 and 2021 2022 and has not recognized any material uncertain tax positions or interest and/or penalties related to income taxes in the consolidated statement of operations for the years ended February 28(29) February 28, 2023, 2022, 2021, and 2020. 2021.

(15) Net Loss Per Share Attributable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per common share:

| | Year Ended February 28(29), | | | Year Ended February 28, | | |
|--|-----------------------------|-------------------|------------------|-------------------------|-------------------|-------------------|
| | 2022 | 2021 | 2020 | 2023 | 2022 | 2021 |
| Net loss | \$ (123,124) | \$ (50,652) | \$ (51,365) | \$ (459,650) | \$ (123,124) | \$ (50,652) |
| Net loss per common share, basic and diluted | <u>\$ (1.93)</u> | <u>\$ (1.72)</u> | <u>\$ (9.13)</u> | <u>\$ (6.45)</u> | <u>\$ (1.93)</u> | <u>\$ (1.72)</u> |
| Weighted average shares used to compute net loss per common share, basic and diluted | <u>63,823,270</u> | <u>29,370,594</u> | <u>5,626,713</u> | <u>71,279,831</u> | <u>63,823,270</u> | <u>29,370,594</u> |

As the Company has reported net losses for each of the periods presented, all potentially dilutive securities are antidilutive. The following potential outstanding shares of common stock were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been antidilutive:

| | Year Ended February 28(29), | | |
|--|-----------------------------|-----------|-----------|
| | 2022 | 2021 | 2020 |
| Stock options | 8,313,513 | 8,723,769 | 7,996,056 |
| Unvested restricted stock units | 2,226,057 | 190,713 | — |
| Shares issued to 2nd.MD employees and subject to vesting | 326,801 | — | — |
| Shares issued to PlushCare employees and subject to vesting | 806,161 | — | — |
| Contingent shares in connection with PlushCare acquisition | 102,111 | — | — |
| Indemnity shares held in escrow in connection with PlushCare acquisition | 27,342 | — | — |
| Shares to be issued to HealthReveal shareholders upon expiration of indemnification period | 28,089 | — | — |
| Common stock warrants | — | — | 317,861 |
| Total | 11,830,074 | 8,914,482 | 8,313,917 |

| | Year Ended February 28, | | |
|--|-------------------------|------------|-----------|
| | 2023 | 2022 | 2021 |
| Stock options | 8,204,127 | 8,313,513 | 8,723,769 |
| Unvested restricted stock units | 4,266,990 | 2,226,057 | 190,713 |
| Shares issued to 2nd.MD employees and subject to vesting | 274,224 | 326,801 | — |
| Shares issued to PlushCare employees and subject to vesting | 537,401 | 806,161 | — |
| Contingent shares in connection with PlushCare acquisition | 102,111 | 102,111 | — |
| Indemnity shares held in escrow in connection with PlushCare acquisition | 27,342 | 27,342 | — |
| Shares to be issued to HealthReveal shareholders upon expiration of indemnification period | 28,089 | 28,089 | — |
| Convertible Senior Notes | 5,700,297 | 5,700,297 | — |
| Total | 19,140,581 | 17,530,371 | 8,914,482 |

F-39 F-37

(16) Commitments and Contingencies

(a) Legal Proceedings

The Company is involved in various claims, inquiries and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters is not expected to have a material adverse effect on the Company's financial position or liquidity. As of February 28, 2022 February 28, 2023, the Company had accruals of \$888 \$3,700 related to legal matters.

On May 8, 2021, a purported class action complaint (*Robbins v. PlushCare, Inc. et al.*) was filed in the United States District Court for the Northern District of California against the Company's wholly owned subsidiary, PlushCare, Inc. The complaint, as amended, alleges that certain of PlushCare's subscription payment practices violate the California Automatic Renewal Law and other state automatic renewal laws and the Federal Electronic Funds Transfer Act, among other claims, arising from allegations that PlushCare failed to provide adequate disclosures to members. The lawsuit seeks restitution of subscription fees, statutory damages for each violation, subject to trebling, reasonable attorneys' fees, and injunctive relief. Under the terms of the agreement to purchase PlushCare, the selling shareholders will indemnify Accolade for losses related to this matter, subject to a cap. As The parties have tentatively agreed on a loss is probable settlement and can be reasonably

estimated, the Company has recorded a contingent liability. The majority of the Company's liability is eligible to be paid through third-party insurance and corresponding the remaining indemnification asset from the selling shareholders of PlushCare. The remainder amounted to \$1,218 at February 28, 2022. February 28, 2023 and was recorded in general and administrative expenses in the statement of operations.

(b) Employment Agreements

Certain officers of the Company have employment agreements providing for severance, continuation of benefits, and other specified rights in the event of termination without cause, including in the event of a change of control of the Company, as defined in the agreements.

(c) Purchase Obligations

The Company has minimum required purchase commitments of \$40,323 pursuant to an agreement primarily related to cloud computing services. Portions of the total purchase commitment are required to be met prior to the end of each contract year, September 30, in each of the fiscal years 2023 through 2027. If total purchases in a contract year do not meet the portion of the commitment required for that year, the shortfall must be prepaid and can be used for future purchases through September 30, 2027. As of February 28, 2022 February 28, 2023, the Company has remaining future purchase commitments under this agreement of \$38,065.

The Company also owes \$735 in future data license fee payments through fiscal 2025 under an agreement with Change Healthcare Holdings which provides various data services to support the Company's product offerings. \$31,995.

(17) Related Party Transactions

Entities affiliated with one of the Company's significant customers owned more than 5% of the Company's outstanding stock during the years year ended February 28(29), 2021 and 2020, February 28, 2021. Revenues related to this customer were \$27,300 during the fiscal year ended February 28, 2021. As of February 28, 2022 February 28, 2023, 2022, and 2021, these entities no longer owned more than 5% of the Company's outstanding stock. Revenues

(18) Restructuring

During the year ended February 28, 2023, the Company initiated several measures to accelerate the integration of recent acquisitions through strategic reductions in the Company's workforce, including increasing hiring in lower cost regions to support its growth, scale, and profitability objectives. As a result, severance expense was recorded for the impacted employees.

F-38

The following table summarizes the amount of severance costs included in the consolidated statements of operations:

| | Year Ended February 28, |
|--|-------------------------|
| | 2023 |
| Cost of revenue, excluding depreciation and amortization | \$ 1,025 |
| Product and technology | 2,149 |
| Sales and marketing | 1,948 |
| General and administrative | 1,943 |
| Total severance costs | \$ 7,065 |

The following is a summary of the changes in severance liabilities related to this customer were \$27,300 and \$31,556 the workforce reductions. These liabilities are included within accrued compensation on the consolidated balance sheets:

| | |
|-----------------------------|-------|
| Balance as of March 1, 2022 | \$ — |
| Severance costs | 7,065 |

| | |
|---------------------------------|----------|
| Cash payments | (3,069) |
| Balance as of February 28, 2023 | \$ 3,996 |

The Company expects remaining severance-related liabilities to be substantially paid out in cash during the first half of fiscal years ended February 28(29), 2021 and 2020, respectively. There were \$2,325 2024. Additional expenses associated with these restructuring activities in accounts receivable outstanding from this customer as of February 28, 2021, fiscal 2024 are not expected to be material.

F-40 F-39

Exhibit 21.1

Accolade, Inc.

Subsidiaries of the Registrant

The following is a list of the Company's consolidating subsidiaries as of February 28, 2022 February 28, 2023.

| Name of Subsidiary | State or Jurisdiction of Incorporation |
|-------------------------------------|--|
| Accolade Technologies s.r.o. | Czech Republic |
| MD Insider, Inc. | Delaware |
| Accolade 2ndMD LLC | Texas |
| 1stMD LLC | Texas |
| PlushCare, Inc. | Delaware |
| PlushCare Technologies Canada, Inc. | Canada |

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the registration statements (Nos. 333-239704, 333-256961 and 333-256961 333-265425) on Form S-8 and registration statement (No. 333-257803) on Form S-3 of our reports dated May 2, 2022 April 27, 2023, with respect to the consolidated financial statements of Accolade, Inc. and subsidiaries and the effectiveness of internal control over financial reporting.

/s/ KPMG LLP

Philadelphia, Pennsylvania

May 2, 2022 April 27, 2023

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rajeev Singh, certify that:

1. I have reviewed this Annual Report on Form 10-K of Accolade, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 2, 2022 April 27, 2023

/s/ Rajeev Singh

Rajeev Singh

Chief Executive Officer

(Principal Executive Officer)

Exhibit 31.2

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Stephen Barnes, certify that:

1. I have reviewed this Annual Report on Form 10-K of Accolade, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 2, 2022 April 27, 2023

/s/ Stephen Barnes

Stephen Barnes

Chief Financial Officer

(Principal Financial Officer)

Exhibit 32.1

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Rajeev Singh, Chief Executive Officer of Accolade, Inc. (the "Company"), and Stephen Barnes, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1. The Company's Annual Report on Form 10-K for the fiscal year ended February 28, 2022 February 28, 2023, to which this Certification is attached as Exhibit 32.1 (the "Annual Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 2, 2022 April 27, 2023

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 2nd 27th day of May, 2022 April, 2023.

/s/ Rajeev Singh

Rajeev Singh

Chief Executive Officer

/s/ Stephen Barnes

Stephen Barnes

Chief Financial Officer

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Accolade, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2023, Refinitiv. All rights reserved. Patents Pending.